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 Chronic obstructive pulmonary disease (COPD) is a prevalent respiratory disease and the 
third leading cause of death worldwide.  Tobacco smoking is not only a major contributor to the 
prevalence of and high mortality in COPD, but a history of smoking predisposes people with 
COPD to being stigmatized.  Stigma, like in anxiety and depression, can adversely affect 
psychological functioning and essential functions for disease management.  Guided by “the 
conceptual model representing the effects of stigma processes on health,” this three-paper 
dissertation includes a) a systematic review of stigma in people with COPD compared to lung 
cancer-related stigma, b) a qualitative study to evaluate and refine a 52-item preliminary COPD 
stigma scale using cognitive interviewing, and c) a quantitative study to examine the validity and 
reliability of the refined COPD stigma scale.  
 In a systematic review, people with COPD or lung cancer are similar in their perceptions 
of stigma: “they did it to themselves.”  Studies have shown that lung cancer-related stigma is 
associated with patient outcomes including increased psychological distress, poor quality of life, 
low help-seeking, poor medication adherence, and low social support.  A small number of 
qualitative studies have described the phenomenon of stigma in people with COPD, and less is 
known about COPD-related stigma in part because there are no existing measures of COPD-
related stigma.   
 In a qualitative study, nineteen people with COPD participated in semi-structured 
cognitive interviews to assess comprehension of the 52-item preliminary COPD stigma scale.  
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Most questionnaire items were understood and interpreted as intended.  Of 52 total items, one 
item was dropped because it was identified as so offensive that many subjects were reluctant to 
answer.  Eleven items were revised to improve the flow of responses to the questionnaire.  
Regarding response options, subjects selected the mid-point (i.e., neutral) response for various 
reasons.  The most frequent reason for choosing the mid-point response was “both equal parts of 
agree and disagree,” followed by “not applicable.”  This qualitative study provided the 
foundation required for further revision and evaluation of the stigma questionnaire using 
psychometric methods.   
 In the quantitative study, we identified the underlying structure and assessed the 
psychometric properties of the revised version of the COPD-related Stigma Scale.  People with 
COPD (n = 148) participated in the mailed questionnaire, including the 51-item COPD-related 
Stigma Scale.  The exploratory factor analysis indicated that the four-factor model with 28 items 
provided a good fit to the data with high internal consistency (α = 0.96).  The COPD-related 
Stigma Scale estimated by 28 items was significantly correlated with other measures—chronic 
illness-related stigma, psychological distress, and physical function—establishing the construct 
validity of the scale.  This finding provided the foundation required for the further evaluation of 
confirming the underlying structure of the COPD-related Stigma Scale.    
In conclusion, the findings in the studies above support that COPD-related stigma may 
adversely affect psychological and physical health.  Researchers may consider further 
investigating the potential harmful effects of stigma on COPD management as well as 








 As the population ages, so do the number of people living with chronic health problems.  
This raises concerns about this population and the stigma associated with chronic health 
problems, which can negatively affect the quality of one’s life (Earnshaw & Quinn, 2012; 
Gullick & Stainton, 2008; Joachim & Acorn, 2000a; Morrell, 2002).  People with chronic 
conditions often experience functional decline, financial difficulties, burdening of family 
members and social isolation (Charmaz, 1983; Schulman‐Green et al., 2012).  They can also 
experience the loss of their previous positive self-image and controllability over their lives 
(Charmaz, 1983).  All of these experiences have the potential for stigmatization.  In addition, 
people with chronic conditions experience feelings of being stigmatized by and discriminated 
against in their social relationships, work opportunities, and healthcare settings, because chronic 
conditions may be regarded as being abnormal compared to others (Joachim & Acorn, 2000b).  
Multiple studies have shown that perceiving stigma and discrimination are associated with 
psychological distress and poor quality of life (Earnshaw & Quinn, 2012; Earnshaw, Quinn, & 
Park, 2012; Jacoby, 2002; Jacoby, Snape, & Baker, 2005; Quinn & Earnshaw, 2011; Schmitt, 
Branscombe, Postmes, & Garcia, 2014; Sehlo & Bahlas, 2013; van der Beek, Bos, Middel, & 
Wynia, 2013). 
 Stigma is a social factor that distinguishes a person with undesirable attributes from 
others and encroaches upon a person’s quality of life.  In ancient times, stigma referred to the 
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mark of being morally disgraced; thus, those who had the mark were regarded as subhuman 
(Goffman, 1963).  Although the concept of being disgraced has shifted with time, the stigmatized 
person still has many disadvantages.  The person is vulnerable to a range of discrimination that 
threatens his/her personal and social identity (Goffman, 1963; Link & Phelan, 2001; Major & 
O'brien, 2005).  These negative impacts of stigma on quality of life have been widely studied, 
and include such areas as mental illness, HIV/AIDS, and tuberculosis (TB).  
 Mental health issues have deep-rooted stereotypic connotations in many cultures.  It is 
often perceived as dangerous, untreatable, and disruptive to social interactions (Hayward & 
Bright, 1997; Ng, 1997; Ottati, Bodenhausen, & Newman, 2005).  For that reason, people who 
suffer from mental illness are discriminated against in various life choices, such as education, 
occupation, place of domicile status, and healthcare access (Corrigan & Watson, 2002; Link & 
Phelan, 2001; Pettit, 2008; Rusch, Angermeyer, & Corrigan, 2005).  In this context, important 
life opportunities and social status are devalued and self-esteem is lowered (Major & O'brien, 
2005).   
HIV/AIDS is another highly stigmatized health problem.  Although HIV/AIDS-related 
stigma has a relatively short history, it affects countries all over the world.  This can arise from 
perceptions linked to socially and morally deviant behaviors, the pernicious disease course, and 
its high degree of contagiousness (Alonzo & Reynolds, 1995; Parker & Aggleton, 2003).  These 
opinions play a role in limiting people living with HIV/AIDS in every aspect of daily life.  They 
are forced to isolate themselves from their home, community, workplaces, and public spaces 
(Ogden & Nyblade, 2005).  They are gradually denied the rights to lead their own lives, and lose 
roles and power as a member of the family and community, which contributes to their 
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stigmatized identity (Earnshaw, Smith, Chaudoir, Amico, & Copenhaver, 2013; Ogden & 
Nyblade, 2005).   
TB is another highly stigmatized health problem, albeit less studied.  TB-related stigma is 
primarily caused by vague perceptions of TB transmission, from dirty air, casual contacts with 
household family members, occurring after other pulmonary infections, or as a precursor to 
cancer (Courtwright & Turner, 2010; Kelly, 1999; Kurspahić-Mujčić, Hasanović, & Sivić, 
2013).  The close associations with HIV and low social and economic status also contributes to 
TB-related stigma (Bond & Nyblade, 2006; Courtwright & Turner, 2010).  In prevalent HIV 
areas, people with TB are also thought to have HIV because of a belief that TB is a sign of HIV 
(Bond & Nyblade, 2006; Courtwright & Turner, 2010).  Thus, people with TB are physically, 
emotionally, and socially isolated from their families and communities, which lead them to 
conceal the diagnosis and be reluctant to seek help (Bond & Nyblade, 2006; Courtwright & 
Turner, 2010; Kelly, 1999; Macq, Solis, & Martinez, 2006).   
 Stigmatization, like other social phenomena, is a complex process.  To understand this 
process, a number of theorists and researchers have attempted to develop conceptual 
frameworks.  Link and Phelan (2001) define a stigma as “the co-occurrence of interrelated 
components of labeling, stereotyping, separation, status loss, and discrimination in a power 
situation” (p. 377). Prior to framing the concept, they revisited existing stigma concepts and 
identified several crucial points, such as variations of definitions, the existence of blind spots due 
to the researchers’ lack of personal experience in the area, and how to holistically view stigma by 
not limiting it to one level.  To allow for the enhanced conceptualization, Link and Phelan (2001) 
emphasized the importance of a comprehensive approach by considering human differences on 
labeling, the individual ways of linking labels to stereotypic characteristics, the rationale for 
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labels, the ensuing disadvantages to quality of life (e.g., employment, housing status, health care, 
etc.), and the role of social, economic, and political power in stigmatization.   
 Deacon (2006) attempted to illuminate the key issues of stigma by reviewing and 
discussing literature reviews on HIV/AIDS-related stigma.  She defines stigma as “the process of 
othering, blaming and shaming (p. 418).”  In defining the concept, she maintains an existing 
stance on stigma as a social process, but asserts that researchers should have a clear sense of the 
relationships between stigma, disadvantage, and discrimination.  According to her explanation, 
discrimination is a part of the negative consequences of stigma; stigma is a disadvantage that 
occurs in existing social inequalities.  The clarification of the these relationships will help to gain 
a better understanding of the complex mechanism of stigma as well as improving strategies for 
research and interventions (Deacon, 2006).   
M. G. Weiss, Ramakrishna, and Somma (2006) and Scambler (2006, 2009) emphasized 
that health-related stigma is manifested in different individuals, and in particular, social and 
cultural contexts.  M. G. Weiss et al. (2006) posit that “the discriminatory social judgments (p. 
280)” on certain health problems play an important role in health-related stigma.  Although these 
views are groundless from a medical and epidemiological point of view, they adversely and 
persistently affect health.   
In addition, other discriminatory social judgments regarding race, ethnicity, gender, etc. 
adversely affect health in concert with health-related stigma.  Thus, M. G. Weiss et al. (2006) 
suggest that studies of health-related stigma should be conducted by considering different social 
and cultural components associated with the stigmatized health problems.  Scambler (2006) 
states that health-related stigmatization is anchored in social structures.  Considering there are no 
settled social structures, research on health-related stigma needs to be formulated and 
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implemented with attention paid to the causal powers of social structure as well as its 
components, including social class, status, roles, culture, and social institutions.  He also stresses 
the inextricable connection between health-related stigmatization and social structures. Although 
there are similarities in effects and outcomes of health-related stigmatization, different social 
structures and cultural norms are involved in its manifestations (Scambler, 2009).  Thus, studies 
of health-related stigma and associated interventions should be culture- and health-problem-
specific (Scambler, 2006, 2009).   
Major, Dovidio, and Link (2018) attempted to integrate the possible consequences of 
health-related stigma by reviewing literature from different disciplines.  They focused on two 
sets of stigma’s impact on health: individual-level psychosocial stress and social/community-
level exclusion.  These negative influences may lead to health disparities between those who are 
stigmatized and those who are not.  For example, those who are stigmatized may be more likely 
to have inadequate access to healthcare resources and increasing exposure to environmental 
threats.  To better understand the linkage between stigma status and its impact on health, Major 
et al. (2018) proposed a conceptual model that presents pathways from stigmatization to health 
outcomes. Their model has six domains: 1) socially conferred marks, 2) moderating factors, 3) 
stigma processes, 4) individual-level responses, 5) social/community-level exclusion, and 6) 
health.  This conceptual model guided this dissertation. 
According to Major et al. (2018)’s conceptual model, the domain of socially conferred 
marks are sources of negative attitudes or stereotypes within a society. These marks can stem 
from socioeconomic status, cultural beliefs, or personal attributes and act as a distinguisher 
between stigmatized and non-stigmatized individuals.  Being poor, mentally ill, disabled, or 
obese are examples of marks.   
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The domain of moderating factors refers to elements that intervene in the path between 
the domain of socially conferred marks and the domain of stigma processes and alter the 
characteristics and strength of stigmatization.  These elements include seven dimensions (i.e., 
concealability, course, disruptiveness, aesthetic qualities, origin or controllability, peril, and 
collectivity) as well as individual and environmental characteristics.   
The domain of stigma processes, developed from the domain of socially conferred marks, 
consists of four types of stigmas: enacted stigma (occurring at the interpersonal and structural 
level), felt stigma, internalized stigma, and anticipated stigma.  Enacted stigma at the 
interpersonal level is described as bias-based negative attitudes toward stigmatized groups and 
discrimination against those groups.  Enacted stigma at the structural level can occur through the 
influence of cultural norms, governmental policies, or institutional practices and adversely 
affects stigmatized individuals’ quality of life.  Felt stigma is described as how stigmatized 
individuals perceive their socially devalued status.  Felt stigma can occur in either the presence 
or absence of enacted stigma.  Internalized stigma refers to stigmatized individuals’ adoption of 
negative attitudes and discrimination, which results from repeated exposure to enacted stigma, 
felt stigma, and/or cultural beliefs.  Anticipated stigma is described as the stigmatized 
individual’s expectation of being confronted with negative attitudes and discrimination due to 
their stigmatized marks.  In response to these processes, stigmatized individuals can experience 
individual-level affective, cognitive, behavioral, and physiological reactions as well as 
community-level exclusions.  The last domain of health is described as health-related 
consequences of the stigma processes.   
Pathways from stigmatization to health outcomes can be bidirectional or multi-directional 
among the six domains.  Due to this complexity, many studies on health-related stigma have 
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used qualitative methods.  Although health-related stigma studies using qualitative methods 
enable a better understanding of the personal, social, and/or cultural differences, these studies 
limit the examination of measurable change.  Thus, researchers are required to conduct both 
qualitative and quantitative studies on health-related stigma and associated interventions (Bos, 
Pryor, Reeder, & Stutterheim, 2013; Pryor & Reeder, 2011).  
 Research on chronic obstructive pulmonary disease (COPD) has taken note of 
psychological distress because of the close association with physical health outcomes (e.g., 
exacerbation and hospitalization) as well as quality of life (Panagioti, Scott, Blakemore, & 
Coventry, 2014; Quint, Baghai-Ravary, Donaldson, & Wedzicha, 2008).  Depression and anxiety 
are the two major symptoms of psychological distress.  These symptoms are prevalent and 
significantly associated with the poor health status of people with COPD (Frei et al., 2014; 
Panagioti et al., 2014).  Several studies have reported that stigma attached to COPD contributes 
to psychological distress and decreased quality of life (A. A. Kaptein et al., 2009; Quint et al., 
2008).  Exploratory studies have provided support for the existence of COPD-related stigma and 
its negative impact on people with the condition (Berger, Kapella, & Larson, 2011; Halding, 
Heggdal, & Wahl, 2011; Lindqvist & Hallberg, 2010).  However, little is known about how 
COPD-related stigma is defined and how a change of COPD-related stigma is measured.      
 This dissertation consists of three studies.  The overall purpose of this dissertation was to 
explore how stigma is manifested in people with COPD and to develop a reliable and valid 
COPD-related stigma scale.  The goal of the first study was to first describe the existing 
literature on stigma in people with COPD and lung cancer and summarize findings using the 
conceptual model proposed by Major et al. (2018).  Secondly the study identifies existing 
measures of COPD-related and lung cancer-related stigma.  The goal of the second study was to 
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verify the relevance of items on the 52-item preliminary COPD-related stigma scale, evaluate the 
scale’s response option, and refine the scale.  The goal of the third study was to 1) assess the 
structure of the 51-item refined COPD-related Stigma Scale, 2) evaluate the psychometric 
properties, including criterion-related validity and internal consistency reliability, and 3) examine 
the construct validity of the instrument with regard to COPD-related stigma and the 
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Stigma in COPD and Lung cancer: A Systematic Review 
 
Abstract 
Objectives: People with chronic obstructive pulmonary disease (COPD) or lung cancer 
are stigmatized by their history of smoking, but little is known about the similarities and 
dissimilarities in stigma associated with each condition.  A comparison of the two could be 
useful in advancing the science.  This systematic review aimed: 1) to compare existing literature 
on stigma in people with COPD or lung cancer and 2) to identify existing measures of COPD-
related and lung cancer-related stigma. 
Methods: We conducted a systematic search of CINAHL/PsycINFO/PubMed/Scopus 
databases for articles related to stigma in COPD or lung cancer through July 2018. We 
performed a quality assessment and synthesized findings according to concepts in the models of 
health-related stigma in people with COPD or lung cancer (Berger et al., 2011; Cataldo, 
Slaughter, Jahan, Pongquan, & Hwang, 2011). 
 Results: A total of 61 studies met criteria for review: 19 addressed stigma in people with 
COPD (3 quantitative, 13 qualitative, and 3 mixed-method) and 42 addressed stigma in people 
with lung cancer (24 quantitative, 15 qualitative, and 3 mixed-method). We identified no well-
established measures of COPD-related stigma; most of the COPD research was qualitative and/or 
employed unvalidated questions about stigma.  The most commonly used measure for lung 





People with COPD linked stigma to smoking, the diagnosis itself, symptoms of COPD (e.g., 
cough and shortness of breath) and stigma triggers such as the use of inhalers and supplemental 
oxygen. People with lung cancer linked stigma to their smoking behavior, their poor prognosis, 
and the type of death. Previous- and current-smokers reported higher levels of stigma than 
people who never smoked.  
Conclusions: People with COPD or lung cancer are similar in their perceptions of 
stigma, “they did it to themselves”.  Studies have shown that lung cancer-related stigma is 
associated with patient outcomes including increased psychological distress, poor quality of life, 
low help-seeking, poor medication adherence, and low social support.  Less is known about 
COPD-related stigma in part because there are no reliable and valid measures of COPD-related 
stigma.  It may be useful to develop a reliable and valid stigma scale specifically designed for 
people with COPD, thereby improving the clarity of conceptualizing COPD-related stigma, as 







 Studies have indicated that stigma is associated with many chronic health conditions 
(Earnshaw & Quinn, 2012; Earnshaw, Quinn, Kalichman, & Park, 2013; Van Brakel, 2006), 
which can be seen in a negative light when these conditions are associated with physical or 
mental deformities, contagious features, and/or maladaptive behaviors, like substance abuse 
(Link, Struening, Rahav, Phelan, & Nuttbrock, 1997).  Accordingly, people who suffer from 
stigmatized chronic health conditions such as leprosy, HIV/AIDS, mental illness, epilepsy, 
disability, and tuberculosis (Van Brakel, 2006) are also perceived as devalued or discreditable.  
As a result, these stigmatized individuals are more likely to be subject to delays in diagnosis 
(Van Brakel, 2006) and are less likely to access and obtain medical care for their symptoms 
(Neal, McGoldrick, & Schear, 2015).  Chronic obstructive pulmonary disease (COPD) and lung 
cancer have been identified as stigmatized chronic conditions (Berger et al., 2011; Chambers et 
al., 2012; Halding et al., 2011) in relation to a causal link to smoking.  Smoking is a significant 
risk factor for these two conditions, but not all COPD or lung cancer are caused by smoking.  
This systematic review will help researchers and clinicians have more comprehensive 
understanding the process of stigmatization in people with COPD or lung cancer as well as 
identify a knowledge gap regarding how best to approach the impact of stigma on these 
populations.        
 
Background 
 Chronic obstructive pulmonary disease (COPD) and lung cancer are prevalent respiratory 
diseases (Adeloye et al., 2015; Torre et al., 2015) and the leading causes of death worldwide.  In 





[WHO], 2017), and, in 2018, an estimated 1.76 million deaths were due to lung cancer (World 
Health Organization [WHO], 2018).  Tobacco smoking has been shown to be a major factor 
associated with the prevalence of— and high mortality in —both COPD and lung cancer.  In 
fact, in the U.S., 75% of COPD and nearly 90% of lung cancers are caused by tobacco smoking 
(U.S. Department of Health and Human Services [USDHHS], 2014, 2016), and 80% of COPD-
related deaths and more than 87% of lung cancer-related deaths are attributed to history of 
smoking (U.S. Department of Health and Human Services [USDHHS], 2014, 2017).  In addition, 
the effects of secondhand smoke cannot be ignored: among never-smokers, secondhand smoke 
exposure has been identified as a risk factor in developing COPD and lung cancer (Brennan et 
al., 2004; He et al., 2012; U.S. Department of Health and Human Services [USDHHS], 2006).  
This causal link between smoking and both diseases is the basis for stigmatizing people with 
COPD or lung cancer. 
 Smoking-related stigma has, ironically, arisen from strategies to raise social awareness 
about the harmful effects of smoking (Evans-Polce, Castaldelli-Maia, Schomerus, & Evans-
Lacko, 2015).  The 1964 Surgeon General’s report played a pioneering role in tobacco control, 
educating the general public about the negative consequences of smoking, and contributing to 
declines in overall smoking rates (Cummings & Proctor, 2014).  This report also provided the 
basis for actions such as policies on smoke-free environments, as well as smoking-cessation 
campaigns, programs, and interventions (U.S. Department of Health and Human Services 
[USDHHS], 2014).  Although these efforts reduced smoking-related disease and death, they also 
played a profound role in stigmatizing both smoking and smokers (Bell, Salmon, Bowers, Bell, 





 As a result of tobacco control actions and policies, smokers have increasingly 
encountered smoking-related discrimination in their daily lives.  In order to create a smoke-free 
environment, smoking has been restricted in public spaces and allowed only in isolated areas.  
Consequently, people who continue to smoke are more likely to be regarded as a public enemy 
and experience being shunned by non-smokers (Bell et al., 2010; Hammond, Fong, Zanna, 
Thrasher, & Borland, 2006; Kim & Shanahan, 2003).  Smokers are also forced to bear a financial 
burden due to increasing taxes on tobacco products, which can be especially stressful for low-
income smokers (Farrelly, Nonnemaker, & Watson, 2012).  Additionally, smokers can be 
rejected by their healthcare providers because of their smoking status (Bell et al., 2010; Lehto, 
2014), and, in fact, studies have shown that healthcare providers have unfavorable attitudes 
towards people with lung diseases who smoked (Bass et al., 2018; Chapple, Ziebland, & 
McPherson, 2004a) that may affect help-seeking behavior.  
 Because of the crucial role of tobacco smoking in developing COPD and lung cancer, the 
stigma attached to smoking has transferred to COPD and lung cancer themselves, and thus is 
naturally extended to people who are suffering from either of the diseases (Yanbaeva, Dentener, 
Creutzberg, Wesseling, & Wouters, 2007).  Given that smoking behavior is controllable, COPD 
and lung cancer are in turn perceived as preventable diseases, and therefore the people who 
contract them are frequently viewed as being responsible for their own condition.  Whether or 
not an individual is responsible for his or her stigmatizing condition can affect how others think 
about and behave towards that individual (Jones et al., 1984), and others’ reactions to the 
condition could be intensified by the perceived controllability of its causes (Weiner, Perry, & 





There is a growing number of empirical research on stigma associated with COPD and 
lung cancer, and studies have shown that people with COPD or lung cancer experience disease-
related stigma — due in part to the pervasive perception that their disease is self-inflicted — and 
because of this are likely to face ‘negative affective responses and behavioral judgements’ 
(Weiner et al., 1988).  Chambers et al. (2012) performed a systematic review of 15 studies and 
reported a negative aspect of stigma experiences in people with lung cancer; a recent systematic 
review built on that prior study also included four non-communicable respiratory diseases, i.e., 
lung cancer, COPD, asthma, and mesothelioma (Shiho Rose, Paul, Boyes, Kelly, & Roach, 
2017).  Of the twenty-five studies reviewed, 20 of them reported stigma experiences in relation 
to lung cancer and four reported stigma experiences associated with COPD.  This review 
reported that people with COPD or lung cancer are more vulnerable to being stigmatized than 
those with other respiratory diseases because of the strong association with tobacco smoking 
(Shiho Rose et al., 2017). 
 Studies have also identified the adverse impact of stigma-related experience on 
psychological health and health behaviors in people with COPD or lung cancer.  In both disease 
groups, stigma experiences were associated with an increased prevalence of depression and 
decreased treatment adherence and quality of life (Chambers et al., 2012; Shiho Rose et al., 
2017).  In those with lung cancer, stigma experiences were associated with increased anxiety, as 
well as a longer period between the time when subjects started to display physical symptoms or 
suspected something was wrong, and when they eventually sought medical help (Shiho Rose et 
al., 2017).  In another study that examined people with lung cancer, higher levels of lung cancer-
related stigma were significantly associated with higher levels of depression (r = 0.40, p < 0.001) 





that examined the relationship between medication adherence and health-related quality of life in 
people with COPD, perceived stigma associated with the use of inhalers was indicated as one of 
the possible factors that led to subjects failing to adhere to their medication regimens and thus 
experiencing a negative impact on their health-related quality of life (Ágh et al., 2015). 
 Although some stigma research on COPD and lung cancer has been conducted, much 
more research is needed to understand COPD-related and lung cancer-related stigma and ways to 
reduce these stigmas.  Compared to research on lung cancer-related stigma, research on COPD-
related stigma is still relatively new and therefore requires theoretical development and empirical 
investigation.  To the end, a comparison between the two stigmas would be useful to help 
researchers deepen their conceptual understanding of the stigmas themselves, as well as to codify 
their similarities and differences beyond their shared roots (i.e., smoking).  This comparison may 
help guide future research in resolving unanswered issues and challenges, such as the underlying 
logic of stigma processes, social structural involvement, and developing valid stigma measures 
(Bos et al., 2013; Dovidio, Pearson, & Orr, 2008; Hatzenbuehler, 2016).  Valid stigma measures 
would play an important role in unpacking these issues and challenges.  Therefore, the purpose 
of this study is 1) to summarize existing literature that addresses key factors in the conceptual 
model described below and 2) to identify existing measures used to examine COPD-related and 
lung cancer-related stigma. 
 
Conceptual Framework 
 This study was guided by a conceptual model that represents the effects of stigma 
processes on health (Major et al., 2018) (see Figure 2-1).  According to this model, stigma is 





group from the non-stigmatized group via social norms, and ‘stigma processes’ refer to 
individual, social, and/or structural processes that elicit distressing responses from the socially-
conferred mark.  The effect of the socially-conferred mark is influenced by a variety of 
‘moderating factors’ (e.g., dimensions of the mark, individual and environmental characteristics); 
these moderating factors play a role in determining the character, intensity, pervasiveness, and 
consequences of stigmatization (Major et al., 2018).  For example, the perception of smoking as 
a voluntary, controllable behavior has led people to perceive both COPD and lung cancer as 
being ‘self-inflicted’; this increases the severity of the stigma processes.  Stigma processes refer 
to individual, social, and/or structural processes that elicit distressing responses from the 
socially-conferred mark.   
For the purposes of this model, ‘stigma processes’ consist of four stigmas: enacted 
stigma, felt stigma (also called ‘perceived stigma’), self-stigma (also called ‘internalized 
stigma’), and anticipated stigma; these stigmas are interrelated.  Exposure to these stigma 
processes creates ‘cognitive, affective, behavioral, and physiological responses’ on an individual, 
social, and community level, all of which gradually cause deteriorating ‘health’ outcomes.  This 
conceptual model can be used to understand the stigma experiences in people with COPD or 
lung cancer, as well as to facilitate a comparison between the two stigmas. 
 
Methods 
Search strategy and eligibility criteria 
 Four electronic databases—CINAHL, PsycINFO, PubMed, and Scopus—were searched 
from 1993 through July 2018.  After consultation with a health sciences librarian, the following 





pulmonary disease’ OR ‘COPD’ OR ‘lung cancer’ OR ‘lung neoplasms.’ Stigma search terms 
included ‘social stigma’ OR ‘shame’ OR ‘stigma.’    
 Studies were included if they 1) were original studies, including either quantitative or 
qualitative designs; 2) described any findings related to stigma among COPD and lung cancer 
populations; 3) were published in English; 4) included people with COPD, irrespective of 
oxygen therapy; and 5) included people with any stage of lung cancer.  Studies that were not 
original studies, such as reviews, systematic reviews, meta-analyses or meta-syntheses were 
excluded.  Case studies, case reports, comments, letters, editorials, biographies, handbooks, 
study protocols, and treatment guidelines were also excluded.  Further, after reviewing all full-
text studies that met the inclusion criteria, the decision was made to exclude studies with only 
non-patient subjects, such as healthcare providers and the general population.  
 
Search outcome 
 The search of the four electronic databases yielded 544 studies, including 270 duplicates.  
After removing duplicates and screening titles and abstracts, 154 studies were selected for full-
text review.  Of these 154 studies, 93 were excluded for the following reasons: non-patient 
subjects, non-human subjects, and lack of focus on COPD-related or lung cancer-related stigma; 
then, 61 remained for this review (see Figure 2-2: PRISMA flow diagram 2009).   
 A data extraction form was created for this review.  Three researchers reviewed the 
included studies and extracted the following data (see Tables 2-1 and 2-2): year and location of 
publication, sample characteristics, type of study design, stigma measures, and results relevant to 
the stigma model.  The features of stigma measures used in quantitative and mixed-method 







 The methodological quality of all included studies was assessed using the Shaw et al. 
(2009) checklists (see Appendices A and B) adapted from the Downs and Black (1998) checklist 
and the Kmet, Lee, and Cook (2004) standard quality assessment criteria for evaluating original 
studies from a variety of fields.  The checklist for quantitative studies comprises 18 items with 
regard to 1) study aims, 2) study design and sample characteristics, 3) data analysis and results, 
and 4) conclusions.  Since some of the items are only applicable to randomized controlled trials, 
an N/A (i.e., not applicable) option is provided for other study designs (Kmet et al., 2004; Shaw 
et al., 2009).  The checklist for qualitative studies comprises 15 items with respect to six 
qualities: 1) study aims and context, 2) sampling, 3) data collection, 4) data analysis, 5) 
reflexivity, and 6) conclusions.  Each checklist item was graded according to the appropriateness 
and adequate description as good (2), fair (1), or poor (0).  A score was calculated for each study 
by summing the scores of all applicable items, then dividing by the total possible sum scores.  
The total possible scores would be [(18 – number of “N/A”) * 2] for quantitative studies and [(15 
– number of “N/A”) * 2] for qualitative studies (Kmet et al., 2004).  The scores were displayed 
as a percentage.      
 
Data synthesis 
 Included studies in the present review (n = 61) were grouped based on research design 
and sample characteristics into six categories (i.e., Tables 2-1-a, 2-1-b, 2-1-c, 2-2-a, 2-2-b, and 2-
2-c).  Table 2-1-a includes studies that use a qualitative design in people with COPD (n = 13); 





1-c includes studies that use a mixed-method design in people with COPD (n = 3).  Table 2-2-a 
includes studies that use a qualitative design in people with lung cancer (n = 15); Table 2-2-b 
includes studies that use a quantitative design in people with lung cancer (n = 24); Table 2-2-c 
includes studies that use a mixed-method design in people with lung cancer (n = 3).  A 
conceptual model representing the effects of the stigma processes on health (Major et al., 2018) 
was used as a framework for synthesizing the results of the included studies (see Figure 2-1).   
 
Results 
Overview of included studies 
 A total of 61 studies were included in this review.  Of those, most studies (n = 42) 
examined stigma associated with lung cancer, and the others (n = 19) examined stigma 
associated with COPD.  Of the qualitative studies (n = 28), 13 explored stigma associated with 
COPD and 15 explored stigma associated with lung cancer.  Of the quantitative studies (n = 27), 
three examined stigma associated with COPD and 24 examined stigma associated with lung 
cancer.  Of the mixed-method studies (n = 6), three examined stigma associated with COPD and 
three examined stigma associated with lung cancer.  Findings were categorized into six groups 
according to major domains of the conceptual model that represents the effects of stigma 
processes on health (Major et al., 2018): socially-conferred mark, moderating factors, stigma 
processes, individual-level responses, social/community-level exclusion, and health effects (see 
Figure 2-1).   
 





 The quality of the studies ranged from 83% to 100% for quantitative studies and from 
70% to 100% for qualitative studies.  In assessing the quality of quantitative studies (n = 27), the 
majority of them employed cross-sectional designs and four studies employed longitudinal 
designs.  Studies employed cross-sectional designs were not assessed on checklist items relevant 
only to randomized controlled trials or cohort study design.  For qualitative studies the most 
frequently unreported item was taking account of deviant or negative cases in the analysis (n = 
24, 72.7%) followed by providing a rationale for termination of data collection (n = 16, 48.5%). 
 
Domain A: Socially-conferred mark 
 In the vast majority of qualitative and quantitative studies, smoking-related stigma was 
identified as the primary source of both COPD-related stigma and lung cancer-related stigma 
(Arne, Emtner, Janson, & Wilde-Larsson, 2007; Berger et al., 2011; Berterö, Vanhanen, & 
Appelin, 2008; Bragadottir, Halldorsdottir, Ingadottir, & Jonsdottir, 2018; Brennan et al., 2004; 
Brown-Johnson et al., 2015; Brown & Cataldo, 2013; Carter-Harris, Hermann, Schreiber, 
Weaver, & Rawl, 2014; Cataldo & Brodsky, 2013; Cataldo, Jahan, & Pongquan, 2012; Cataldo 
et al., 2011; Chambers et al., 2015a; Chambers et al., 2015b; Chapple et al., 2004a; Criswell, 
Owen, Thornton, & Stanton, 2016; Dirkse et al., 2014; Earnest, 2002; Else-Quest, LoConte, 
Schiller, & Hyde, 2009; Ernst, Mehnert, Dietz, Hornemann, & Esser, 2017; Esser et al., 2017; 
Gonzalez & Jacobsen, 2012; Gysels & Higginson, 2008; Halding et al., 2011; Hamann et al., 
2014; Harrison et al., 2015; Harrison, Robertson, Goldstein, & Brooks, 2017; Jonsdottir & 
Jonsdottir, 2007; Lebel et al., 2013a; Lebel et al., 2013b; Lehto, 2014; Lindgren, Storli, & 
Wiklund-Gustin, 2014; Liu et al., 2016; LoConte, Else-Quest, Eickhoff, Hyde, & Schiller, 2008; 





Poehlman, 2016; S. Rose et al., 2018; Scott, Crane, Lafontaine, Seale, & Currow, 2015; Shen et 
al., 2015; Shen, Hamann, Thomas, & Ostroff, 2016; Simmons et al., 2009; Tod, Craven, & 
Allmark, 2008; Webb & McDonnell, 2018; J. Weiss et al., 2017; Williamson et al., 2018).  
Studies showed that the smoking-related stigma played a huge role in perceptions of both COPD 
and lung cancer as self-inflicted diseases among those with COPD or lung cancer as well as the 
general public.   
 In studies of people with COPD, in addition to the smoking-related stigma, two other 
sources of the stigma were identified, i.e., physical symptoms and associated behaviors, and the 
use of therapeutic devices.  These two sources of the stigma incurred unpleasant responses due to 
either visible signs or an underlying assumption about smoking, or both.  Physical symptoms and 
associated behaviors, as one source, included breathlessness, uncontrollable cough and phlegm, 
slow-paced walking and frequent stops while walking (Berger et al., 2011; Gysels & Higginson, 
2008; Harrison et al., 2015; Harrison et al., 2017; Hartman, ten Hacken, Boezen, & de Greef, 
2013; A. Kaptein et al., 1993; Malpass, Kessler, Sharp, & Shaw, 2015; O'Neill, 2002; Svedsater 
et al., 2017).  The use of therapeutic devices such as supplemental oxygen and inhaler were 
identified as another source of COPD-related stigma (Berger et al., 2011; Earnest, 2002; 
Goldbart, Yohannes, Woolrych, & Caton, 2013; Gupta et al., 2011; Harrison et al., 2017; 
Hartman et al., 2013; Malpass et al., 2015; Neri et al., 2006; Partridge, Dal Negro, & Olivieri, 
2011; Svedsater et al., 2017).   
 In studies of people with lung cancer, smoking-related stigma was the major source of 
lung cancer-related stigma, but cancer-related stigma also played a role in stigmatization: 
specifically, a lung cancer diagnosis is depicted as a horrible death or an incurable disease with a 





help-seeking behavior (Berterö et al., 2008; Chapple et al., 2004a; Liu et al., 2016; Pujol et al., 
2017; Rohan et al., 2016; Scott et al., 2015; Tod et al., 2008; Webb & McDonnell, 2018).  
Combined with smoking-related stigma, people with lung cancer were less likely to seek needed 
healthcare.  In some culture, people still believe the myth that lung cancer was also regarded as 
contagious (Liu et al., 2016), or it was considered to be a dirty disease because of the smoking 
behavior (Occhipinti et al., 2018; Rohan et al., 2016).   
 
Domain B: Moderating factors 
 Few studies specifically explored the moderating factors that influence characteristics of 
COPD-related or lung cancer-related stigma and its impact on health.  A study of COPD-related 
stigma (Berger et al., 2011) found that four dimensions (i.e., concealability, disruptiveness, 
aesthetics, and origin/responsibility) could be understood to influence COPD-related stigma.  
The dimension in particular to note was origin/responsibility in relation to COPD-related stigma: 
many participants explicitly put the blame for their illness on their history of smoking (Berger et 
al., 2011).  The dimension of origin/responsibility was also observed in a study of lung cancer-
related stigma (LoConte et al., 2008); in this study, past or current smoking status was associated 
with higher levels of perceived cancer-related stigma.  Almost thirty percent of respondents 
reported that their past or current behavior contributed to their disease (LoConte et al., 2008).  
 
Domain C: Stigma processes 
 Stigma processes were explored in more detail in qualitative studies than in quantitative 
studies.  In qualitative studies, all four stigmas (enacted stigma, felt stigma, self-stigma, and 





between COPD-related stigma and lung cancer-related stigma.  Enacted stigma occurred at the 
interpersonal level found in studies of both COPD-related stigma and lung cancer-related stigma, 
with respondents reporting experiences of discrimination from friends, family, acquaintances, 
and healthcare professionals (Berger et al., 2011; Bragadottir et al., 2018; Brown & Cataldo, 
2013; Chapple et al., 2004a; Gysels & Higginson, 2008; Halding et al., 2011; Hamann et al., 
2014; Harrison et al., 2015; Jonsdottir & Jonsdottir, 2007; Lehto, 2014; Liu et al., 2016; O'Neill, 
2002; Occhipinti et al., 2018; Rohan et al., 2016; Scott et al., 2015; Tod et al., 2008; Webb & 
McDonnell, 2018).  Enacted stigma occurring at the structural level was observed only in studies 
of lung cancer-related stigma; respondents indicated that little research funding was allocated for 
lung cancer compared with other cancer diseases (Chambers et al., 2015b; Chapple et al., 2004a; 
Lehto, 2014; Rohan et al., 2016; Scott et al., 2015).   
Qualitative studies of the two stigmas showed that enacted stigma was inter-correlated 
with the other three stigma processes (i.e., felt stigma, self-stigma, and anticipated stigmas).  
Thus, once individuals with COPD or lung cancer experienced negative reactions and 
discrimination in relation to the socially-conferred marks (i.e., enacted stigma), they were likely 
to experience the other three stigma processes as well (Berger et al., 2011; Bragadottir et al., 
2018; Brown & Cataldo, 2013; Chapple et al., 2004a; Halding et al., 2011; Hamann et al., 2014; 
Harrison et al., 2015; Lehto, 2014; Liu et al., 2016; Malpass et al., 2015; Occhipinti et al., 2018; 
Scott et al., 2015; Tod et al., 2008).   
 In quantitative studies, stigma processes were selectively examined to seek associations 
between the selected stigma process and psychosocial/physical health effects.  Of the four stigma 
processes, felt stigma and self-stigma were frequently examined in studies of both COPD-related 






Domain D: Individual-level responses 
 Individual-level responses (e.g., affective, cognitive, and behavioral responses) were 
explored in greater detail in qualitative studies than in quantitative studies.  In most qualitative 
studies, respondents with COPD or lung cancer similarly experienced affective responses such as 
self-conscious emotions (e.g., shame, guilt, and/or embarrassment) and negative emotions (e.g., 
anxiety, fear, regret, and/or low self-worth).  In quantitative studies, those affective responses 
were examined to demonstrate the experience of COPD-related stigma or lung cancer-related 
stigma.  In addition, those affective responses were assessed to determine the impact of these two 
stigmas on health-related outcomes [e.g., medication adherence (Gupta et al., 2011; Neri et al., 
2006), psychological adjustment (Else-Quest et al., 2009), symptom severity (Cataldo & 
Brodsky, 2013), help-seeking behavior (S. Rose et al., 2018) or quality of life (Brown-Johnson et 
al., 2015; Cataldo et al., 2012; Cataldo et al., 2011; Chambers et al., 2015a; Ernst et al., 2017; 
So, Chae, & Kim, 2017)]. 
 In qualitative studies, respondents within the two disease groups also reported similar 
cognitive responses such as hiding their diagnosis (Berterö et al., 2008; Chapple, Ziebland, 
McPherson, & Summerton, 2004b; Hamann et al., 2014; Liu et al., 2016; Occhipinti et al., 2018; 
Westerman, Sprangers, Groen, van der Wal, & Hak, 2007), ruminating on other causes of their 
disease (Arne et al., 2007; Bragadottir et al., 2018; Brown & Cataldo, 2013; Chapple et al., 
2004a; Halding et al., 2011; Lehto, 2014; Lindgren et al., 2014; Occhipinti et al., 2018; 
Westerman et al., 2007), trying to reframe their prior history of smoking (Harrison et al., 2015), 
or pretending to be independent (Berterö et al., 2008; Harrison et al., 2015) and healthy 





similar cognitive responses such as hiding their diagnosis (Gonzalez et al., 2015; Williamson et 
al., 2018) and ruminating on other causes of their diseases (Harrison et al., 2017; J. Weiss et al., 
2017). 
 In qualitative studies, respondents within the two disease groups reported both negative 
and positive behavioral responses.  Negative behavioral responses included tending to avoid 
social activities (Berger et al., 2011; Berterö et al., 2008; Gysels & Higginson, 2008; Harrison et 
al., 2015; Jonsdottir & Jonsdottir, 2007; Liu et al., 2016), non-adherence to medical treatments 
(Berger et al., 2011; Goldbart et al., 2013), and/or being less willing to seek further information 
and resources (Lindgren et al., 2014; Scott et al., 2015).  Positive behavioral responses included 
respondents attempting to quit smoking (Arne et al., 2007; Bragadottir et al., 2018; Halding et 
al., 2011) and find a support group (Webb & McDonnell, 2018) or expressing interest in playing 
an advocacy role (Hamann et al., 2014).  Few quantitative studies explored behavioral responses 
in reaction to stigma processes.  Negative behavioral responses such as non-adherence with 
medical treatments were identified in respondents with COPD (Gupta et al., 2011; Neri et al., 
2006).   
 Some differences in individual-level responses between COPD-related stigma and lung 
cancer-related stigma were identified in qualitative studies.  Respondents with lung cancer 
reported fear of death or therapeutic nihilism, due to the public perception of the tragic death but 
self-inflicted disease in lung cancer (Berterö et al., 2008; Pujol et al., 2017; Tod et al., 2008) and 
others’ incredulous reactions to their survival which made them feel unwelcomed (Rohan et al., 
2016).  Respondents with COPD, on the other hand, were relatively optimistic about their 







Domain E: Social/Community-level exclusion 
 A few studies explored social/community-level exclusion.  As for similarities, 
respondents in the two diseases were affected by healthcare providers’ negative reactions to their 
history of smoking (Berger et al., 2011; Chapple et al., 2004a; Hamann et al., 2014; Webb & 
McDonnell, 2018).  When smoking-related stigma existed, those respondents were more likely to 
keep their distance from healthcare providers and/or less likely to be involved in treatment 
decision-making.   
 As for differences, respondents with COPD tended to avoid social activities so that they 
could control their limitations (Berger et al., 2011; Gysels & Higginson, 2008; Halding et al., 
2011; Jonsdottir & Jonsdottir, 2007); while those with lung cancer tended to express a sense of 
grievance against a perceived inadequacy of existing social support and resources such as lack of 
research funding for lung cancer compared to other cancer groups (Chambers et al., 2015b; 
Chapple et al., 2004b; Hamann et al., 2014; Lehto, 2014; Occhipinti et al., 2018; Rohan et al., 
2016; Scott et al., 2015; Webb & McDonnell, 2018).   
 
Domain E: Potential health effects 
 Both COPD-related stigma and lung cancer-related stigma had similar health effects.  In 
qualitative studies, stigma in the two diseases hindered respondents from seeking help for their 
diseases (Arne et al., 2007; Bragadottir et al., 2018; Chapple et al., 2004a; Halding et al., 2011; 
Harrison et al., 2015; Harrison et al., 2017; Jonsdottir & Jonsdottir, 2007; Scott et al., 2015; Tod 
et al., 2008).  A quantitative study showed that lung cancer-related stigma was significantly 





Harris et al., 2014); in a similar way, both COPD-related and lung cancer-related stigma were 
barriers to respondents engaging in disease-related health interventions (Chambers et al., 2015b; 
Harrison et al., 2015) and following treatment recommendations (Ernst et al., 2017; Goldbart et 
al., 2013; Gupta et al., 2011; Hartman et al., 2013; Neri et al., 2006; Simmons et al., 2009).   
 
Stigma measures 
 Across the quantitative and mixed-method studies, a variety of scales were used to 
measure levels of stigma in people with COPD or lung cancer (see Table 2-3).  There is no 
established scale to measure COPD-related stigma; as such studies tend to use a set of items that 
reflect COPD-related stigma.  For example, some studies used items about attitudes toward the 
use of medication device (e.g., inhaler or supplemental oxygen) (Gupta et al., 2011; Neri et al., 
2006; Partridge et al., 2011).  Another study used a set of items that ask about the perceived 
social consequences of having respiratory diseases for the purpose of measuring the quality of 
life (A. Kaptein et al., 1993).  Only one study measured self-conscious emotions with regard to 
COPD-related stigma using a set of scales, including the Brief Fear of Negative Evaluation 
Scale, the Shame and Guilt Scale, and the Self-Compassion Scale (Harrison et al., 2017).   
 In studies of lung cancer-related stigma, the Cataldo Lung Cancer Stigma Scale was the 
most frequently used (Brown-Johnson et al., 2015; Carter-Harris et al., 2014; Cataldo & 
Brodsky, 2013; Cataldo et al., 2012; Cataldo et al., 2011; Chambers et al., 2015a; Chambers et 
al., 2015b; S. Rose et al., 2018; Shen et al., 2016), though the Social Impact Scale was also 
frequently used (Ernst et al., 2017; Esser et al., 2017; Gonzalez & Jacobsen, 2012; Gonzalez et 
al., 2015; Schroyen et al., 2017a; Schroyen et al., 2017b).  The State Shame and Guilt Scale, the 





in several studies, and some studies used a set of items independently developed by the 
investigators to measure lung cancer-related stigma (Else-Quest et al., 2009; Lebel et al., 2013a; 
Lebel et al., 2013b; LoConte et al., 2008; J. Weiss et al., 2017).  The Cataldo Lung Cancer 
Stigma Scale is the only scale that was developed and psychometrically tested for measuring 
lung cancer-related stigma (Cataldo et al., 2011).   
 
Discussion 
 With this systematic review, we identified similarities between COPD-related stigma and 
lung cancer-related stigma.  Smoking-related stigma was involved in the development of these 
two stigmas, and some shared similarities were also found in domains such as stigma processes, 
individual-level responses, social/community-level exclusion, and potential health effects.   
 Similarities notwithstanding, it is of note that no research examined these two stigmas 
together.  Specifically, COPD-related stigma was investigated individually in most instances and 
was only examined in conjunction with asthma in a few studies.  However, lung cancer-related 
stigma was frequently studied and compared with stigmas in other cancer groups.  Many studies 
pointed out that cancer-related stigma, irrespective of cancer type, is associated with poor 
psychological symptom adjustment (Else-Quest et al., 2009; Esser et al., 2017; Gökler-
Danışman, Yalçınay-İnan, & Yiğit, 2017; Lebel et al., 2013a; Schroyen et al., 2017a; Schroyen 
et al., 2017b; So et al., 2017) and an increased risk of negative effects on cancer treatment and 
recovery (Simmons et al., 2009).  Several studies demonstrated higher levels of lung cancer-
related stigma than those of other cancer groups, such as those with head and neck cancer (Lebel 
et al., 2013a; Lebel et al., 2013b) and those with breast, prostate, or colon cancers (Ernst et al., 





 One of the major differentiating factors between COPD and lung-cancer related stigma is 
a more generalized stigma relating specifically to cancer.  Cancer-related stigma stems from an 
age-old notion that cancer is regarded as a death sentence and in certain societies that is further 
compounded by a myth that cancer is a form punishment in (Daher, 2012) and/or a belief that 
cancer is a consequence of one’s behavior, such as smoking, obesity, unsafe sex, or sedentary 
lifestyle (Lebel & Devins, 2008).  With those socio-cultural backgrounds, lung cancer has a 
universal image of a life-threatening disease, along with that of a self-inflicted disease due to a 
causal link to smoking behavior, which forms a unique characteristic of lung cancer-related 
stigma.  Thus, certain issues between people with lung cancer and their family members—as 
well as healthcare providers—have been reported: for example, lung cancer-related stigma might 
lead to patients’ therapeutic nihilism (Chambers et al., 2012) and negatively affected clinicians’ 
referral patterns (Wassenaar et al., 2007).  Given that early detection and prompt treatment can 
be an important factor that determines the outcomes of lung cancer treatment, lung cancer-related 
stigma should be resolved by a comprehensive approach including changing cultural beliefs 
(Rigney, Studts, & Criswell, 2017).   
 Although smoking is one of the sources of COPD-related stigma—as it is with lung 
cancer-related stigma—this review also found two unique, COPD-specific stigma sources: 
physical symptoms and associated behaviors, as well as the use of therapeutic devices.  These 
sources of COPD-related stigma are similarly found in stigma research for chronic illnesses such 
as inflammatory bowel disease (IBD) and diabetes mellitus (Schabert, Browne, Mosely, & 
Speight, 2013; Taft & Keefer, 2016).  People with IBD have experienced feelings of shame and 
embarrassment from symptoms (e.g., abdominal pain, fatigue, diarrhea, etc.) and ostomy (e.g., 





2016);  people with diabetes, either type 1 or type 2, experience stigma from daily insulin 
injections and/or perceptions that diabetes results from a poorly managed diet and weight 
(Browne, Ventura, Mosely, & Speight, 2013, 2014).  COPD-related stigma should be assessed 
and considered in line with the individual treatment plan, as perceived stigma experiences may 
discourage people with chronic illnesses, including COPD, from actively engaging in medical 
care and adherence to treatment protocols (Disler, Gallagher, & Davidson, 2012). 
 This systematic review showed a remarkable difference in measures between COPD-
related stigma and lung cancer-related stigma.  Whereas a validated scale has been used to 
measure the phenomenon of lung cancer-related stigma, to our knowledge, there is no validated 
scale to measure the phenomenon of COPD-related stigma.  Much remains to be done in 
developing measures for the phenomenon of COPD-related stigma.   
Based on these findings, more research—such as interventional studies—is needed to 
lessen the adverse impact of lung cancer-related stigma on quality of care and health outcomes.  
Available studies of COPD-related stigma are more limited than those of lung cancer-related 
stigma.  Qualitative studies in this review have described the presence of stigma-related 
perceptions and experiences in people with COPD, with strong consistency across these studies.  
It is, nevertheless, challenging to assess the extent of COPD-related stigma and its potential 
effects on health due to a dearth of scales of COPD-related stigma.  These results, taken together, 
suggest a greater need for more research with valid measures.   
 
Limitations 
 This systematic review provided an overview of stigma experiences from people with 





of this comparison are strengthened by integrating both quantitative and qualitative studies.  
Several limitations should be considered when interpreting the findings from this systematic 
review: first, although the included studies of this review were results from the systematic 
search, only studies published in English were taken into account, which might limit the scope of 
our results.  Moreover, this systematic review excluded studies that invited only non-patient 
groups (e.g., general populations, healthcare providers, or caregivers) to explore COPD-related 
or lung cancer-related stigma.  Thus, it might be possible that relevant findings from other 
sources were not captured.  Second, a conceptual model representing the effects of stigma 
processes on health (Major et al., 2018) was employed as a framework for synthesizing the 
results of the included studies: this method facilitates the assessment of the present state of 
COPD-related stigma and lung cancer-related stigma individually and simultaneously.  However, 
the findings may have been affected by selection bias in the process of the synthesis.  Third, 
studies on stigma experiences may be susceptible to a social desirability response bias, which 
may limit the strengths of the self-reported results of included studies in this systematic review.   
 
Conclusion 
 Although some stigma research on COPD and lung cancer has been conducted, much 
more research is needed to understand both lung cancer and COPD-related stigma and ways to 
reduce these stigmas. Studies in this systematic review focused on identifying the impact of the 
two stigmas on individuals’ psychological health and quality of life.  The stigma processes for 
both diseases evoked negative responses that may affect health behaviors and quality of life in an 
undesirable way.  Although there are many similarities between COPD-related stigma and lung 





related stigma comes into play with both stigmas, so blame attached to smoking is prominent in 
those with COPD or lung cancer and while lung cancer-related stigma is also associated with 
cancer-related stigma, COPD-related stigma is shaped by the visibility of symptoms and 
medication devices.  However, studies in this review could not explain why some people with 
lung cancer or COPD are stigmatized and others are not.  Understanding what makes it different 
could be an important step in demonstrating the pathway from stigma processes to health.  Since 
there is no valid measure of COPD-related stigma, research on the development of a valid 
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Figure 2-1. A conceptual model of the effects of stigma processes on health. Adapted from 
“Stigma and its implications for health: introduction and overview.” by B. Major, J. F. Dovidio, B. 
G. Link, and S. K. Calabrese, 2018, The Oxford handbook of stigma, discrimination, and health, 







Figure 2-2. PRISMA 2009 Flow Diagram. Adapted from “Preferred reporting items for 
systematic reviews and meta-analysis: The PRISMA Statement,” by D. Moher, A. Liberati, J. 










Research Aim Sample Design and 
Measures 





































COPD who use 
long-term 
supplemental 
oxygen (N = 27) 
 







of a case-series 
 
- Pulmonary 
function test using 
the ENACT 
AirWatch device 
- Brief Symptom 
Inventory 





































oxygen need to 
rethink their 
social roles and 
status within the 
family and 
community in a 
different way. 
Self-stigma can 



















programs (N = 
21) 
 




never (n = 3); 
former or 







































Research Aim Sample Design and 
Measures 


























Arne et al. 
(2007), 
Sweden 











COPD or with 
suspected 
COPD (N = 10) 
 




never (n = 0); 
former (n = 6); 

































NA Self-stigma can 













COPD who had 
relapsed to 
smoking three 
or more times 
(N = 7) 
 














- from their 
healthcare 
professionals 











- little self-worth  
- anger, sorrow, 











NA Due to enacted 
stigma, subjects 
can be reluctant 
to seek help 









Research Aim Sample Design and 
Measures 


























odor in order 





















(N = 18) 
 















in relation to 





























his family doctor 























(N = 16) 
 




never (n = 0); 
former or 

























































































Research Aim Sample Design and 
Measures 




























stigma   













- Subjects work 













not to cause 
any 
inconvenience. 
- Subjects avoid 
using oxygen in 
front of others. 
- due to high 
health 
insurance costs 















life in a society 




COPD (N = 18) 
 




never (n = 2); 
former (n = 11); 














- from their 
society 




Felt stigma:  
- Subjects felt 





- felt being 
exiled in the 
world of the 
healthy 
- felt they do not 
receive the 
anticipated 
support in their 
social circles  
Social support 
from their social 
circle is reduced 
















Research Aim Sample Design and 
Measures 






























- Subjects felt 
unfairly treated 




- Subjects felt 
they are no 
longer a 
member of a 
healthy society. 
- Subjects work 










































on the long-term 
i) People with 



















- oxygen  
Enacted stigma: 
- from a club 
secretary 






















Research Aim Sample Design and 
Measures 




















































COPD (N = 8) 
 
Age (range) = 
60-74 yrs  
 
Smoking status: 
never (n = 0); 
former (n = 7); 








COPD as a self-
inflicted disease 
 
The notion that 
people with 
COPD are 
labeled as a 
smoker 
Felt stigma: 
- Subjects felt 










dignity tend to 
be threatened 
when physically 







- guilt and 
shame 











as a COPD 
patient. 
- Subjects hide 
and isolate 
themselves 













Research Aim Sample Design and 
Measures 




































To explore how 
patients who 














with an acute 
exacerbation 
COPD (N = 6) 
 




never (n = 0); 
former (n = 5); 




















- During acute 
exacerbation of 
COPD, subjects 
are more likely 












































impact of the 

















Research Aim Sample Design and 
Measures 




























- To avoid 
others’ 
judgment, 
subjects tend to 
isolate 
themselves. 
disease even in 






- Subjects are 













in people with 





part in an 8-
week MBCT 
course 
i) Asthma (n = 
6) 


























- oxygen  
- cane  
Enacted stigma: 
























- Subjects rush 
themselves to 
do the next 
thing to hide 


























Research Aim Sample Design and 
Measures 








































never (n = 26); 
former (n = 8); 
current (n = 5) 
 
ii) COPD (n = 
33) 
 




never (n = 15); 
former (n = 13); 
current (n = 5) 
 
Clinical experts 
(n = 4) 
- Disease severity 
using either the 
Asthma Control 
Test or the COPD 
Assessment Test 



































To gain a better 
understanding 
of having COPD 
from the lived 
experience for 
patients and 
their families  
i) People with 
COPD (n = 22)  
 




never (n = 1); 
former (n = 17); 














































Research Aim Sample Design and 
Measures 


























ii) Families (n = 
15) 
make subjects 
feel devalued.  
 
Self-stigma: 
- Some subjects 
think about 
themselves as 











- regret (about 










COPD such as 
nicotine 
addiction. 











- Subjects try to 
quit smoking. 
Note. Pathway from Stigma in COPD or Lung cancer to health*: Findings are organized by domains in a conceptual model representing the effects of the stigma 



































F. Potential Health Effects 











COPD) on the 
quality of life 
of the patient 
People with 
asthma or COPD 
(n = 274) 
 










- Lung function using a 
Spirometry 
- Quality of life using a 
set of six subscales 
comprised of valid 
instruments 
i) Anxiety, depression, 
and sleep disorders 
using the Symptom 
Check List 
ii) Optimism and Stigma 
using the Respiratory 
Illness Opinion Survey 
iii) Activity Daily Living 
- Symptoms (dyspnea, 











like to be 
absent from 
work. 
NA An increased stigma level 
was significantly 
correlated with an 
increased risk of absence 
from work.  










therapy in a 
large group of 
People using 
oxygen (N = 1504) 
- COPD (n = 1041) 
 









- Demographic and 
clinical information 
- Oxygen utilization 


















NA Of those who possess a 
portable oxygen device, 
only 40% of them used it 



































F. Potential Health Effects 








- Interstitial lung 
disease (n = 169) 
- Fibrosis post-TB 
(n = 142) 
- Bronchiectasis (n 
= 89) 
- Cancer (n = 50) 
- Kyphoscoliosis (n 
= 43) 
- Obesity (n = 62) 
- Obstructive sleep 
apnoea (n = 44) 
 - Neuromuscular 
disease (n = 8) 
developed by 
investigators 
Gupta et al. 
(2011), 
India 














People with COPD 
(n = 1276) 
 












- Potential attitudes, 
beliefs, and perceptions 
























NA i) Most subjects, those 
with COPD (86.8%) and 
the general public 
(84.2%), agreed that 
inhaler use regarded as a 
social stigma.  
 
ii) Most subjects, those 
with COPD (89.5%) and 
the general public 
(87.8%), agreed with 
inhibition for inhaler use in 
public.  
 
iii) Most subjects, those 


































F. Potential Health Effects 
affected by Stigma 
Processes 
the general public 
(93.3%), preferred to keep 
the inhaler use a secret. 
Note. Pathway from Stigma in COPD or Lung cancer to health*: Findings are organized by domains in a conceptual model representing the effects of the stigma 








Research Aim Sample Design and 
Measures 
Pathway from Stigma in COPD to health* 
A. Socially-
conferred 




































To gain an 










People with asthma 
(n = 1022) or COPD 
(n = 719) 
 
Age (mean): 
- asthma = 36.7 yrs  
- COPD = 62.4 yrs 
 
Smoking status: 
former or current 
smokers (%) 
- asthma = 54% 





i) Qualitative phase 
- in-depth individual 
interviews (n = 120) 
 
ii) Quantitative phase 
- A 47-item 
questionnaire based 
on the qualitative 
interviews 
- Asthma control 
using the Asthma 
Control 
Questionnaire 





- inhaler and 
oxygen  



















People with mild to 
severe COPD (N = 
115) 
 
Age (mean) = 65 yrs 
 











- Physical activity 

































Research Aim Sample Design and 
Measures 
Pathway from Stigma in COPD to health* 
A. Socially-
conferred 


































- Pulmonary function 
using a spirometer 
- Dyspnea using the 
MMRC 
- Exercise capacity 







i) To gain an 
understanding 






















People with COPD  
 
i) Qualitative phase  
– COPD only (n = 
15) 
Age (mean) = 73 yrs 
Smoking status: 
never (n= 0); former 
(n = 13); current (n = 
2) 
 
ii) Quantitative phase  
- COPD (n = 70) 
Age (mean) = 70.8 
yrs 
Smoking status: 
never (0%); former 
(94.3%); current 
(5.7%)  
- Healthy control (n = 
63) 










ii) Quantitative phase  
- Self-conscious 
emotions (using the 
Brief Fear of 
Negative Evaluation 
Scale, the Shame 
and Guilt scale, and 
the self-compassion 


































- rumination (on 
causes of 
COPD) 













NA Tend to delay 
medical care 




























Research Aim Sample Design and 
Measures 
Pathway from Stigma in COPD to health* 
A. Socially-
conferred 































- Self-efficacy (using 
the Pulmonary 
rehabilitation 
adapted index of 
self-efficacy) 
- Psychological 
symptoms (using the 
HADS) 




higher levels of 
shame and 
lower levels of 
pride as well 





Note. Pathway from Stigma in COPD or Lung cancer to health*: Findings are organized by domains in a conceptual model representing the effects of the stigma 









Research Aim Sample Design and 
Measures 
Pathway from Stigma in COPD or Lung cancer to health* 
A. Socially-
conferred mark 


































people with lung 
cancer 
People with 





















- gasping for air 
- high death 
rate 
- a horrible 
death 
Enacted stigma  
- from 
acquaintances 






















turned away  
- felt upset 
when looking at 
lung cancer 
patient’s image 









- Subjects work 
on finding 
alternative 
causes of lung 











- due to 
smoking 
 
Lung cancer is 
less likely to be 








can be a barrier 








Research Aim Sample Design and 
Measures 
Pathway from Stigma in COPD or Lung cancer to health* 
A. Socially-
conferred mark 























- Subjects do 
not want to join 
a support group 
due to fear of 
stigma. 
Chapple et 
al. (2004b),  
United 
Kingdom 







benefits of people 
with lung cancer 
People with 















- Subjects do 












- Subjects do 
not want to be 








feelings (to look 














you tired?”), and 
to search for 
People newly 
diagnosed with 
small cell lung 
cancer (N = 23) 
 










quality of life 














- Subjects tend 









Research Aim Sample Design and 
Measures 
Pathway from Stigma in COPD or Lung cancer to health* 
A. Socially-
conferred mark 

































- Individual quality 













and pretend to 




- Subjects do 
not want to be 













symptoms of lung 
cancer 
People with 
lung cancer (N 
= 20) 
 




status: never (n 
= 3); former (n 









- cancer is 




















changes in the 
image of 




- fear of death 
and a cancer 
diagnosis 
- blame with 

















Research Aim Sample Design and 
Measures 
Pathway from Stigma in COPD or Lung cancer to health* 
A. Socially-
conferred mark 








































To gain an insight 
of the impact of a 
diagnosis of 
inoperable lung 
cancer on the 
patients’ life 
situation and 
quality of life 
People with 
inoperable lung 
cancer (N = 23)  
 










Interviews using a 
general interview 
guide 
- Quality of life 




- cancer is 




















- fear of death 







- Subjects tend 
to conceal their 
diagnosis. 
- Subjects do 
not want to be 
labeled as a 
lung cancer 












Research Aim Sample Design and 
Measures 
Pathway from Stigma in COPD or Lung cancer to health* 
A. Socially-
conferred mark 

























- Subjects limit 
their social 
activities. 

























i) People with 
lung (n = 10) or 
head/neck 
cancer (n = 10) 
 





(n = 10); 









































- shame and 
guilt 
- fear of being 
































Research Aim Sample Design and 
Measures 
Pathway from Stigma in COPD or Lung cancer to health* 
A. Socially-
conferred mark 





































ii) to examine 
how participants 
discursively 












status: never (n 











- from their 
healthcare 
professionals 















- Subjects feel 
that they are 
differently 








people who do 















- Subjects work 
on finding 
alternative 










Research Aim Sample Design and 
Measures 
Pathway from Stigma in COPD or Lung cancer to health* 
A. Socially-
conferred mark 





























To determine the 
main themes of 
lung cancer-
related stigma to 
provide a 
blueprint for item 
development  
People with 






status: never (n 
= 19); former (n 
= 32); current 


















































- Subjects try to 
inform others 
that they are 
not smokers. 
- Subjects tend 





























Research Aim Sample Design and 
Measures 
Pathway from Stigma in COPD or Lung cancer to health* 
A. Socially-
conferred mark 































































lung cancer (N 
= 11) 
 



























- feel alienated 
- uncomfortable 










Lung cancer is 







health could be 
worsened. 













Research Aim Sample Design and 
Measures 
Pathway from Stigma in COPD or Lung cancer to health* 
A. Socially-
conferred mark 























relative to the role 






























they had made 
different 
choices. 
- Subjects work 
on finding 
alternative 
causes of lung 
cancer. 
Scott et al. 
(2015), 
Australia 
To explore the 
attitudes and 
beliefs of people 
with lung cancer 
and general 
practitioners (GP) 
in relation to 
stigma as a 
barrier to the 
diagnosis of lung 
cancer 
i) People with 
lung cancer (n 
= 20) 
 




status: never (n 
= 7); former (n 
= 13); current 











- cancer is 




- from their 
healthcare 
professionals 















- Subjects are 
hesitant to seek 
medical advice 
Lung cancer is 









can be a barrier 
to the diagnosis 








Research Aim Sample Design and 
Measures 
Pathway from Stigma in COPD or Lung cancer to health* 
A. Socially-
conferred mark 





























seeking help for 
symptoms due 
to smoking-
related stigma.  














Liu et al. 
(2016), 
China 





with lung cancer 
in China 
People with 
lung cancer (N 
= 17) 
 















- cancer is 
regarded as a 
death sentence 
- lung cancer is 




















- guilt and 
shame 
- a sense of 
loss and self-
abasement 
- feelings of 
inferiority 














ability to work 
Shamefulness 

















Research Aim Sample Design and 
Measures 
Pathway from Stigma in COPD or Lung cancer to health* 
A. Socially-
conferred mark 

























of lung cancer 
- decreased 
ability to work 
- difficulties in 
caring for self 
and family 
- hair loss and 
deteriorated 
























- Subjects tend 
to conceal their 
disease or 
diagnosis. 
- Subjects seek 
explanations to 
give to others 
that lung 
cancer is not an 
infectious 




- Subjects often 
limit their social 
activities. 
















ii) to make 
recommendations 
to better serve 
People with 
lung cancer (N 
= 21) 
 




status: never (n 
= 4); former (n 












- cancer is 
regarded as a 
death sentence 
 - lung cancer 




- from general 
community 
- from their 
healthcare 
professionals 










- self-blame  
- worthless 
Lung cancer is 














Research Aim Sample Design and 
Measures 
Pathway from Stigma in COPD or Lung cancer to health* 
A. Socially-
conferred mark 























this population of 





















To gain an insight 
of preconceptions 
about lung 






lung cancer (N 
= 23) 
 
















- lung cancer is 




















- guilt and 
shame 























Research Aim Sample Design and 
Measures 
Pathway from Stigma in COPD or Lung cancer to health* 
A. Socially-
conferred mark 









































people with lung 






i) People with 
lung cancer (n 
= 16) 
 















- smoking is 
























behavior that is 
regarded as a 
dirty and 
disgusting act, 
which leads to 
Affective 
responses: 
- shame and 
guilt 
- self-blame 
- disgust with 






- Subjects tend 
to conceal their 
diagnosis. 
- Subjects try to 
inform others 
that they are 
non-smokers. 
- Subjects work 
on finding 
alternative 
causes of lung 
cancer. 
Subjects 
















Research Aim Sample Design and 
Measures 
Pathway from Stigma in COPD or Lung cancer to health* 
A. Socially-
conferred mark 





































To gain a better 
understanding of 





of living with lung 
cancer, and their 
desire and ability 






lung cancer (N 
= 18) 
 




status: never (n 
= 2); former (n 
= 12); current 

















- cancer is 
















must be dying 



















- Subjects look 




get a better 
understanding 




















Note. Pathway from Stigma in COPD or Lung cancer to health*: Findings are organized by domains in a conceptual model representing the effects of the stigma 
processes on health (Major et al., 2017); EORTC QLQ-C30: the European Organization for Research and Treatment of Cancer Core Quality of Life Questionnaire; 



































F. Potential Health 






i) to gauge the 














their cancer  
People with 
stage IV 
NSCLC (n = 
96)  




(n = 8); 
former (n = 
77); current 




(n = 30) 





cancer (n = 
46) 








- Social support  
- Health status 




- Depression using 
the CES-D 
- Shame and guilt 
using the State 
Shame and Guilt 
Scale 
- Perceived cancer-
related stigma using 6 





Felt stigma Affective: 




NA i) The perceived cancer-
related stigma level was 
significantly higher in 
people with lung cancer 
(score = 1.93) than other 
cancers (score = 1.45). 
 
ii) People who identified 
that their behavior 
contributed to their 
cancer showed higher 
levels of shame, guilt, 
depression, and anxiety, 
irrespective of cancer 
type. 
 
iii) A history of smoking 
correlated with 
increased levels of guilt 
and shame, irrespective 
of cancer type. 
 
iv) Among people with 
lung cancer, current and 
former smokers showed 
higher levels of guilt and 
shame as well as 
perceived lung cancer 
stigma than never 
smokers. 


































F. Potential Health 














people with lung, 




NSCLC (n = 
96)  







(n = 30) 





cancer (n = 
46) 







- Perceived stigma 
using a one-item 
developed by 
investigators  
- Self-blame using the 
State Shame and 
Guilt Scale 
- Self-esteem by 
Rosenberg Self-
Esteem Scale 




- Anger using the 
Spielberger State-
Trait Anger Inventory 
- Depressed affect 
using the CES-D 
- Causal attributions 













NA i) Compared to people 
with other cancers, 
those with lung cancer 
showed significantly 
higher agreement with a 
statement ‘My behavior 
contributed to my 
cancer,’ i.e., internal 
causal attributions. 
 





esteem, anxiety, anger, 
and depressed affect).  
 






of cancer type.  
 
iv) Self-blame mediated 
the link between 
perceived stigma and 
psychological 
adjustment, irrespective 


































F. Potential Health 






To develop an 
instrument of 
perceived stigma 
by people with 
lung cancer 
based on the HIV 
Stigma Scale and 
evaluate the 
psychometric 




(n = 186) 
 





(n = 39); 
former or 




sectional study using 
psychometric analysis 
 
- Cataldo Lung 
Cancer Stigma Scale 
(CLCSS) 
- Self-esteem using 
The Rosenberg Self-
Esteem Scale 
- Depression using 
CES-D 
- Social support and 
social conflict using 
The Social Support 
indices from the Multi-
center AIDS Cohort 
Coping and Change 
Study 
- Quality of life using 









Felt stigma Affective: 


















depression (r = 0.62), 
social conflict (r = 0.62), 
and decreased quality of 
life (r = - 0.62), self-
esteem (r = - 0.72), and 
social support (r = - 







i) to examine the 
relationship of 
lung cancer 
stigma (LCS) with 
depression and 
QOL  






(n = 190) 
 










- Smoking status 
- Lung cancer stigma 
using the CLCSS 





Felt stigma Affective 
- depression 




depression (r = 0.68) 
and decreased quality of 
life (r = - 0.65). 
 
ii) After controlling for 
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former (n = 
130); current 
(n = 21) 
- Quality of life using 
the Quality of Life 
Inventory 
status, and depression, 
lung cancer stigma has 
a significant and unique 
contribution to the 













in people with 
lung cancer  
People with 
NSCLC 
(Stage II - IV) 
(n = 95)  
 





(n = 12)); 
former (n = 
68); current 







- Stigma using the 
Social Impact Scale 
- Avoidant coping 
using the 6-item 
Cognitive Avoidance 
Subscale of the 
Coping Responses 
Inventory 
- Social support using 









using the CES-D 
- History of 




Felt stigma Affective 
- depression 
NA Felt stigma is 
significantly positively 
associated with 
depression in people 
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mood episode section 
of the Structured 







To examine the 
relationship of 






(n = 144) 
 





(n = 30); 
former and 







- Lung cancer stigma 
using the CLCSS 
- Anxiety using the 
Spielberger State 
Anxiety Questionnaire 
- Depression using 
the CES-D 
- Symptom severity 






Felt stigma Affective 
- anxiety 
- depression 
NA i) Among people with 
lung cancer, there is a 
strong positive 
relationship between 
lung cancer stigma and 
anxiety (r = 0.41), 
depression (r = 0.56), 
and the lung cancer 
symptom severity (r = 
0.48).  
 
ii) After controlling for 
age, anxiety, and 
depression, lung cancer 
stigma has a unique and 







To examine the 
association of 
stigma with (i) 
distress and (ii) 
subjective well-
being in lung or 
head and neck 
cancer from the 




(n = 107) 
 












- Psychosocial impact 
of stigma using the 
Affect Balance Scale 
and the CES-D 


















NA i) People with lung 
cancer showed higher 
levels of self-blame than 
those with head and 
neck cancer. 
 
ii) After controlling for 
stressful life events, 
higher levels of stigma is 
significantly correlated 
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(n = 99) 
 




as a questionnaire 
- Illness intrusiveness 
using the Illness 
Intrusiveness Ratings 
Scale 
- Benefit finding using 
the Post-Traumatic 
Growth Inventory 
- Self-blame using a 
rating scale 








iii) Subjects who 
reported limited reliance 
on benefit finding 
reported decreasing 
subjective well-being 
with increasing stigma; 
whereas subjects who 
reported more reliance 
on benefit finding 
reported that their 
subjective well-being 






i) to describe 
Positive Health 
Changes (PHCs) 
in survivors of 
lung or head and 
neck  
ii) to determine 
whether 
behavioral self-




(n = 107) 
 


















- Positive health 
changes using a 2-
item indicator 
- Behavioral self-
blame using a rating 
scale  
- Stigma using the 
Explanatory Interview 
Catalogue as a 
questionnaire  
- Sociodemographic 




















NA i) People with lung 
cancer showed 
significantly higher self-
blame than people with 
head and neck cancer. 
 
ii) Subjects who reported 
self-blame were more 
likely to adopt more 
positive health changes 
than those who did not 
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neck cancer 
(n = 99) 
 
















ii) to explore 
whether lung 
cancer stigma has 
a unique 
contribution to the 
explanation of 
QOL 
iii) to determine 
whether study 




(n = 149) 
 





(n = 30); 
former and 







- Stigma using the 
CLCSS 
- Anxiety using the 
Spielberger State 
Anxiety Questionnaire 
- Depression using 
the CES-D 
- Quality of life using 










NA i) There was a significant 
negative relationship 
between lung cancer 
stigma and quality of life. 
 
ii) After controlling for 
significant covariates, 
lung cancer stigma had 
a significant and unique 
role in explaining the 
quality of life. 
 
iii) Lung cancer stigma, 
depression, anxiety, and 
quality of life did not 





To gain an insight 
of i) the impact of 
stigma on lung 
cancer patients’ 
psychological 
distress and QOL 






(n = 151) 
 












distress using the 





Felt stigma Affective 
- anxiety 
- depression 
NA Stigma and shame were 
positively associated 
with global distress and 
negatively associated 
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mediators of the 
effect 
former and 
current (n = 
125) 




- Stigma using the 
CLCSS 
- Social constraints 
using the Social 
Constraints Scale 
- Threat and 
Challenge appraisal 






















(n = 117) 
 





never (n = 
26); former 
and current 








- Clinical information 
- Diagnosis 
concealment using a 
brief self-report 
measure 
- Coping strategies 
using the Coping 
Responses Inventory 






















by 26% of 
subjects) 
 
NA i) Those who concealed 
their diagnosis reported 
a significantly higher 
frequency of drinking 
alcohol than those who 
did not conceal. 
 
ii) Those who concealed 
their diagnosis reported 
significantly higher 
internalized shame 
related to lung cancer 
diagnosis than those 
who did not conceal. 
 
iii) Those who used 
positive reappraisal as a 
coping strategy were 
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- Trait social anxiety 
and social avoidance 
using the Liebowitz 
Social Anxiety Scale 
- Social support using 
the Enhancing 
Recovery in Coronary 
Heart Disease 
- Anxiety and 
depression using the 
Hospital Anxiety and 
Depression Scale 
- Cancer-specific 
distress using the 22-
item intrusion 
subscale of the 
Impact of Events 
Scale-Revised 
- Self-esteem using 
the Rosenberg Self-
esteem Scale 
- Stigma using the 
Social Impact Scale 
to conceal their 
diagnosis. 








as a potential 







(n = 141) 
 
































ii) Post-traumatic growth 
(positive experience 
related to cancer) could 
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ii) to determine 
whether these 
relationships differ 




Hospital Anxiety and 
Depression 
- Stigma using the 




growth using the 
Posttraumatic Growth 
Inventory 
- Smoking status and 




for those who quit 
smoking after lung 
cancer diagnosis.  













(n = 231) 
 





(n = 60); 
former (n = 
149); current 






- Demographic and 
clinical information 





Subscale (6 items) of 
the Consumer 
Assessment of Health 
Care Providers and 
Systems Program 
- Lung cancer stigma 
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i) to compare the 
extent of personal 
responsibility, 
regret, and 
medical stigma in 
current, former, 
and never 
smokers with lung 
cancer 
ii) to examine the 
impact of personal 
responsibility, 
regret, and 






(n = 213) 
 













(n = 34); 
former (n = 
141); current 






- Demographic and 
medical information 
- Psychological 
adjustment using the 
Impact of Event 
Scale-Revised 
- Depressive 
symptoms using the 
CES-D 
- Distress using the 
Distress 
Thermometer 
- Physical functioning 
using the Medical 
Outcomes Study 
Short Form  
- Symptom bother 
using the Memorial 
Symptoms 
Assessment Scale-
Short Form  
- Satisfaction with 
healthcare using a 
10-item author-
constructed scale 
- Supportive care 
















NA i) Current or former 
smokers showed higher 
Personal Responsibility 
and Regret than never 
smokers. 
 
ii) Younger age was 
associated with higher 
Personal Responsibility. 
 





symptoms (r = 0.49), 
psychological needs (r = 
0.41), use of avoidance 
coping strategies (r = 
0.37), and negatively 
associated with 
satisfaction with 
healthcare (r = - 0.57). 
 
iv) Among never 
smokers, Regret was 
positively associated 
with depressive 
symptoms (r = 0.67), 
distress (r = 0.47), 
symptom bother (r = 
0.47), psychological 
needs (r = 0.50), 
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- Coping strategies 





needs (r = 0.36), total 
supportive care needs (r 
= 0.39), and avoidance 
coping strategies (r = 
0.36).  
 
v) Among never 
smokers, Medical 
Stigma was positively 
associated with 
depressive symptoms (r 
= 0.67), distress (r = 
0.52), symptom bother (r 
= 0.46), psychological 
needs (r = 0.44), patient 
care support needs (r = 
0.41), total supportive 
care needs (r = 0.41), 
and avoidance coping (r 
= 0.59), and negatively 
associated with 
satisfaction with 




















(n = 297); 
prostate 







- Stigmatization using 






















i) Stigmatization was 





ii) Body image partly 
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using the Patient 
Health Questionnaire-
9 
- Body image using 
the 20-item German 
Body Image 
Questionnaire 
- Physical quality of 




Treatment of Cancer 
Quality of Life 
Questionnaire 
- Visibility of the 
disease  



















To investigate the 
effect of these two 
stigmas (cancer 
and aging) on the 




65 years old 
(n = 101) 
- lung cancer 
(n = 24) 
- breast 











- Demographics and 
medical information 
- Cognitive level using 
the Mini-Mental State 
Examination 
- Self-perception of 











NA NA i) There was a 
significantly positive 
association between 
both [self-perception of 
aging and cancer] and 
global health.  
 
ii) There was a 
significantly positive 
association between 
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cancer (n = 
5) 
 





Attitudes to Aging 
Questionnaire 
- Cancer view using 
the Social Impact 
Scale-Modified 
version 




Treatment of Cancer 




iii) There was a 
significantly positive 
association between 






To investigate the 
effect of these two 
stigmas (cancer 
and aging) on the 
health of elderly 
oncology patients 




65 years old 
(n = 101) 
- lung cancer 
(n = 24) 
- breast 








cancer (n = 
5) 
 






- Demographics and 
medical information 
including updated 
treatment and death 
event 
- Cognitive level using 
the Mini-Mental State 
Examination (T0) 
- Self-perception of 
aging using the 
Attitudes to Aging 
Questionnaire (T0, 











NA NA i) Those who died before 
the end of the 1-year 
follow-up showed more 
negative self-perception 
of aging and cancer 
view, poorer global and 
physical health than 
those who completed 
the follow-up. 
 
ii) There was a 
significant association 
between both [self-
perception of aging and 
cancer view] and mental 
health outcomes over 
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T3: n = 75 
T6: n = 64 
T12: n = 58 
 




status: NR   
- Cancer view using 
the Social Impact 
Scale-Modified 
version (T0, T3, T6, 
T12) 




Treatment of Cancer 
Quality of Life 
Questionnaire Core 





To evaluate the 
reliability and 
validity of the 



























- Cancer stigma using 
the Korean Cancer 
Stigma Scale adapted 
from the CLCSS 




Treatment of Cancer 













NA i) Increased cancer-
related stigma was 
statistically significantly 
associated with 
decreased global and 
functional subscales of 
the quality of life. 
 




and symptom subscale 
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i) to gain an 
insight of the 
experiences of 
people with lung 
cancer  







(n = 174) 
 





(n = 22); 
former (n = 
119); current 






- Lung cancer-related 
stigma using a 63-
item questionnaire 





































i) Current smokers were 
significantly more likely 
to feel different by their 
healthcare professionals 
than former or never 
smokers. 
 
ii) Former or current 
smokers were 
significantly more likely 
to report self-blame than 
never smokers. 
 
iii) Current smokers 
were more likely to feel 
personal stigma than 
former smokers and 
never smokers; former 
smokers were more 
likely to feel personal 
stigma than never 
smokers. 
Ernst et al. 
(2017), 
Germany 
i) To investigate 
levels of stigma in 
four major cancer 
groups  
ii) to examine the 
association 
People with 
cancer (n = 
858) 
- breast 




















i) All dimensions of 
stigmatization (i.e., 
social rejection, financial 
insecurity, internalized 
shame, and social 
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between stigma 
and QOL  
- colon 
cancer (n = 
168) 
- lung cancer 
(n = 125) 
- prostate 
cancer (n = 
268) 
 






and medical data 
- Stigmatization using 
the Social Impact 
Scale-German 
version 




Treatment of Cancer 





using the Patient 
Health Questionnaire-
9-German version 
life (physical, role, 
emotional, cognitive, and 
social) were significantly 
negatively correlated. 
 





emotional functioning.    
 
iii) Those with lung 
cancer reported the 
highest levels of 









To gain a better 
understanding of 
the experience of 
grief by people 
with cancer in 
relation to 
perceptions of 
illness, with a 
focus on the 























- Grief symptoms 
using the Prolonged 
Grief Disorder Scale-
patient form 
- Illness perception 
using the Perceived 
Illness Scale 
- Identity centrality 


















NA i) Negative experienced 
discrimination was 
significantly correlated 
with negative illness 
perceptions and more 
grief symptoms. 
 
ii) Negative experienced 
discrimination, 
hopefulness, and identity 
centrality showed a 
partial mediating effect 
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to Identity Scale (one 
of the subscales of 
the collective self-
esteem scale) 
- Discrimination using 
the Discrimination 
and Stigma Scale 
- Hope using the 
State Hope Scale 
perception on grief 
symptom.  
Rose et al. 
(2018), 
Australia 








people with lung 
cancer 





(n = 274) 
 





(n = 42); 
former (n = 
202); current 










- Help-seeking from 


















NA i) There was a significant 
and positive association 
between lung cancer 




ii) There was no 
significant association 
between lung cancer 
stigma and both [help-
seeking behaviors and 
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- Group identification 
using the author-
developed item 




- Social support using 





- Lung cancer stigma 










increases in hope 
on daily social, 
role, and physical 
functioning in lung 
cancer patients 
who undergo 
cancer treatment  
People with 
lung cancer 
(n = 50) 
 





or former (n = 
43); current 







i) Level-1 predictor 
variables 
- Treatment day 
- Daily affect using 
the Positive Affect 
and Negative Affect 
Schedule-Expanded 
Form 
- Physical symptoms 









Social isolation i) At the between-person 
level, those who 
reported less hope 
showed poor social and 
role functioning in both 
same-day and next-day 
models. 
 
ii) At the within-person 
level, levels of hope 
were positively 
associated with daily 
physical, social, and role 
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- Daily hope using the 
State Hope Scale 
- Lung cancer stigma 
using 5 items from 
the CLCSS 





using the European 
Organization for 
Research and 
Treatment of Cancer 
Quality of Life Core 
Questionnaire 30 
iii) Level-2 variables 
- Demographics 
- Depression and 
anxiety using the 
Hospital Anxiety and 
Depression Scale 
iii) At the within-person 
level, stigma was 
inversely associated with 
social and role 

















(n = 101) 
 





























NA i) Internalized stigma 
(i.e., self-stigma) and 
constrained disclosure 
were significantly and 
positively correlated (r = 
0.20). 
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well-being across 
12 weeks in 





(n = 37); 
former (n = 
56); current 
(n = 8) 
- Internalized stigma 
using the adapted 




disclosure using two 
adapted items from 
an HIV-stigma scale 
- Emotional and 
physical/functional 











reported greater levels 
of stigma than former or 
never smokers; those 
who were former 
smokers reported 
greater levels of stigma 
than never smokers.  
 
iii) There were significant 
and positive 
associations between 





iv) There were 
significant and positive 
associations between 
constrained disclosure 




v) At the 6-week follow-
up, there were 
significant and inverse 
associations between 
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Stigma Processes 
vi) At the 12-week 
follow-up, there was a 
significant and inverse 
association between 
internalized stigma and 
emotional well-being.  
 
Note. Pathway from Stigma in COPD or Lung cancer to health*: Findings are organized by domains in a conceptual model representing the effects of the stigma 
processes on health (Major et al., 2017); CES-D: the Center for Epidemiologic studies-Depression Scale; CLCSS: the Cataldo Lung cancer Stigma Scale; NA: not 










Research Aim Sample Design and 
Measures 













































and [the time from 
symptom onset to 
medical help-
seeking behavior] 
People with lung 
cancer (N = 93) 
 
Age (mean) = 62 yrs 
 
Smoking status: 
never (n = 30); 
former (n = 33); 







- Healthcare system 
distrust (using the 9-
item Revised Health 
Care System 
Distrust Scale) 
- Lung cancer 
stigma (using the 
CLCSS) 
- Smoking status 




- Social desirability 








interviews to assess 
demographic 
information, initial 
symptoms, and time 
Smoking-
related stigma 
NA NA NA Lung cancer 

















Research Aim Sample Design and 
Measures 






































potential links of 






People with lung 
cancer (n = 8) 
Age (mean) = 65 yrs 
 









- medical and 
smoking status 
- Depression (using 
the CES-D) 








- Shame and Guilt 
(using the State 









Felt stigma Affective: 






















Research Aim Sample Design and 
Measures 






























- the patient-partner 
dyad interview for 15 
minutes (once) 
- A patient only 
interview for 10 





To examine the 





the aim of 
reducing stigma in 
people with lung 
cancer 
People with lung 
cancer (N = 25) 
 




never (n = 5); former 










- smoking behaviors 
- cancer-related 
information 
b. the Psychological 
Wellness 
intervention via 
telephone for six 
weeks (once per 
week) 
c. after 3 months 
from the intervention 
- in addition to 
baseline measures 
- psychological 
distress (using the 
HADS)  
- cancer-related 











- guilt and hate 
 
Cognitive: 
- Subjects try to 
suppress 
negative 










subjects try to 
set a goal or 






















Research Aim Sample Design and 
Measures 






























Impact of Events 
Scale) 





- depression (using 
CES-D) 
- stigma about lung 
cancer (using the 
CLCSS) 
 
ii) Qualitative phase 
- Semi-structured 
interviews (n = 14) 
 
Note. Pathway from Stigma in COPD or Lung cancer to health*: Findings are organized by domains in a conceptual model representing the effects of the stigma 
processes on health (Major et al., 2017); CES-D: the Center for Epidemiologic studies-Depression Scale; CLCSS: the Cataldo Lung cancer Stigma Scale; HADS: 






Table 2-3. Measures of COPD-related and lung cancer-related stigma 
Stigma-related 
measures 
Outcome (Variables) Items/structures Included studies References 
Respiratory Illness 
Opinion Survey 
Optimism and Stigma NA Kaptein et al. (1993) Kinsman et al. (1976) 
Cataldo Lung Cancer 
Stigma Scale 
Perceived stigma • 31 items 
• 4 subscales 
o Stigma and shame 
o Social isolation 
o Discrimination 
o Smoking status 
Cataldo et al. (2011; 2012; 2013) 
Brown Johnson et al. (2014) 
Carter-Harris et al. (2014) 
Chambers et al. (2015a; 2015b) 
Shen et al. (2016) 
Rose et al. (2018) 
Cataldo et al. (2011) 
• 5 items Steffen et al. (2018): an adapted version 
Korean Cancer Stigma 
Scale 
Perceived stigma • 24 items 
• 6 subscales 
o Social isolation 




o Lack of medical support 
So et al. (2017) Cataldo et al. (2011) 
Social Impact Scale Perceived stigma • 24 items 
• Subscales 
o Social rejection 
o Financial insecurity 
o Internalized shame 
o Social isolation 
Gonzalez et al. (2012; 2015) 
Schroyen et al. (2017a; 2017b): French 
version 
Esser et al. (2017): German version 
Ernst et al. (2017): German version 
Fife et al. (2000) 
Perceived Cancer-
Related Stigma 
Perceived stigma 6 items LoConte et al. (2008) NA 
Perceived stigma Perceived stigma 1 item Else-Quest et al. (2009) NA 
Explanatory Model 
Interview Catalogue 
Perceived stigma 13 items Lebel et al. (2013a; 2013b) Weiss (1997) 
Shame and Stigma 
Scale 
Perceived stigma and 
internalized stigma 
• 21 items 
• 2 subscales 
o Perceived stigma 
o Internalized stigma 






Outcome (Variables) Items/structures Included studies References 
State Shame and Guilt 
Scale 
Generalized guilt and 
shame 
• 10 items 
• 2 subscales 
o Shame 
o Guilt 
LoConte et al. (2008) 
Else-Quest et al. (2009) 
Dirkse et al. (2014) 
Marschall et al. (1994) 
Generalized guilt, 
shame, and pride 
• 15 items 




Harrison et al. (2017) 
Cancer Responsibility 
and Regret Scale 
Guilt and blame • 11 items 
• 3 subscales 
o Personal responsibility 
o Regret 
o Medical stigma 
Criswell et al. (2016) 
Williamson et al. (2018): an adapted 
version 
NA 
Behavioral self-blame Behavioral self-blame 1 item Lebel et al. (2013a; 2013b) Christensen et al. 
(1999) 
Attitudes toward and 
experiences with lung 
cancer 
Stigma and self-blame 6 items Weiss et al. (2017) NA 
Discrimination and 
Stigma Scale 
Discrimination • 37 items 
• 3 subscales 
o Positive experienced 
discrimination 
o Negative experienced 
discrimination 
o Anticipated discrimination 
Gökler-Danışman et al. (2017) Thornicroft et al. (2009) 
 





Cognitive Interviewing of the COPD-related Stigma Scale 
 
Abstract 
Objectives: People with chronic obstructive pulmonary disease (COPD) are stigmatized 
by their history of smoking.  Stigma, like anxiety and depression, can adversely affect 
psychological functioning and quality of life.  Although a small number of qualitative studies 
have described the phenomenon of stigma in people with COPD, no existing measures of COPD-
related stigma currently exist.  This qualitative research aimed to evaluate and refine a 52-item 
preliminary stigma questionnaire for people with COPD, with the ultimate goal of reducing the 
number of items.  Items were constructed using a five-point Likert scale, with higher scores 
indicating higher stigma level.  The conceptual model of the effects of stigma processes on 
health guided this research (Major et al., 2018, p.9). 
Methods: Nineteen people with COPD (6 men and 13 women) participated in semi-
structured cognitive interviews.  During the two rounds of cognitive interviews, each participant 
was invited to only one interview.  These 90-minute interviews assessed meaning, 
comprehension, interpretation, and relevance of the items.  All interviews were audiotaped and 
transcribed verbatim.  Atlas.ti 8.2 qualitative software was used for interview data management.  
Results: Most questionnaire items were understood and interpreted as intended.  Of a 




subjects were reluctant to answer.  Eleven items were revised to improve the flow of responding 
to the questionnaire.  The rest 40 items were retained without modification.  Regarding response 
options, subjects selected the mid-point (i.e., neutral) response for various reasons.  The most 
frequent reason for choosing the mid-point response was “both equal parts of agree and 
disagree,” followed by “not applicable.”   
Conclusions: This qualitative research provided the foundation required for further 
evaluation of the stigma questionnaire using psychometric methods.  Although the individual 
experience of stigma varies, all subjects reported experiencing one or more forms of stigma.  
Through cognitive interviewing, we found that the COPD-related Stigma Scale was generally 
well received by people with COPD.  Although participants did not feel highly stigmatized, their 
responses during cognitive interviews suggested that they had not previously thought of their 
experiences in terms of stigma, and the cognitive interviewing process raised their awareness of 
that possibility.  In the next phase of this research, we would conduct a survey with 4-point 
Likert scale and further examine results to determine if the instrument can be shortened, 





Because chronic obstructive pulmonary disease (COPD) is generally considered an easily 
preventable, smoking-related disease (C. D. Mathers & Loncar, 2006), many people believe that 
those with COPD are responsible for their condition.  In individuals with COPD, this 
stigmatization has a negative effect on psychological and social well-being, leading to sub-
optimal health-seeking behaviors, such as not using oxygen properly and consistently (Earnest, 
2002; Goldbart et al., 2013), not using inhalers (Gupta et al., 2011), not seeking medical advice 
(Arne et al., 2007), and not engaging in pulmonary rehabilitation programs (Harrison et al., 
2015).  Because stigma is associated with emotions such as shame and guilt, it can contribute to  
increased emotional burden (Odencrants, Ehnfors, & Grobe, 2007; Partridge et al., 2011) and 
avoidance of social interactions (Gysels & Higginson, 2008).  However, little is known about 
COPD-related stigma.  Although its measurement will facilitate better understanding of the 
experience of those with COPD, no instrument currently exists to assess the stigma experience in 
this population.  Furthermore, a more refined measure of COPD-related stigma will be used in 
further developing a theoretical framework that can guide further development of COPD-related 
stigma research and intervention.   
 
Background 
 COPD is one of the main diseases causally linked to tobacco smoking (USDHHS, 2014).  
Tobacco smoking accounts for more than 75% of cases of COPD and 80% of COPD-related 
deaths (USDHHS, 2014; 2017).  Despite these statistics, 39% of people with COPD continue to 
smoke (Centers for Disease Control and Prevention, 2012).  For these individuals, the health 




disease progression, and decrease the risk of developing comorbidities such as coronary heart 
disease and stroke (Stratelis, Mölstad, Jakobsson, & Zetterström, 2006). Therefore, smoking 
cessation is a key strategy for preventing and managing COPD (Ford, 2015; Vestbo et al., 2013). 
As smoking control efforts in the United States have changed the public image of 
smoking and tobacco use, and increased public consciousness of its adverse health effects for 
smokers as well as nonsmokers, some smoking control advocates have taken advantage of stigma 
as a tool for promoting public health (Bell et al., 2010).  Because smoking is now regarded as an 
undesirable behavior, and smoking-related disease, such as COPD, is considered self-inflicted, 
social awareness about smoking affects behavior in people with COPD: for example, they try to 
conceal their diagnosis or to find other causes for their COPD, like occupational particulates and 
chemicals. 
 COPD-related stigma has been reported in qualitative studies that examined the lived 
experience of people with COPD.  Due to public attitudes toward smoking, those who had 
histories of smoking were struggling with their past (Jonsdottir & Jonsdottir, 2007; Lindgren et 
al., 2014).  When common symptoms of COPD like dyspnea, chronic cough, and sputum 
production became observable by others, people with COPD experienced negative reactions, 
which triggered self-conscious emotions such as embarrassment, shame, and guilt, leading to 
withdrawal from social activities and loss of employment (Gysels & Higginson, 2008; Malpass 
et al., 2015; O'Neill, 2002).   
Common treatments such as inhalers and/or supplemental long-term oxygen have been 
used to reduce symptoms and improve health status among people with COPD (Celli et al., 2004; 
Vestbo et al., 2013).  However, adherence rates among people with COPD have only been about 




embarrassment about the use of inhalers and/or supplemental oxygen in public for fear of how 
they appear to others (Berger et al., 2011; Earnest, 2002; Goldbart et al., 2013; Gupta et al., 
2011; Partridge et al., 2011).   
In addition to self-consciousness about symptoms and use of treatment equipment (e.g., 
inhalers and/or supplemental oxygen) in public, people with COPD exhibited feelings of shame 
for having been diagnosed with the disease.  A COPD diagnosis has been found to be 
emotionally distressing, which impedes people from following up with their doctors and taking 
control of their own life (Arne et al., 2007; Lindgren et al., 2014).  Learning that COPD was a 
consequence of their smoking, they reported shame at having a self-inflicted disease (Arne et al., 
2007).  Further, some people diagnosed with COPD, regardless of the severity, minimized their 
past smoking history in order to diminish feelings of shame and guilt (Lindgren et al., 2014).  
These qualitative studies played an important role in exploring and understanding the deeply felt 
phenomenon of stigma among people with COPD.  However, the findings from these qualitative 
studies are limited to describing factors that contribute to COPD-related stigma, such as which 
group of people are vulnerable to COPD-related stigma, what characteristics of COPD-related 
stigma distinguish it from other stigmas, and how COPD-related stigma interacts with both 
psychological distress and health-related behaviors.    
To advance the science of COPD-related stigma, we need a valid measure for use in 
research with larger samples.  Based on the findings from their study, Berger et al. (2011) 
initiated the development of a COPD-related stigma scale, for which they interviewed 
participants living with COPD to learn about how COPD affected their social relationships and 
how they experienced COPD-related stigma.  They found that participants perceived the 




constructed a preliminary 60-item COPD-related stigma scale. Because the psychometrics of this 
scale have not yet been studied, it should be evaluated and refined before psychometric 
validation.      
An expert group was organized to review the preliminary 60-item COPD-related stigma 
scale to determine whether its items reflected COPD-related stigma.  The group consisted of the 
current research team and two other researchers (Dr. Berger and Dr. Kapella).  The scale was 
administered to fourteen people with COPD (Bickmann & Larson, Unpublished); descriptive 
statistics (i.e., mean scores of the scale item) were used to gauge how well the items performed 
with the population of people with COPD.  After individual reviews, the expert panel discussed 




 Cognitive interviewing assesses respondents’ cognitive process while they are answering 
survey questions, in order to identify measurement errors that may occur (Collins, 2003).  It 
enables researchers to determine whether a scale’s response options and items are understood 
and interpreted as the researchers intended them, and that the items collectively are both 
parsimonious and comprehensive.  Diagnosing potentially problematic items enables appropriate 
revisions that will better reflect the concepts or behaviors of interest.   
To provide consistency, a semi-structured interview protocol was developed for use in 
the standardized cognitive interviews.  The interview protocol was based on the four-stage 
cognitive model suggested by Tourangeau (1984), which explores four questions: (1) Do the 




(2) Are study participants able to recall relevant information (retrieval)? (3) How do study 
participants come to the responses (judgment)? and (4) Is it easy or difficult to select and report 
an answer (response)? (Tourangeau, Rips, & Rasinski, 2000, pp. 1-22).  By using these four 
questions, potential problems in the questionnaire were systematically explored.  
 Verbal probing techniques have the advantage of maintaining the interviewer’s control of 
the interview, focusing on potential erroneous areas, and reducing the participants’ burden of 
verbalizing their thought processes (Willis, 2005).  Retrospective, instead of concurrent, probing 
techniques are appropriate for the current study because they focus on the flow of the 
questionnaire items and closely reflect the actual context of answering the questionnaire (Collins, 
2015; Willis, 2005).  Using a retrospective verbal probing cognitive interview technique, this 
study was able to create a safe space for study participants to express their thoughts, perceptions, 
and/or attitudes about the items.     
 
Statement of purpose 
 The purpose of this study was to refine the preliminary COPD-related stigma scale using 
cognitive interviewing techniques and, specifically, to improve the accuracy of the scale items 




 This study employed a cross-sectional, descriptive, qualitative study design.  Cognitive 




COPD-related stigma scale, and to refine and evaluate the items with the aim of improving the 
validity of the instrument.  
 
Participants and Setting 
 A convenience sample was used to select potential study participants from the University 
of Michigan Health System’s pulmonary clinic and pulmonary rehabilitation center in Ann 
Arbor.  Potential participants were considered if they (a) were aged 50 years or older; (b) were 
diagnosed with or were told by their primary care provider that they had COPD, emphysema, or 
chronic bronchitis; and (c) spoke English as their first language.  Those who were 
simultaneously diagnosed with other stigmatized diseases such as severe mental illness, 
HIV/AIDS, lung cancer, or physical deformities were excluded from study participation.  The 
University of Michigan Institutional Review Board reviewed and approved all study materials.   
To recruit study participants, 37 potential participants were approached.  Of those, 17 
were either not interested or not eligible to participate: 13 (35.1 %) refused, 3 (8.1%) were not 
eligible, and 1 (2.7%) was eligible but could not participate due to illness.  Of the 20 who were 
consented, 19 (51.4%) completed the interview, with one who consented but did not complete 
the interview.  Of the 19, nine participated in the first round of interviewing and the remaining 
10 participated in the second round.  Upon completion of the interview, study participants 
received a $50 gift card.  
 
Study procedures 
 Cognitive Interviews. Two rounds of semi-structured cognitive interviews were 




participant was interviewed only once, either in the first or second round.  After the first round, 
the research team discussed whether the sample represented sufficient demographic variability. 
After the second round of the cognitive interviews, the research team discussed whether data 
saturation was achieved.  
The interviews, which lasted approximately 1.5 hours, were conducted by the same 
interviewer (SW) in either the participant’s home, a clinic, or a quiet and private space in a 
public area.  After participants completed the 52-item COPD-related stigma scale, the 
interviewer asked semi-structured questions about each individual item using the cognitive 
interviewing technique, ending with questions and a request for comments about the entire scale.  
Examples of semi-structured questions are provided in Table 3-1.  The interviews were audio 
recorded and transcribed verbatim.   
Data Analysis.  Descriptive statistics were calculated using IBM SPSS Statistics for 
Windows, Version 25.0.  The transcripts were analyzed via ATLAS.ti 8.0 qualitative data 
analysis software (ATLAS.ti Scientific Software Development GmbH, Berlin, Germany).  The 
data analysis process was guided by the steps proposed by Miller, Chepp, Willson, and Ryan 
(2014), which assist in synthesizing and reducing a large amount of narrative data in order to 
produce meaningful information about the performance of each questionnaire item.  The 
interviewer (SW) made summaries of each interview transcript along with the interview notes 
(familiarization).  The research team, including the interviewer, synthesized and summarized 
interviews by each item to understand how study participants answered questions, how they 
came to their answers, and any difficulties in their response process (summarization).  Then the 
research team produced common themes by comparing summaries across study participants 




how participants interpreted the items, how they mapped their responses, and whether they had 
any difficulties in completing the items (conclusion).  Following these steps, the research team 




 Nineteen people with COPD (≥ 50 years old) participated in one-on-one, in-person 
cognitive interviews from March 2018 through October 2018.  Participants’ demographic 
characteristics are shown in Table 3-2.  The mean age of participants was 65.5 years (range: 50-
82), 13 (68.4%) were female, 15 (78.9%) were Caucasian or White, and 15 (78.9%) had a 
college degree or higher.  Nine (47.4%) were married, 13 (68.4%) were living with other adults, 
12 (63.2%) were retired, and only one (5.3%) was working full-time.  All participants had a 
history of smoking: 16 (84.2%) were former smokers and 3 (15.8%) were still smoking at the 
time of the interview. 
 
Cognitive Interview Results 
Study participants reported they understood the instructions and response options of the 
52-item COPD-related Stigma Scale.  They also reported that there were no difficulties in 
answering items from beginning to end.  Some participants said that the scale covered a wide 
range of stigma experiences in relation to COPD when they were asked whether there were 
additional items that should be considered.   
After the first round of the cognitive interviews, no items were eliminated by the research 




of the 52-item COPD-related Stigma Scale was used for the second round of cognitive interview, 
after which one item was eliminated, and three were revised.   
a. Item Analysis: retained items. Of a total of 52 items, 40 items were retained without 
modification.  The team discussed these items in terms of word/phrase choices, redundancy, 
and/or relevance based on participants’ comments.  Instead of revising at this point, those items 
were reserved for further evaluation with a larger sample to ensure the appropriateness of 
revision.   
a-1. A word choice: Some participants commented that for #43 (Having COPD is 
disgusting to me), it would be appropriate to ask, “Having COPD is disappointing,” 
“Having COPD is regrettable,” or “Having COPD makes me angry/upset.”  However, 
other participants commented that there was nothing wrong with the wording of #43, 
although they disagreed with the statement, Having COPD is disgusting to me.   
a-2. Redundancy: Several items were shown to be similar.  For example, 
participants reported that #33 (Having COPD makes me feel unclean) and #35 (Most 
people think that a person with COPD is disgusting) seemed to explore perceptions 
towards COPD, albeit from different angles.  As another example, they reported that #10 
(Others blame a person with COPD for having smoked) and #11 (Others think people 
with COPD are idiots for having smoked) seemed to invoke the notion of self-inflicted 
disease.  Participants also reported that #25 (Telling someone I have COPD is risky) and 
#37 (I am very careful who I tell that I have COPD) seemed to explore concealing 
COPD.  
a-3. Relevance: Study participants indicated that a few items were probably less 




answered #26 (People with COPD lose their jobs when their employers find out), they 
mentioned that they had not thought about this issue because they were already retired.  
As another example, when participants answered #32 (It is easier to avoid new 
friendships than worry about telling someone that I have COPD), they responded that 
they were not quite as worried about new friendships as young people.   
b. Item Analysis: deleted item.  One item (i.e., #12) was dropped from the 52 items.  
Most participants were surprised and complained about #12 (People think of COPD as a dirty 
disease) being too offensive; hence, they were reluctant to answer.  When they looked at this 
item, they easily connected “a dirty disease” to a transmittable disease.  Shortly after reading the 
item, some participants tried to understand it by thinking of possible examples in relation to 
COPD, such as bringing up sputum while coughing or smelling bad due to smoking.  
Considering the actual environment (i.e., a self-administered survey), this item raised concerns 
about the possibility of being misinterpreted or being unanswered.  During the analysis process, 
the research team realized that #31 (Most people believe that a person who has COPD is dirty) 
addressed a similar concept and decided to eliminate it.   
 c. Item Analysis: modified item.  Eleven of 52 items were revised (see Table 3-3).  Eight 
items were modified to improve the flow of responding to the questionnaire.  The 8 items were: 
(1) #1 (People shy away from me when they see I’m wearing oxygen), (2) #2 (No one seems 
embarrassed by my coughing), (3) #3 (My family doesn’t like me to use my inhaler in public), (4) 
#6 (I avoid using my oxygen in public, so others won’t think I’m ill), (5) #7 (It embarrasses me to 
use the inhaler in front of other people), (6) #9 (I’m more likely to be embarrassed by my 
symptoms when I’m among strangers), (7) #18 (I avoid using oxygen in front of other people), 




stigma experiences associated with either using an inhaler/supplemental oxygen or having 
COPD-related symptoms, some participants left these items blank and explained that these items 
were not applicable to them.  At the completion of the first round of the cognitive interviews, the 
research team decided to apply a skip logic to these 8 items to avoid interruption while 
responding to the questionnaire items.  For example, before going to item 1, participants 
answered a yes-or-no question of “Do you use supplemental oxygen for COPD?” If they 
answered “no,” they could skip item 1 and go to the next item.  The revised items were applied 
to the second round of the cognitive interviews and showed improvement.    
 Of the 11 items, three were changed to improve clarity or wording based on participants’ 
comments and suggestions.  The 3 items were: #14 (Health care providers have been abrupt with 
me about smoking), #31 (Most people believe that a person who has COPD is dirty), and #34 
(Since learning I have COPD, I feel set apart and isolated from the rest of the world).  When 
participants answered #14, they were confused about whether they should think about all past 
and current health care providers.  To increase clarity, #14 was revised to “Some health care 
providers have been abrupt with me about smoking.”  Item 31 was discussed along with #12 
because these two items displeased many participants and made them hesitant to respond.  The 
research team decided to revise #31 by using the word “unclean” instead of “dirty.” Item 12 was 
dropped.  Regarding #34, some participants commented that they partly agreed with this item 
because it asked two different feelings.  The research team decided to change “set apart” into 
“singled out” to improve the clarity of #34. 
d. Response Option Analysis.         
 None of the participants had problems with matching items and response categories.  A 




strongly agree, suggesting that they wanted a more nuanced response options; no one suggested 
having fewer options.  Several participants were confused about items that required responding 
in the opposite direction, such as #2 (No one seems embarrassed by my coughing).  In those 
cases, they corrected wrong answers they found while in the cognitive interviews.  
 Of the 52 items of COPD-related Stigma Scale, the mid-point option (i.e., neutral) was 
selected 17.41% (ranged from 0% to 47.37%) of the time in both rounds of the cognitive 
interviewing (see Figure 3-2).  Interestingly, participants were less likely to select the mid-point 
option when they had to explain the reason.  More specifically, 20.94% (ranged from 0% to 
66.67%) of answers were the mid-point option in the first round of the cognitive interviews and 
14.23% (ranged from 0% to 50%) in the second round of the cognitive interviews.  Only those 
who participated in the second round of the cognitive interviews were required to give detailed 
information on why they selected the neutral option.  The most frequently described reason was 
“both equal parts of agree and disagree” (31.40%) and followed by “not applicable” (27.91%) 
(see Figure 3-3).  For example, a participant gave her reason for choosing neutral regarding #48 
(I have stopped socializing with some people because of their reactions to my having COPD): “I 
might avoid it if there's a few people there that I know will make me uncomfortable … so if it's 
more of an intimate group of 10 or 12 couples and a couple of them are nasty, I'll not go. But if 
it's more than that, I don't care, I can be on the other side of the room.”  She chose neutral 
because she partially agreed with #48.  
 
Discussion 
The present study was part of the development of a scale to measure COPD-related 




employing cognitive interviewing technique to assess the validity of the COPD-related Stigma 
Scale based on item content and response categories.  Findings from the present study support 
employing cognitive interviewing technique to improve the clarity and relevance of items and 
the accuracy of participants’ responses.    
Cognitive interviewing verified that most items were understood and interpreted as 
intended, including instructions and response categories.  It also allowed us to discover potential 
problems with the items and response.  Potential problems were related to (a) the wording and 
tone of the items and (b) the design of response categories.  The problems were straightforward 
and could be readily addressed in the process of revisions after each round of cognitive 
interviews.   
For several items that inquired whether COPD-related stigma is associated with morality, 
participants exhibited non-verbal cues (e.g., slightly pouting lips or knitted brow) and verbal 
sounds such as “hmm,” “ha!” or “really!” and stated that the language of some of the items—“I 
was surprised” or “…unclean has a different connotation…”—did not accurately describe the 
experience of COPD-related stigma.  Because many of the items in the COPD-related Stigma 
Scale were derived from Berger et al.’s (2001) HIV stigma scale, they might lack relevance to 
people with COPD.         
By adding a question probing the meaning of neutral responses in the second round of 
cognitive interviews, we found that the proportion of neutral responses was reduced from 
20.94% (n = 9) to 14.23% (n = 10).  Of the total number of neutral responses, less than 13% 
were selected for reasons of true neutrality.  As seen in Figure 3-3, 31.4% of participants chose 
the neutral option because, depending on varying possible interpretations of the items, they could 




indifference to (10.47%) or lack of knowledge about (17.44%) an item.  Some of these uses of 
the neutral option could be interpreted as hiding participants’ true reactions to the items (Baka, 
Figgou, & Triga, 2012).  While the neutral option might indicate that the participant did not have 
a strong opinion about a particular item, in some cases we observed that participants read the 
item again carefully and changed the original answer after thinking about why they chose the 
neutral option.  Hence, if the neutral option were not provided, participants might either agree or 
disagree with the item (Weijters, Cabooter, & Schillewaert, 2010), which raises the concern that 
a neutral option may increase the likelihood of response bias. 
 
Limitations 
This qualitative study allowed us to evaluate the COPD-related Stigma Scale, detect the 
existence of potential problems, and refine the problematic items.  However, we cannot entirely 
exclude the possibility of remaining errors (Beatty & Willis, 2007), because it may be impossible 
to articulate all cognitive processes.  Also, verbalizing one’s cognitive process might require 
careful training (Willis, 2005).  Although study participants were well informed about the 
cognitive interviewing technique, they may have given incomplete explanations to probing 
questions. 
Another limitation is the generalizability of the study findings.  Participants were 
recruited from a single academic health system in the United States, which may not be 
representative of the broader population.  Most participants were Caucasian/White (78.9%) and 
not actively engaged in employment (94.7%).  Further evaluations are needed to ensure that the 
COPD-related Stigma Scale reflects the stigma experiences of people of other racial/ethnic 






The results from this study show that all participants experienced some form of stigma 
due to their COPD.  Through cognitive interviewing, we found that the COPD-related Stigma 
Scale was generally well received by people with COPD.  Although responses to the COPD-
related Stigma Scale indicated that participants did not feel highly stigmatized, their responses 
during cognitive interviews suggested that they had not previously thought of their experiences 
in terms of stigma, and the cognitive interviewing process raised their awareness of that 
possibility.  Additional research with diverse and larger groups of people with COPD is needed 
for a thorough evaluation of the COPD-related Stigma Scale.  Moreover, given the possible 
adverse impacts of COPD-related stigma on health, and the benefit of better understanding and 
assessment of COPD-related stigma, the COPD-related Stigma Scale should be psychometrically 
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Table 3-1. Sample of cognitive interviewing probes 
 
It’s embarrassing not to be able to keep up with others when we’re walking. SD D N A SA 
1) When you answered this question, what kinds of thoughts did you have? 
2) What does the term “keep up with others” mean to you? 
3) For those who choose a “Neutral” option, would you give a reason for that? 
4) How could we say this question better? 




Table 3-2. Demographic Characteristics of Subjects (N = 19) 
Characteristics  
Age (years) Mean age (SD) [range] N (%) 
50 – 59   3 (15.8%) 
60 – 69  11 (57.9%) 
70 – 79  4 (21.2%) 
> 80  1 (5.3%) 
Total 65.5 (8.8) [50 – 82]  
Gender   
Female  13 (68.4%) 
Male  6 (31.6%) 
Race/ethnicity  
Caucasian / White 15 (78.9%) 
Black / African American 1 (5.3%) 
American Indian / Native American 1 (5.3%) 
Other 2 (10.5%) 
Education  
< 12th grade 4 (21.1%) 
Some college 9 (47.4%) 
College degree 4 (21.1%) 
Advanced degree 2 (10.5%) 
Relationship status  
Never married 1 (5.3%) 
Married 9 (47.4%) 
Divorced 4 (21.1%) 
Widowed 4 (21.1%) 
Missing 1 (5.3%) 
Living arrangement  
Alone 4 (21.1%) 
With other adult(s) 13 (68.4%) 
With other adult(s) and dependent(s) 2 (10.5%) 
Occupational status  
Homemaker 1 (5.3%) 
Retired 12 (63.2%) 
Disability 4 (21.1%) 
Leave of absence 1 (5.3%) 
Employed full-time 1 (5.3%) 
Smoking status  
Current 3 (15.8%) 




Table 3-3. Overview of problematic items indicated by participants during cognitive interviewing 
Type of stigma Item 
no. 
Original item Problems Revised item 
Perceived (Felt) 
stigma 
1 People shy away from me when they see I’m 
wearing oxygen. 
This item is only applicable to 
those who use supplemental 
oxygen. 
 
A skip function was added to these items that 
allow participants to skip if the item does not 
apply to them. For example, “Do you use 
supplemental oxygen for COPD? If no, please 
go to the next item.” 
Self-stigma 6 I avoid using my oxygen in public, so others 
won’t think I’m ill. 
Anticipated 
stigma 
18 I avoid using oxygen in front of other people. 
Perceived (felt) 
stigma 
3 My family doesn’t like me to use my inhaler in 
public. 
This item is only applicable to 
those who use an inhaler in public. 
For example, some use an inhaler 
only in private places such as a 
restroom. 
Self-stigma 7 It embarrasses me to use the inhaler in front 
of other people. 
Perceived (Felt) 
stigma 
2 No one seems embarrassed by my coughing. This item is only applicable to 





9 I’m more likely to be embarrassed by my 
symptoms when I’m among strangers. 
Perceived (felt) 
stigma 
21 Others are put off by my coughing and 
sputum. 
Self-stigma 34 Since learning I have COPD, I feel set apart 
and isolated from the rest of the world. 
“Set apart” and “isolated” should 
not be used in the same item, 
because it is possible to feel 
isolated but not set apart, which 
makes it difficult to answer. 
Since learning I have COPD, I feel singled out 
and isolated from the rest of the world. 
Self-stigma 6 I avoid using my oxygen in public, so others 
won’t think I’m ill. 
Some participants noted that the 
reason (“others won’t think I’m ill”) 
may not be their case. 




Type of stigma Item 
no. 
Original item Problems Revised item 
Self-stigma 19 I plan my activities carefully, so others won’t 
notice I can’t do as much as I used to. 
 Retained as the same 
Enacted stigma 14 Health care providers have been abrupt with 
me about smoking. 
 Some health care providers have been abrupt 
with me about smoking. 
Perceived (Felt) 
stigma 
12 People think of COPD as a dirty disease.  Deleted 
Perceived (Felt) 
stigma 
31 Most people believe that a person who has 
COPD is dirty. 
 Most people believe that a person who has 

































Figure 3-1. Refinement Process for the COPD-related Stigma Scale 
Cognitive 
Interviewing 
Round 1 (n = 9) 
Cognitive 
Interviewing 












































Figure 3-3. Relative frequency of each reason for selecting the neutral option 
 
 























   
Psychometric Evaluation of the COPD-related Stigma Scale 
 
Abstract 
Objectives: Stigma experiences in people with chronic obstructive pulmonary disease 
(COPD) have been reported in qualitative studies.  COPD-related stigma contributes to 
psychological distress and affects help-seeking behavior.  Despite the seriousness of COPD-
related stigma, no well-established stigma measure exists for this population.  The primary 
purpose was to identify the underlying constructs of the COPD-related Stigma Scale and 
evaluate the reliability and validity of the scale.  The secondary purpose was to assess the 
usability of the scale to predict psychological distress.      
Methods: A descriptive, cross-sectional, correlational study using a mailed survey 
method was conducted.  Participants (N = 148; mean age = 64.1 years) completed the 51-item 
COPD-related Stigma Scale.  Eight COPD-specific stigma items were not included in this 
analysis because they were only applicable to some participants and not others (e.g., those who 
use oxygen and inhalers), leaving 43 items for this analysis.  Item-level analysis, including 
evaluating the ceiling and floor effects, the inter-item correlations, and the item-total 
correlations, was used to reduce the number of items.  Cronbach’s alpha coefficients were used 




underlying structure.  Convergent validity was used to evaluate whether the COPD-related 
Stigma Scale measures accurately and is correlated with related constructs.  
Results: In the item-level analysis, 13 items were deleted, leading 30 items for factor 
analysis.  The four-factor model with 28 items (α = 0.96) was derived from factor analysis: social 
stigma (α = 0.95), self-blame (α = 0.90), physical limitation (α = 0.84), and self-inflicted disease 
(α = 0.70).  Moderate to high correlations were found between the 28-item COPD-related Stigma 
Scale and the Stigma Scale for Chronic Illness 8-item (r = 0.84, p < 0.0001), the Hospital 
Anxiety and Depression Scale (r = 0.53, p < 0.0001), and the PROMIS Physical Function Short 
Form 10a (r = -0.36, p < 0.0001).  However, correlation with Charlson Comorbidity Index was 
not significant.  Mean scores of the 28-item COPD-related stigma were higher in women than 
men.  Mean scores of physical limitation subscale were significantly higher in those who use 
supplemental oxygen than those who do not as well as those who use inhalers than those who do 
not.  
Conclusions: Findings support that the 28-item COPD-related Stigma Scale is a reliable 
and valid scale for people with COPD.  The findings from this study will assist in 
conceptualizing COPD-related stigma and explore relationships with other health outcome 
variables and the quality of life.  Further research is needed to confirm this four-factor model and 
in a larger sample to examine the potential for including the eight items that were deleted 
because they were not relevant to all participants.  





 Chronic obstructive pulmonary disease (COPD) is a chronic, progressively worsening 
lung disease that causes difficulties in breathing.  COPD treatment focuses on slowing the 
progress of the disease by mitigating symptoms, preventing acute COPD exacerbations, and 
enhancing exercise tolerance (U.S. Department of Health and Human Services [USDHHS], 
2016).  To reduce the risk factors for adverse outcomes and promote COPD patients’ health-
related quality of life, a combination of treatment interventions, such as smoking cessation, 
pharmacological therapy, long-term oxygen therapy, nutrition, and pulmonary rehabilitation, 
plays a pivotal role in COPD treatment (Celli et al., 2004; McCarthy et al., 2015).  
Notwithstanding these treatment interventions, high rates of non-adherence to COPD treatment 
are a significant obstacle to better clinical outcomes and health-related quality of life (Holmgren, 
DiBonaventura, Karlsson, Bergstrom, & Ding, 2016; Jamal, Menon, Yousoof, & Vardhan, 
2016).   
 The major barriers to treatment adherence include cultural factors, psychological issues, 
and patients’ lack of understanding of the complex prescribed treatment for COPD and its 
importance in managing the disease (Sanduzzi et al., 2014).  Additional factors such as COPD 
patients’ self-conscious emotions of embarrassment about the use of inhalers (Jamal et al., 2016) 
and comorbid psychological diseases such as anxiety and depression (Franssen & Rochester, 
2014; Panagioti et al., 2014; Turan, Yemez, & Itil, 2014) also contribute to poor treatment 
adherence.  Further, an issue that cannot be overlooked is COPD-related stigma, which has the 
potential to influence adherence to COPD treatment.  This issue has received scant attention 
(Earnest, 2002; Gysels & Higginson, 2008; Harrison et al., 2015); thus, little is known about the 




this association more fully, the authors conducted a review of the literature on COPD-related 
stigma, which revealed a dearth of measures of COPD-related stigma.  Because an inability to 
accurately measure this phenomenon may impede further understanding of factors associated 
with stigma, the authors refined the preliminary 51-item COPD-related Stigma Scale (see 
Chapter 3).  In this chapter, we described the reliability and validity of the scale and evaluated 
the factor structure of the COPD-related Stigma Scale.   
 
Background 
In 2004, approximately 64 million people worldwide were estimated to have COPD (C. 
Mathers, Fat, & Boerma, 2008), and approximately 3 million died from the disease, accounting 
for 5.1% of total deaths.  Due to the high prevalence and mortality of COPD, the World Health 
Organization (WHO) has deemed it a globally burdensome disease (C. Mathers et al., 2008).  In 
the United States, an estimated 15.7 million adults had COPD in 2013 (Wheaton, Cunningham, 
Ford, & Croft, 2015).  Although the mortality rate from COPD decreased slightly from 1999 to 
2011, COPD is still the third leading cause of death worldwide (Ford, 2015; Vestbo et al., 2013).  
COPD is especially burdensome because deteriorating lung function hampers economic 
and social activities as well as the activities of daily living.  Compared to people who do not 
report COPD, those with COPD are less likely to be employed, more likely to experience 
difficulties in walking and climbing stairs, and more likely to use a medical device to manage 
their health condition (Wheaton et al., 2015).  Respiratory symptoms of COPD, such as chronic 
dyspnea, cough, and sputum production, play a part in increasing the burden of this disease. 
People with COPD also experience symptoms such as pain, fatigue, depression, anxiety, 




risk of comorbidities, such as pneumonia, osteoporosis, respiratory infection, myocardial 
infarction, angina, fractures, and glaucoma than do people without COPD (Soriano, Visick, 
Muellerova, Payvandi, & Hansell, 2005).   
In addition, symptoms such as psychological distress and cognitive impairment may 
negatively affect disease management and daily functioning.  For example, psychological 
distress—including depression and anxiety (Panagioti et al., 2014)—experienced by people with 
COPD is associated with low self-confidence or self-efficacy, loss of interest in daily activities, 
irritability, and difficulty with concentration and memory, all of which significantly reduce 
health-related quality of life and increase healthcare utilization (Laurin, Moullec, Bacon, & 
Lavoie, 2012; Panagioti et al., 2014).   Cognitive dysfunction is often comorbid with COPD: 
mild cognitive impairment affects 25% of people with COPD (Yohannes, Chen, Moga, Leroi, & 
Connolly, 2016).  Cognitive decline can cause difficulties in complying with prescribed 
treatments (Zawada, Bratek, & Krysta, 2015) and increase the risk of impaired activities of daily 
living and instrumental activities of daily living (Martinez, Richardson, Han, & Cigolle, 2014).  
 COPD-related stigma also places a substantial burden on people living with COPD 
because it contributes to psychological distress and affects help-seeking behavior.  When people 
are diagnosed with COPD, they tend to regard it as a self-inflicted disease, which may make 
them sink into a slough of shame that interferes with help-seeking (Arne et al., 2007; Berger et 
al., 2011; Lindgren et al., 2014).  As the disease progresses, dyspnea, cough, and sputum 
production worsen, and the visibility of those symptoms may trigger COPD-related stigma 
(Berger et al., 2011; O'Neill, 2002).  When people with COPD exert effort breathing in front of 
others, they may feel embarrassment, blame themselves, and fear others’ negative reactions 




of inhalers and supplemental oxygen, can also serve as triggers for stigma.  When people with 
COPD use these treatments in public, they feel shame in showing illness and/or dependence on 
the devices (Earnest, 2002; Gupta et al., 2011; Partridge et al., 2011) because others are staring at 
them (Goldbart et al., 2013).  As a result, people who experience COPD-related stigma are more 
likely to conceal their disease (Lindgren et al., 2014), avoid outside activities (Earnest, 2002; 
O'Neill, 2002), be isolated (Jonsdottir & Jonsdottir, 2007), be non-compliant with the treatment 
as prescribed (Neri et al., 2006), and experience threats to their sense of self-worth (Earnest, 
2002). 
 Furthermore, people with COPD, who expect support from healthcare professionals, 
instead experience disease-related stigma and can be disappointed about the preconceived 
notions that COPD is a self-inflicted disease.  Because they are frequently asked by their 
healthcare providers about smoking habits, they may feel that their condition, concerns, and 
needs are not considered as important as their smoking status (Gysels & Higginson, 2008; 
Halding et al., 2011; O'Neill, 2002).  People with COPD often perceive their healthcare 
providers’ attitudes towards smoking and/or smokers as condemnatory, which makes them feel 
that they have a socially unacceptable disease (Berger et al., 2011; Gysels & Higginson, 2008).  
These negative reactions of health professionals can cause people with COPD to feel depressed 
and helpless, and can limit their health-seeking behaviors (Berger et al., 2011; Gysels & 
Higginson, 2008).   
 Despite the seriousness of COPD-related stigma, no well-established stigma measure 
exists for this population.  The author conducted a systematic literature review with the aim of 
comparing the existing literature on stigma in people with COPD and in people with lung cancer 




Although the literature review revealed that both COPD and lung cancer are considered self-
inflicted diseases due to patients’ history of smoking, there were differences between the two 
conditions.  For example, when it comes to stigma triggers, lung cancer-related stigma was 
brought about by smoking-related stigma.  In contrast, COPD-related stigma was triggered not 
only by smoking-related stigma, but by symptoms such as cough and phlegm, and the use of 
inhalers/oxygen in public.  The systematic literature review revealed that no well-established 
measure of COPD-related stigma exists.  
 Developing reliable and valid measures of COPD-related stigma is required not only to 
make sense of the phenomenon of stigma in people with COPD, but also to advance our 
knowledge of COPD-related stigma.  Therefore, a preliminary 60-item COPD-related Stigma 
Scale was developed by Larson, Kapella, and Berger based on the findings from their qualitative 
study on stigma in people with COPD (Berger et al., 2011) and the HIV Stigma Scale developed 
by (Berger et al., 2001).  The initial 60 items were reviewed by two experts on stigma (Dr. 
Berger) and COPD (Drs. Larson and Kapella).  Eight items were removed to decrease 
redundancy and increase relevance to the target population.  The 52-item preliminary COPD-
related Stigma Scale was refined through cognitive interviewing methodology to improve clarity 
and accuracy, resulting in the 51-item COPD-related Stigma Scale (see Chapter 3).   
 
Conceptual Framework 
 This study was guided by the general factor model (DeVellis, 2016).  The model assumed 
that an observed item score is caused by a latent variable and multiple latent variables would 
serve as causes of variation in a set of items.  We performed exploratory factor analysis (EFA) to 




COPD-related Stigma Scale) and evaluate whether the items reliably measure the intended 
constructs.  Then, a large number of the original items can be reduced by eliminating items that 
do not fit into the derived factors (DeVellis, 2016).  
 
Statement of purpose 
The primary purpose of this study was to describe the psychometric properties of the 
COPD-related Stigma Scale, including reliability and validity, and identify the underlying 
constructs of the scale.  The secondary purpose of this study was to examine the usability of the 
newly revised version of the COPD-related Stigma Scale, whether the scale predicts 








Study participants were recruited from the University of Michigan Health System’s 
pulmonary and medical clinics in Ann Arbor.  Potential participants were included if they (a) 
were aged 50 years or older; (b) were diagnosed with or were told by their primary care provider 
that they had COPD, emphysema, or chronic bronchitis; and (c) spoke English as their first 
language.  Those who were simultaneously diagnosed with other stigmatized diseases such as 




participation.  All study procedures and materials were approved by the University of Michigan 
Institutional Review Board.   
 
Measures 
 COPD-related Stigma Scale. The COPD-related Stigma Scale consisted of 51 items.  
Some items were about stigmatization by others (e.g., “Some people act as though it's my fault I 
have COPD.”), a feeling of shame (e.g., I blame myself for having COPD.), social isolation (e.g., 
I have lost friends by telling them I have COPD.), discrimination (e.g., If they learn I have 
COPD, I worry about people discriminating against me.), concealing (e.g., I work hard to keep 
my COPD a secret.), and smoking (e.g., People have told me that getting COPD is what I 
deserve for having smoked cigarettes.).  Each stigma item was rated on a 4-point Likert scale (1 
= strongly disagree, 4 = strongly agree) (see Appendix D).  A higher score is interpreted as an 
increased frequency of stigma experience. 
   Stigma Scale for Chronic Illness. The Stigma Scale for Chronic Illness 8 items (SSCI-
8), a well-established and valid instrument, was used to demonstrate the convergent validity of 
the COPD-related Stigma Scale.  The SSCI-8, a shortened version of the 24-item SSCI, was 
developed to assess stigma for people with chronic conditions (Molina, Choi, Cella, & Rao, 
2013; Rao et al., 2009).  The SSCI-8 has a 5-point Likert scale from 1 (Never) to 5 (Always) and 
assesses enacted stigma and internalized stigma.  Five items assess enacted stigma (e.g., Because 
of my illness, some people avoided me.), two items measure internalized stigma (e.g., I felt 
embarrassed about my illness.), and one item (Because of my illness, I felt left out of things.) is a 
combined measure of both enacted and internalized stigma (Molina et al., 2013).  A raw summed 




frequency of stigma experience.  The SSCI-8 showed good internal consistency reliability 
(Cronbach’s alpha = 0.85 - 0.92) and significant correlations with the PROMIS global health 
scale (physical health domain: r = -0.25 ~ -0.63; mental health domain: r = -0.34 ~ -0.60) 
(National Institutes of Neurologic Disorders and Stroke, 2010) (see Appendix E).  In this study, 
Cronbach’s alpha was 0.91. 
 Comorbid Conditions. The Charlson Comorbidity Index (CCI) was developed to form a 
taxonomy for concomitant conditions which are significant predictors of hospital mortality (M. 
E. Charlson, Pompei, Ales, & MacKenzie, 1987).  Each condition is assigned a different weight 
based on its adjusted risk of mortality.  The CCI total score calculation is based on the sum of the 
weights of all comorbid conditions for the individual, with a higher score associated with higher 
mortality.  The CCI has been extensively validated to examine the impact of comorbid 
conditions on patients (M. Charlson, Wells, Ullman, King, & Shmukler, 2014; Frenkel, 
Jongerius, Mandjes‐van Uitert, Munster, & Rooij, 2014; Radovanovic et al., 2014; Tessier, 
Finch, Daskalopoulou, & Mayo, 2008) (see Appendix F).  In this study, Cronbach’s alpha was 
0.55. 
 Psychological Distress. The Hospital Anxiety and Depression Scale (HADS) is a 14-
item, four-point scale developed to assess two common emotional disorders, i.e., anxiety and 
depression, in general medical patients (Zigmond & Snaith, 1983).  The HADS consists of two 
7-item subscales, one each for anxiety and depression.  A higher score indicates more severe 
emotional distress.  Psychometric properties have been assessed in numerous studies of versions 
in different languages (Bjelland, Dahl, Haug, & Neckelmann, 2002; Mykletun, Stordal, & Dahl, 




depression from 0.67 to 0.90 (Bjelland et al., 2002) (see Appendix G).  In this study, Cronbach’s 
alpha was 0.89. 
 PROMIS Physical Function. PROMIS Physical Function (Short Form-10a) is a 10-
item, five-point scale that evaluates patients’ capability to perform various physical activities 
(Cella et al., 2010).  This includes basic and advanced activities of daily life (Cella et al., 2015).  
Examples of items include “Does your health now limit you in walking more than a mile?” and 
“Are you able to do chores such as vacuuming or yard work?”  Response scales have five 
options: 1 = unable to do, 2 = with much difficulty, 3 = with some difficulty, 4 = with a little 
difficulty, and 5 = without any difficulty.  A lower score indicates poorer physical functioning 
(Cella et al., 2010) (see Appendix H). A PROMIS measure of physical functioning has been 
validated in the general population as well as in individuals with chronic conditions, including 
chronic obstructive pulmonary disease (Cook et al., 2016; Schalet et al., 2016).  The PROMIS 
Physical Function Short Form (SF)-10a is correlated with the PROMIS Physical Function full 
item version (r = 0.96), which correlates with two well-established questionnaires measuring the 
same concept, i.e., the Health Assessment Questionnaire (r = -0.8) and SF-36 (r = -0.88) and 
demonstrates good reliability (Cella et al., 2010).  In this study, Cronbach’s alpha was 0.91. 
 
Procedures 
From February 2019 to July 2019, a questionnaire was mailed to 691 potential 
participants at their home addresses.  It included demographic questions, the 51-item COPD-
related Stigma Scale, the Stigma Scale for Chronic Illness (Molina et al., 2013), the Charlson 
Comorbidity Index (M. E. Charlson et al., 1987), the Hospital Anxiety and Depression Scale 




(PROMIS) Physical Function Short-form 10a (Cella et al., 2010).  Participants who had not 
responded within eight weeks received another mail carrying the same set of questionnaires as a 
reminder.  Participants who returned the questionnaire received a $10 gift card for their time.  
Of the 691 questionnaires, 51 were returned as non-deliverable because of incorrect 
address and 5 were returned with a note that the addressee had died.  Of the 635 remaining 
questionnaires, 150 were returned after the two mailings (23.62 % response rate).    
 
Data analysis 
 All analyses were conducted using IBM SPSS Statistics for Windows, Version 26.0.  
Demographic variables and study measures were described using means and standard deviations 
or using proportions with 95% confidence intervals.  Two participants did not answer most items 
on the COPD-related Stigma Scale (64.7%, 82.4%), and were therefore not included in the 
analyses.   
 Item analysis was used to reduce the number of items prior to factor analysis.  
Distributional characteristics of 51 items were examined, including mean, range, the frequency 
and percentage of each response category, and percentages of minimum and maximum responses 
for the floor and ceiling effects.  Of the 51 items, eight items were only applicable to participants 
using supplemental oxygen and/or an inhaler and having COPD-related symptoms; hence, these 
items were not included for the subsequent analysis.  In the next step inter-item correlations and 
item-total correlations were assessed; items were deleted if they had consistently low (r < 0.3) or 
high (r > 0.7) correlations with other items, removal did not negatively affect the Cronbach’s 
alpha, and they were reviewed by a COPD content expert and judged as not crucial for the scale.  




if they were considered to be redundant, removal did not have a negative effect on the 
Cronbach’s alpha, and a COPD expert judged them as not crucial for the scale.  
The dimensional structure of the COPD-related Stigma Scale was assessed using 
exploratory factor analysis (EFA), which was performed on 30 items of the COPD-related 
Stigma Scale.  To evaluate factor analysis suitability, the Kaiser-Meyer-Olkin (KMO) Measure 
of Sampling Adequacy and Bartlett’s Test of Sphericity were conducted.  A KMO value greater 
than 0.5 (range from 0 to 1) is considered suitable for the factor analysis (Dziuban & Shirkey, 
1974; Kaiser, 1974), as is a Bartlett’s test of sphericity value at a significance level of p < 0.05.    
To determine the appropriate number of factors, the eigenvalue rule (Kaiser, 1960), the 
scree test (Cattell, 1966), and the parallel analysis were used.  Factors that contain an eigenvalue 
of 1.0 or greater are retained by the eigenvalue rule (Kaiser, 1960).  The scree test uses a plot 
based on the eigenvalues of the extracted factors (DeVellis, 2016).  A sharp breaking point in the 
plot was considered to determine the ‘right’ number of factors (Cattell, 1966).  To reduce the 
limitations of each method, e.g., arbitrariness, subjectivity, and ambiguity (Hayton, Allen, & 
Scarpello, 2004), parallel analysis was used along with the eigenvalue rule and the scree test.  To 
conduct parallel analysis, random data that contains corresponding eigenvalues to the research 
data were generated (DeVellis, 2016; Hayton et al., 2004; Williams, Onsman, & Brown, 2010).  
To determine the number of factors, the magnitude of eigenvalues from both the research data 
and the randomly generated data were compared; factors for eigenvalues of the research data that 
were greater than those of the random data were retained (DeVellis, 2016; Hayton et al., 2004).   
To increase the interpretability, extracted factors were rotated using the varimax method, 
which would provide clearer factor loading patterns and help researchers interpret findings from 




evaluated.  Item-to-factor loading greater than 0.40 was considered the cut-off value for this 
study.  When an item loads on two or more factors, both the strength of the relationship between 
the item and the factor as well as the nature of the latent variable, i.e., the theoretical perspective, 
were considered together (Johnson & Rogers, 2006; Yong & Pearce, 2013).  
The internal consistency reliability of the COPD-related Stigma Scale was assessed using 
Cronbach’s alpha coefficients.  The convergent validity of the COPD-related Stigma Scale was 
assessed by demonstrating correlations with the Stigma Scale for Chronic Illness 8 items (SSCI-
8).  The convergent validity was also assessed by examining relationships between the COPD-
related Stigma Scale score and scores from the CCI, the HADS, and the PROMIS Physical 
Function Short Form.   
Using independent sample t-tests, the COPD-related Stigma Scale scores were compared 
between groups: 1) those who were versus were not using supplemental oxygen, 2) those who 
were versus were not using inhalers, and 3) those who were versus were not having COPD-
related symptoms.  The COPD-related Stigma Scale scores were also compared among smoking 
status groups using a one-way analysis of variance.  
Using multiple linear regression analysis, the association between COPD-related Stigma 
Scale scores and the other measures, including demographic variables was examined.  The 
associations were also examined between each subscale—social stigma, self-blame, physical 
limitation, and self-inflicted disease—and the other measures. 






 Demographic characteristics of participants (N = 148) are shown in Table 4-1.  The mean 
age of participants was 64.1 years (range: 51-84), 73 (49.3%) were female, 134 (90.5%) were 
Caucasian or White, and 83 (56.1%) had a college degree or higher.  Fifty-seven (38.5%) were 
married, 107 (72.3%) were living with other adults, dependents, or other adults and dependents, 
60 (40.5%) were retired, and 24 (16.2%) were employed either part- or full-time or were self-
employed.  All participants had a history of smoking: 35 (23.6%) were former smokers, and 113 
(76.4%) were still smoking either regularly or once in a while.  A majority of participants 
(83.1%) were using an inhaler, and 32 (21.6%) were using supplemental oxygen for COPD. 
 
Item Analysis and Item Reduction 
 There was no evidence of ceiling or floor effects; all 51 items encompassed the full range 
of response options (see Appendix I).  Most of the inter-item correlation coefficients for items 4, 
12, 13, 19, 21, and 28 were low (r ≤ 0.3), and these items were deleted from the scale.  Item 13 
was restored because this item reflects attitudes towards help-seeking, an important potential 
effect of stigma.  Further, items 8, 24, 25, 32, 33, 37, 48, and 51 were deleted from the scale 
because they were deemed to be redundant to other items on the scale, removing them did not 




 Once the 13 items were deleted in the item analysis, the factorability tests showed that the 
factor analysis was suitable with the 30-item COPD-related Stigma Scale.  The KMO measure of 




sphericity was significant (𝜒2(378) = 2746.685, p < 0.0001), indicating that the correlation 
structure is adequate for factor analysis.  The principal component analysis with varimax rotation 
was used to reduce the number of items and identify the number and meaning of factors that 
underlie the 30 items.  We retained items with factor loadings ≥ 0.40.   
Initial eigenvalues yielded a five-factor solution, which accounted for 69.27% of the total 
variance.  Eigenvalues combined with parallel analysis (Table 4-2) and a scree plot suggested a 
three-factor solution, which explained 61.48% of a total variance.  Given these findings, we 
examined possible solutions from a three-, four- and five-factor solution to maximize the 
explained variance and the internal consistency.  We examined the influence of Cronbach’s alpha 
value for the total 30 items and subscales as well as double loaded items across factors.  As a 
result, two items were dropped, leaving 28 total items.   
The four-factor solution was regarded as the best fit for the data, which explained a total 
of 66.41% of the variance for the entire set of items.  The first factor, labeled social stigma, was 
comprised of 10 items that explained 49.30% of the variance with factor loadings from 0.618 to 
0.857.  The items loaded on the first factor were related to enacted stigma at the interpersonal 
level and social isolation.  The second factor, labeled self-blame, was comprised of nine items 
that explained 7.69% of the variance with factor loadings from 0.530 to 0.709.  These items 
referred to self-conscious emotions that relate to having COPD and disclosure of having COPD.  
The third factor, labeled physical limitation, was comprised of five items that explained 5.03% of 
the variance with factor loadings from 0.545 to 0.730.  These items were related to changes in 
physical capabilities due to having COPD.  The fourth factor, labeled self-inflicted disease, was 
comprised of four items that explained 4.39% of the variance with factor loadings from 0.510 to 




fourth factor explained less than 5 % of the variance, we selected the four-factor solution because 
it improved the interpretability of the factors.  Factor loadings from the rotated factor-loading 
pattern matrix, along with mean and standard deviation scores of each item, is shown in Table 4-
3. 
 
Internal Consistency Reliability 
 The Cronbach’s α coefficient for the 28-item version of the COPD-related Stigma Scale 
was 0.96 and, for the four factors—subscales of social stigma, self-blame, physical limitation, 
and self-inflicted disease—were 0.95, 0.90, 0.84, and 0.70, respectively (see Table 4-4).  
Reliability was strong for the 28-item COPD-related Stigma Scale and the social stigma, self-
blame, and physical limitation subscales, but acceptable for the self-inflicted disease subscale. 
 
Convergent Validity 
 Convergent validity was assessed via correlations between the 28-item version of the 
COPD-related Stigma Scale scores and the SSCI-8, CCI, HADS, and PROMIS Physical 
Function scores (see Table 4-5).  The mean scores of the total 28 items COPD-related Stigma 
Scale and the SSCI-8 scores was highly correlated (r = 0.84).  The mean scores of each factor 
(i.e., social stigma subscale, self-blame subscale, physical limitation subscale, and self-inflicted 
disease subscale) and the SSCI-8 scores were moderately or highly correlated (r = 0.76, 0.77, 
0.69, and 0.64, respectively).  Individuals with higher stigma scores were more likely to report 
psychological distress (r = 0.53, p < 0.0001) and more likely to demonstrate poorer physical 
functioning (r = -0.36, p < 0.0001).  However, stigma scores were not significantly correlated 






 Group comparisons were conducted to determine if stigma varied by demographics (see 
Table 4-6).  Mean scores for the 28-item COPD-related Stigma Scale were significantly higher in 
women than in men [F(1, 146) = 9.25, p = 0.003], as were those of the social stigma, self-blame, 
and self-inflicted disease subscales [F(1, 146) = 7.34, p = 0.008; F(1, 146) = 7.94, p = 0.006; 
F(1, 146) = 11.64, p = 0.001, respectively].  In addition, physical limitation subscale scores were 
significantly higher in those who use supplemental oxygen versus those who do not [F(1, 146) = 
13.72, p < 0.0001] and in those who use inhalers versus those who do not [F(1, 146) = 14.04, p < 
0.0001].   
 
Multiple Linear Regression Analysis 
 Results of multiple linear regression analysis were shown in see Table 4-7.  Results 
indicated that there was a collective significant effect between other measures and 1) the 28-item 
COPD-related Stigma Scale in model 1 [F(34,121) = 2.94, p < 0.0001], 2) social stigma subscale 
in model 2 [F(34,121) = 1.99, p = 0.006], 3) self-blame subscale in model 3 [F(34,121) = 2.14, p 
= 0.002], 4) physical limitation subscale in model 4 [F(34,121) = 4.28, p < 0.0001], and self-
inflicted disease subscale in model 5 [F(34,121) = 1.98, p = 0.006].  After controlling of other 
measures, the HADS was a significant predictor in all models, and the PROMIS physical 






 Findings from this study support the reliability and validity of the 28-item COPD-related 
Stigma Scale.  From the factor analysis, four factors were derived and entitled social stigma, self-
blame, physical limitation, and self-inflicted disease.  While the social stigma subscale measures 
social reactions to people with COPD, the other three subscales—self-blame, physical limitation, 
and self-inflicted disease—measure self-conscious emotions of having COPD and internalization 
of social reactions to them, which implies that COPD is an emotionally burdensome disease for 
individuals with COPD.   
 Given the heightened burden encountered in people with COPD, we sought to develop a 
concise but comprehensive stigma scale that assesses all possible aspects of stigma in people 
with COPD based on literature (Berger et al., 2011) as well as our previous qualitative study (see 
Chapter 3).  However, we could not include eight items that described stigma experiences related 
to the visible characteristics of having COPD, including the use of supplemental oxygen/inhaler 
and eye-catching symptoms, in our analysis because quite a small number of participants could 
answer those items.  These items have been reported as meaningful stigma cues that can lead to 
feelings of shame and embarrassment as well as being isolated from society (Earnest, 2002; 
Goldbart et al., 2013; Gysels & Higginson, 2008; O'Neill, 2002).  Although we could not include 
these items to the scale, we found in our group comparison that people who use the supplement 
oxygen or inhaler showed higher levels of stigma in the physical limitation domain than those 
who do not use these treatment devices.  Considering the evidence in the literature and our study, 
those eight items should be dealt with in the future study.    
 In addition, we took iterative steps to identify a shorter set of items that reflected various 




numerical findings from statistical analysis and empirical evidence from a qualitative study and 
experts’ review.  For example, item 13, “Some health care providers have been abrupt with me 
about smoking,” was flagged for dropping from the scale because of the low inter-item 
correlation coefficients with most items.  However, this item assesses potential barriers to 
effective health communications, and there is no item to cover similar aspect; thus, this item was 
retained.  Findings from our cognitive interview study (see Chapter 3) supported our decision.  
The following are excerpts from this cognitive interview study in that regard; “…I have had 
health care providers be abrupt with me and I thought, "Well, I won't be back," is the kind of 
thoughts I had…[ICS103]”, “…one nurse I remember, … I was in my mother-in-law's when she 
was dying in the hospital, … when I came in, the nurse looked at me with total disgust and said, 
"I can smell cigarette smoke on you."  And I said, "Yeah, you probably can."…I mean it was just 
terrible, the way she said it was, "You idiot, I can smell cigarette smoke on you."  It was a 
terrible thing to say…[ICS204]”, and “…when the doctor years ago said to me about that-- just 
the way he worded how my condition was. It was scary, … it’s better to come across with 
solutions how to improve your life quality and your health, to not come across judgmental. … 
[ICS210].”    
Along with breathing difficulties and progression of the disease itself, COPD-related 
stigma can be one factor in the psychological distress that people with COPD often experience 
(Kunik et al., 2005; Maurer et al., 2008).  As hypothesized, our study found that the HADS was a 
significant predictor of the total 28-item COPD-related Stigma Scale and all four subscales.  This 
finding is in line with literature on the impact of stigma on psychological distress.  Regarding the 




emotions in people with COPD are significantly associated with anxiety and depression, and 
health-related quality of life.   
This psychological distress-stigma relationship was also found in other chronic 
respiratory illnesses.  A study in people with lung cancer showed that perceived stigma was a 
significant contributor to depressive symptoms (Gonzalez & Jacobsen, 2012).  In other studies, 
lung cancer-related stigma was strongly associated with depression and quality of life (Cataldo et 
al., 2012) as well as lung cancer symptom severity (Cataldo & Brodsky, 2013).  In a study in 
people with asthma, higher levels of stigma were significantly associated with poorer 
psychological health and poorer asthma control (Andrews, Jones, & Mullan, 2013).  Given these 
consistent relationships between health-related stigma and psychological distress, we should 
carefully consider the impact of COPD-related stigma on psychological distress. 
In terms of physical function, this study found that people with COPD can experience 
self-conscious feelings due to their physical limitations, which is distinguishable from other 
chronic illness-related stigmas.  This could be explained in several ways.  First, limited physical 
functioning may cause emotional distress (Looper & Kirmayer, 2004) related to a component of 
seeking help to others or characteristics of COPD, i.e., a self-inflicted disease.  Second, limited 
physical functioning can be regarded as undesirable, particularly when individuals are relatively 
younger than those who show similar levels of decline in physical function (Bierman & Statland, 
2010).  Third, how society views individuals with COPD may affect how they perceive their 
disease.  Some qualitative studies reported that people with COPD felt embarrassment (Svedsater 
et al., 2017) or were aware of the potential stigma (Berger et al., 2011) with regard to decreased 




being physically active, it may provide helpful information when examining self-conscious 
emotions related to physical limitations in subsequent studies.    
Although this study supported the convergent validity of the 28-item COPD-related 
Stigma Scale with measures of psychological distress and physical function, evaluating the 
associations between the 28-item COPD-related Stigma Scale and comorbid conditions did not 
support the convergent validity.  This may suggest that the impact of comorbid conditions on 
levels of COPD-related stigma could be minor. 
 The 28-item COPD-related Stigma Scale may be more comprehensive than the general 
stigma scale for chronic illness (i.e., SSCI-8), and thus more appropriate for people with COPD.  
The SSCI-8 assesses two domains—enacted stigma and internalized stigma, whereas the 28-item 
COPD-related Stigma Scale assesses four stigma domains specific to COPD—social stigma, 
self-blame, physical limitation, and self-inflicted disease.  The social stigma domain includes 
most items of the enacted stigma domain and shows a high correlation between the two domains 
(r = 0.75).  The internalized stigma domain is encompassed by and shows moderate to high 
correlations with the self-blame (r = 0.73) and physical limitation (r = 0.77) domains.  In 
addition to those shared items, the social stigma domain includes additional items assessing 
socializing with friends and acquaintances as well as negative images or beliefs toward people 
with COPD.  The domains of self-blame and physical limitation encompass items that may 
assess perceived social identity in relation to a stigmatized condition and ensuing behavioral 
changes.  In terms of the self-inflicted disease domain, because this domain reflects stigma 
experiences from healthcare providers and others, it may be conceptually important in 
understanding COPD-related stigma.  Items in the self-inflicted disease domain not only ask 




healthcare providers and others, which can shed light on the help-seeking behaviors of people 
with COPD, because several studies indicate that those who anticipate stigma by healthcare 
workers were less willing to seek healthcare (Chin & Armstrong, 2019; Earnshaw & Quinn, 
2012).  Therefore, the 28-item COPD-related Stigma Scale provides a more global view of 
COPD-related stigma than does the SSCI-8.  
 
Limitations 
 This study has several limitations, one of which is the limited generalizability of the 
findings.  Participants were recruited from a single academic health system in the United States, 
which may not be representative of the broader population, and the vast majority of participants 
were Caucasian/White (90.1%) and not actively employed (83.9%).  Further evaluations are 
needed to ensure that the COPD-related Stigma Scale reflects the stigma experiences of people 
from diverse groups and geographically different regions.  Further, we expected to compare 
levels of COPD-related stigma in groups: those who ever smoked vs. never smoked, those who 
use vs. do not use supplemental oxygen, and those who use vs. do not use inhalers.  However, 
due to the unequal sample sizes of the groups, findings from the group comparisons should be 
interpreted carefully.  Another limitation is that social desirability may tempt participants to 
provide untruthful answers.  If this happens, item validity is compromised.   
 
Conclusion 
This study used quantitative methods to develop and test the 28-item COPD-related 
Stigma Scale for evaluating patient-reported stigma experiences in people with COPD.  Findings 




new instrument includes four domains—social stigma, physical limitation, self-blame, and 
smoking—that reflect COPD-related stigma.  The findings of this study can be used to 
understand the underlying concepts of stigma in people with COPD and its impact on their 
psychological and physical health.  Further research is needed to evaluate the stability of the 
derived four-factor model across groups of individuals or over time, and to determine how the 
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Table 4-1. Demographic and Clinical Characteristics of Subjects (N = 148) 
Characteristics Mean (SD) [range] N (%) 
Age (years) 64.06 (7.27) [51 – 84]  
Age Groups   
50 – 59  45 (30.4%) 
60 – 69 66 (44.6%) 
70 – 79 34 (23.0%) 
> 80 3 (2.0%) 
Gender  
Female 73 (49.3%) 
Male 75 (50.7%) 
Race/ethnicity  
Caucasian / White 134 (90.5%) 
Black / African American 8 (5.4%) 
Other 5 (3.5%) 
American Indian / Native American and Caucasian 2 (1.4%) 
Greek and Caucasian 1 (0.7%) 
Sinhalese 1 (0.7%) 
Western Europe 1 (0.7%) 
Missing 1 (0.7%) 
Education  
≤ 12th grade 65 (43.9%) 
Some college 58 (39.2%) 
College degree 17 (11.5%) 
Advanced degree 8 (5.4%) 
Relationship status  
Never married 22 (14.9%) 
Married 57 (38.5%) 
Partnered 6 (4.1%) 
Separated 6 (4.1%) 
Divorced 44 (29.7%) 
Widowed 12 (8.1%) 
Missing 1 (0.7%) 
Living arrangement  
Alone 37 (25.0%) 
No dependents 2 (1.4%) 
With other adult(s) 82 (55.4%) 
With dependent(s) only 8 (5.4%) 




Characteristics Mean (SD) [range] N (%) 
Missing 2 (1.4%) 
Occupational status  
Homemaker 5 (3.4%) 
Unemployed 6 (4.1%) 
Retired 60 (40.5%) 
Disability 51 (34.5%) 
Leave of absence 2 (1.4%) 
Employed part-time 4 (2.7%) 
Employed full-time 15 (10.1%) 
Self-employed 5 (3.4%) 
Smoking status  
Current 113 (76.4%) 
a. On a regular basis 91 (61.5%) 
b. Only once in a while 22 (14.9%) 
Former 35 (23.6%) 
Duration of having COPD (years) 8.84 (7.87) [0 – 39]§  
Supplemental oxygen usage  
Yes 32 (21.6%) 
No 116 (78.4%) 
Inhaler usage  
Yes 123 (83.1%) 
No 25 (16.9%) 
COPD symptoms such as cough, phlegm, or shortness of breath  
Yes 129 (87.2%) 
No 19 (12.8%) 
Stigma Scale for Chronic Illnesses-
8 items 2.06 (0.83) [1.0 – 5.0]  
Charlson Comorbidity Index 3.48 (3.51) [0 – 20]  
Hospital Anxiety and Depression 
Scale (14 items) 2.02 (0.58) [1 – 3.5]  
PROMIS Physical Function-10 
items 3.43 (0.79) [1.6 – 5.0]  
Note. COPDSS = COPD-related Stigma Scale; SD = Standard Deviation; PROMIS = Patient-Reported Outcomes 









from factor analysis 
Criterion value from 
parallel analysis Decision 
1 19.351 2.268544 Accept 
2 2.754 2.046756 Accept 
3 2.249 1.894408 Accept 
4 1.762 1.813212 Reject 
5 1.577 1.706183 Reject 
Note. Factors from the actual data with eigenvalues greater than the corresponding values from the parallel analysis 





Table 4-3. Factor Loadings from Rotated Factor-Loading Pattern Matrix (N = 112) 
Item 28-item COPDSS Factor Loading 
Mean (SD) 1 2 3 4 
35. Most people with COPD are rejected when others find out. 1.79 (0.65) 0.857 0.275 0.026 0.144 
34. Most people think that a person with COPD is disgusting. 1.81 (0.70) 0.773 0.308 0.087 0.183 
31. It is easier to avoid new friendships than worry about telling someone that I have 
COPD. 
1.87 (0.72) 0.769 0.152 0.260 0.043 
30. Most people believe that a person who has COPD is unclean. 1.87 (0.68) 0.765 0.146 0.217 0.056 
39. Most people are uncomfortable around someone with COPD. 2.01 (0.75) 0.715 0.340 0.138 0.332 
50. People who know I have COPD tend to ignore my good points. 1.76 (0.65) 0.715 0.412 0.089 0.166 
29. People with COPD are treated like outcasts. 2.10 (0.74) 0.708 0.199 0.225 0.200 
38. If they learn I have COPD, I worry about people discriminating against me. 1.95 (0.79) 0.689 0.327 0.222 0.264 
47. I have stopped socializing with some people because of their reactions to my 
having COPD. 
1.91 (0.77) 0.685 0.481 0.185 0.180 
43. I have been hurt by how people reacted to learning I have COPD. 1.94 (0.77) 0.618 0.560 0.193 0.248 
22. I feel guilty because I have COPD. 2.42 (0.88) 0.096 0.709 0.371 0.030 
23. People's attitudes about COPD make me feel worse about myself. 2.24 (0.93) 0.269 0.687 0.344 0.248 
42. Having COPD is disgusting to me. 2.17 (0.78) 0.439 0.624 0.101 0.190 
44. I regret having told some people that I have COPD. 1.99 (0.74) 0.557 0.616 0.146 0.154 
46. Some people act as though it's my fault I have COPD. 2.54 (0.92) 0.361 0.613 0.035 0.480 
41. I worry that people may judge me when they learn I have COPD. 2.12 (0.76) 0.474 0.596 0.210 0.205 
26. I work hard to keep my COPD a secret. 1.94 (0.76) 0.456 0.560 0.065 0.044 
27. I feel I am not as good a person as others because I have COPD. 2.10 (0.91) 0.378 0.549 0.354 0.047 
Reversed 40. I never feel the need to hide the fact that I have COPD. 2.17 (0.82) 0.385 0.530 0.201 -0.084 
16. My COPD puts a burden on my friends and loved ones. 2.25 (0.92) -0.012 0.258 0.730 0.068 
15. Having COPD has changed my view of what I can do. 2.95 (0.91) 0.142 0.166 0.724 0.219 
5. It's embarrassing not to be able to keep up with others when we're walking. 2.83 (0.97) 0.225 0.016 0.700 0.176 
14. I feel flawed because I have COPD. 2.42 (1.02) 0.426 0.222 0.610 0.291 
18. I plan my activities carefully so others won't notice I can't do as much as I used 
to. 




Item 28-item COPDSS Factor Loading 
Mean (SD) 1 2 3 4 
10. Others blame a person with COPD for having smoked. 3.13 (0.85) 0.145 0.229 0.229 0.731 
11. Others think people with COPD are idiots for having smoked. 2.92 (0.92) 0.100 0.231 0.368 0.675 
13. Some health care providers have been abrupt with me about smoking. 2.52 (0.97) 0.215 -0.186 0.263 0.510 
45. People have told me that getting COPD is what I deserve for having smoked 
cigarettes. 
2.33 (0.96) 0.326 0.580 -0.111 0.557 
Note. COPDSS = COPD-related Stigma Scale; SD = Standard Deviation; F1 = social stigma subscale; F2 = self-blame subscale; F3 = physical limitation subscale; 












Table 4-4. The 28-item version COPD-related Stigma Scale Reliability 
 Cronbach’s Alpha 
28-item COPD-related Stigma Scale 0.96 
Social Stigma (Factor 1: 10 items) 0.95 
Self-blame (Factor 2: 9 items) 0.90 
Physical limitation (Factor 3: 5 items) 0.84 














PF F1 F2 F3 F4  SSCI-8 (E) SSCI-8 (I) 
28-item COPDSS 1.00     0.84** 0.78** 0.79** 0.07 0.53** -0.36** 
F1 0.91** 1.00    0.76** 0.75** 0.64** 0.06 0.45** -0.30** 
F2 0.93** 0.81** 1.00   0.77** 0.72** 0.73** 0.07 0.46** -0.27** 
F3 0.79** 0.59** 0.65** 1.00  0.69** 0.55** 0.77** 0.05 0.58** -0.50** 
F4 0.76** 0.59** 0.62** 0.57** 1.00 0.64** 0.63** 0.56** 0.06 0.32** -0.18* 
Note. COPDSS = COPD-related Stigma Scale; F1 = social stigma subscale; F2 = self-blame subscale; F3 = physical limitation subscale; F4 = self-inflicted disease 
subscale; SSCI-8 = Stigma Scale for Chronic Illness 8-item version; HADS = Hospital Anxiety and Depression Scale; PROMIS Physical Function = Patient-
Reported Outcomes Measurement Information System Physical Function Short-Form 10a 






Table 4-6. Group comparisons of 28-item COPD-related Stigma Scale scores 
 Gender [Mean (SD)] 
 Total (n = 148) Female (n = 73) Male (n = 75)   F(1, 146) p-value 
28-item COPDSS 2.24 (0.55) 2.38 (0.59) 2.11 (0.48)   9.25 0.003 
Social Stigma 1.91 (0.59) 2.04 (0.63) 1.78 (0.52)   7.34 0.008 
Self-blame 2.21 (0.62) 2.35 (0.69) 2.07 (0.52)   7.94 0.006 
Physical Limitation 2.57 (0.71) 2.68 (0.73) 2.46 (0.67)   3.47 0.064 
Self-inflicted disease 2.74 (0.67) 2.93 (0.67) 2.57 (0.61)   11.64 0.001 
 Age [Mean (SD)] 
 Total 
(n = 148) 
50 – 59 years 
(n = 45) 
60 – 69 years 
(n = 66) 
70 – 79 years 
(n = 34) 
≥ 80 years 
(n = 3) F(3, 144) p-value 
28-item COPDSS 2.24 (0.55) 2.34 (0.60) 2.26 (0.52) 2.07 (0.53) 2.37 (0.23) 1.67 0.176 
Social Stigma 1.91 (0.59) 1.99 (0.64) 1.91 (0.59) 1.79 (0.54) 1.83 (0.40) 0.71 0.546 
Self-blame 2.21 (0.62) 2.30 (0.65) 2.22 (0.62) 2.05 (0.58) 2.35 (0.89) 1.06 0.368 
Physical Limitation 2.57 (0.71) 2.71 (0.74) 2.60 (0.69) 2.29 (0.67) 2.87 (0.12) 2.73 0.046 
Self-inflicted disease 2.74 (0.67) 2.84 (0.64) 2.77 (0.66) 2.51 (0.69) 3.25 (0.25) 2.40 0.071 
 Education [Mean (SD)] 
 Total 
(n = 148) 
≤ 12th grade  
(n = 65) 
Some college  
(n = 58) 
College degree  
(n = 17) 
Advanced degree 
(n = 8) F(3, 144) p-value 
28-item COPDSS 2.24 (0.55) 2.14 (0.43) 2.41 (0.62) 2.11 (0.63) 2.15 (0.55) 2.97 0.034 
Social Stigma 1.91 (0.59) 1.80 (0.49) 2.05 (0.62) 1.87 (0.75) 1.80 (0.59) 2.10 0.103 
Self-blame 2.21 (0.62) 2.09 (0.52) 2.38 (0.70) 2.05 (0.63) 2.21 (0.57) 2.67 0.050 
Physical Limitation 2.57 (0.71) 2.48 (0.60) 2.76 (0.70) 2.31 (0.80) 2.40 (1.10) 2.88 0.038 
Self-inflicted disease 2.74 (0.67) 2.68 (0.65) 2.89 (0.69) 2.60 (0.70) 2.56 (0.42) 1.57 0.199 
 Race/Ethnicity [Mean (SD)] 
 Total 
(n = 147) 
Black / African 
American (n = 8) 
Caucasian / 
White (n = 134) 
Other 
(n = 5) 
 
F(2, 144) p-value 
28-item COPDSS 2.24 (0.55) 2.05 (0.40) 2.24 (0.56) 2.47 (0.47)  0.93 0.395 
Social Stigma 1.91 (0.59) 1.74 (0.41) 1.90 (0.60) 2.32 (0.33)  1.57 0.213 




Physical Limitation 2.56 (0.70) 2.40 (0.53) 2.57 (0.71) 2.55 (0.79)  0.22 0.805 
Self-inflicted disease 2.74 (0.67) 2.31 (0.44) 2.76 (0.67) 3.00 (0.61)  2.12 0.124 
 Relationship status [Mean (SD)] 
 Total  
(n = 147) 
Never married 
(n = 22) 
Married 
(n = 57) 
Partnered 
(n = 6) 
Separated 
(n = 6) 
Divorced 
(n = 44) 
Widowed 
(n = 12) F(5, 141) p-value 
28-item COPDSS 2.24 (0.55) 2.21 (0.39) 2.12 (0.58) 2.52 (0.54) 2.55 (0.84) 2.32 (0.55) 2.25 (0.35) 1.46 0.207 
Social Stigma 1.90 (0.58) 1.90 (0.48) 1.77 (0.61) 2.01 (0.54) 2.37 (0.93) 1.96 (0.59) 2.03 (0.26) 1.60 0.163 
Self-blame 2.20 (0.62) 2.15 (0.45) 2.10 (0.64) 2.56 (0.58) 2.35 (0.97) 2.31 (0.65) 2.15 (0.45) 1.10 0.364 
Physical Limitation 2.56 (0.71) 2.63 (0.59) 2.39 (0.75) 3.07 (0.62) 2.90 (0.65) 2.64 (0.72) 2.50 (0.52) 1.75 0.126 
Self-inflicted disease 2.73 (0.66) 2.58 (0.61) 2.71 (0.72) 3.00 (0.69) 3.00 (0.94) 2.78 (0.60) 2.71 (0.52) 0.68 0.641 
 Living arrangement Mean (SD)] 
 
Total  
(n = 146) 
Alone  
(n = 37)  
No dependents 
(n = 2) 
With other 
adults  
(n = 82) 
With 
dependents 




(n = 17) F(4, 141) p-value 
28-item COPDSS 2.24 (0.55) 2.23 (0.51) 2.07 (0.15) 2.2 (0.57) 2.44 (0.67) 2.43 (0.51) 0.93 0.450 
Social Stigma 1.91 (0.59) 1.89 (0.56) 2.05 (0.07) 1.87 (0.61) 2.18 (0.83) 2.00 (0.50) 0.62 0.651 
Self-blame 2.21 (0.63) 2.22 (0.62) 2.06 (0.08) 2.15 (0.64) 2.47 (0.63) 2.35 (0.60) 0.77 0.549 
Physical Limitation 2.56 (0.71) 2.61 (0.67) 1.90 (0.14) 2.47 (0.70) 2.6 (0.74) 2.94 (0.74) 2.04 0.091 
Self-inflicted disease 2.75 (0.66) 2.59 (0.62) 2.38 (0.53) 2.76 (0.67) 2.81 (0.75) 3.07 (0.63) 1.74 0.144 
 Occupational status Mean (SD)] 
 
Total  
(n = 148) 
Home-
maker  
(n = 5) 
Un-
employed  
(n = 6) 
Retired 
(n = 60) 
Disability 
(n = 51) 
Leave of 
absence 
(n = 2) 
Part-time 
employed 
(n = 4) 
Full-time 
employed 
(n = 15) 
Self-
employed 
(n = 5) F(7, 140) p-value 
28-item COPDSS 2.24 (0.55) 2.55 (0.47) 2.36 (0.74) 2.19 (0.60) 2.29 (0.53) 1.75 (0.15) 2.28 (0.30) 2.21 (0.49) 2.25 (0.35) 0.63 0.734 
Social Stigma 1.91 (0.59) 2.18 (0.35) 2.06 (0.77) 1.86 (0.66) 1.96 (0.55) 1.25 (0.35) 2.10 (0.14) 1.84 (0.55) 1.86 (0.38) 0.75 0.630 
Self-blame 2.21 (0.62) 2.49 (0.57) 2.43 (0.65) 2.18 (0.68) 2.19 (0.64) 1.56 (0.47) 2.31 (0.43) 2.25 (0.48) 2.22 (0.34) 0.60 0.754 
Physical Limitation 2.57 (0.71) 2.64 (0.70) 2.50 (1.06) 2.47 (0.72) 2.74 (0.69) 2.50 (0.71) 2.30 (0.35) 2.44 (0.66) 2.60 (0.68) 0.74 0.636 




 Smoking status [Mean (SD)] 
 Total 
(n = 148) 
Yes, regularly 
(n = 91) 
Yes, occasionally 
(n = 22) 
Not anymore 
(n = 35) 
 
F(2, 145) p-value 
28-item COPDSS 2.24 (0.55) 2.23 (0.57) 2.15 (0.50) 2.34 (0.54)  0.86 0.426 
Social Stigma 1.91 (0.59) 1.90 (0.59) 1.86 (0.58) 1.96 (0.61)  0.24 0.786 
Self-blame 2.21 (0.62) 2.22 (0.63) 2.04 (0.48) 2.29 (0.68)  1.17 0.313 
Physical Limitation 2.57 (0.71) 2.50 (0.75) 2.49 (0.60) 2.80 (0.62)  2.46 0.089 
Self-inflicted disease 2.74 (0.67) 2.75 (0.70) 2.69 (0.68) 2.75 (0.56)  0.10 0.908 
 Supplemental Oxygen use [Mean (SD)] 
 Total (n = 148) Yes (n = 32) No (n = 116)   F(1, 146) p-value 
28-item COPDSS 2.24 (0.55) 2.36 (0.58) 2.21 (0.54)   1.96 0.164 
Social Stigma 1.91 (0.59) 1.92 (0.67) 1.90 (0.57)   0.02 0.899 
Self-blame 2.21 (0.62) 2.30 (0.69) 2.18 (0.60)   0.80 0.372 
Physical Limitation 2.57 (0.71) 2.96 (0.56) 2.46 (0.71)   13.72 0.000 
Self-inflicted disease 2.74 (0.67) 2.88 (0.70) 2.71 (0.65)   1.74 0.189 
 Inhaler use [Mean (SD)] 
 Total (n = 148) Yes (n = 123) No (n = 25)   F(1, 146) p-value 
28-item COPDSS 2.24 (0.55) 2.28 (0.57) 2.08 (0.40)   2.64 0.106 
Social Stigma 1.91 (0.59) 1.92 (0.61) 1.83 (0.45)   0.54 0.462 
Self-blame 2.21 (0.62) 2.23 (0.66) 2.09 (0.41)   1.09 0.298 
Physical Limitation 2.57 (0.71) 2.66 (0.67) 2.10 (0.72)   14.04 0.000 
Self-inflicted disease 2.74 (0.67) 2.76 (0.69) 2.64 (0.52)   0.72 0.396 
 COPD Symptoms [Mean (SD)] 
 Total (n = 148) Yes (n = 129) No (n = 19)   F(1, 146) p-value 
28-item COPDSS 2.24 (0.55) 2.24 (0.55) 2.27 (0.58)   0.04 0.848 
Social Stigma 1.91 (0.59) 1.91 (0.58) 1.91 (0.67)   0.00 0.987 
Self-blame 2.21 (0.62) 2.20 (0.62) 2.27 (0.68)   0.21 0.644 
Physical Limitation 2.57 (0.71) 2.58 (0.69) 2.44 (0.80)   0.67 0.413 




Note. SD = Standard Deviation; COPDSS = COPD-related Stigma Scale; Social Stigma = Factor 1; Self-blame = Factor 3; Physical Limitation = Factor 3; Self-






Table 4-7. Multivariate Regression Analysis 
 
Model 1 Model 2 Model 3 Model 4 Model 5 
28-item COPDSS Social Stigma Self-blame Physical Limitation Self-inflicted disease 
Variables B SE B Sig. B SE B Sig. B SE B Sig. B SE B Sig. B SE B Sig. 
Age                 
[50 – 59 years] -0.59 0.34 0.082 -0.42 0.40 0.295 -0.66 0.41 0.110 -0.66 0.39 0.096 -0.95 0.44 0.032 
[60 – 69 years] -0.47 0.31 0.135 -0.31 0.37 0.392 -0.48 0.38 0.207 -0.59 0.36 0.105 -0.84 0.40 0.040 
[70 – 79 years] -0.58 0.31 0.067 -0.36 0.37 0.333 -0.58 0.38 0.131 -0.83 0.36 0.023 -0.94 0.40 0.022 
[≥ 80 years] 0     0   0   0   0   
Gender                
Female 0.20 0.10 0.046 0.19 0.12 0.117 0.31 0.12 0.012 0.09 0.12 0.454 0.16 0.13 0.212 
Male 0     0   0   0   0   
Race/Ethnicity                
African American -0.70 0.34 0.044 0.19 0.12 0.117 -0.63 0.42 0.136 -0.33 0.39 0.410 -1.08 0.44 0.016 
Caucasian -0.15 0.31 0.630 0.19 0.12 0.117 -0.14 0.37 0.702 0.27 0.35 0.450 -0.33 0.40 0.409 
Other 0     0   0   0   0   
Education                
≤ 12th grade 0.09 0.20 0.650 -0.01 0.24 0.955 0.10 0.25 0.678 0.17 0.24 0.475 0.17 0.26 0.528 
Some college 0.29 0.20 0.145 0.20 0.24 0.394 0.30 0.24 0.228 0.38 0.23 0.102 0.38 0.26 0.149 
College degree 0.04 0.24 0.874 0.10 0.29 0.716 0.00 0.30 0.998 0.05 0.28 0.872 -0.02 0.32 0.947 
Advanced degree 0     0   0   0   0   
Relationship status                
Never married 0.36 0.25 0.148 0.30 0.29 0.298 0.44 0.30 0.145 0.32 0.29 0.272 0.34 0.32 0.285 
Married -0.07 0.19 0.712 -0.19 0.22 0.397 0.03 0.23 0.909 -0.18 0.22 0.404 0.12 0.25 0.634 
Partnered 0.52 0.30 0.086 0.21 0.35 0.557 0.64 0.36 0.080 0.64 0.34 0.064 0.75 0.38 0.053 
Separated 0.27 0.28 0.336 0.42 0.33 0.208 0.29 0.34 0.399 -0.17 0.32 0.605 0.43 0.36 0.242 
Divorced 0.31 0.19 0.113 0.18 0.22 0.434 0.43 0.23 0.068 0.19 0.22 0.390 0.40 0.25 0.108 
Widowed 
 
0     0   0   0   0   





Model 1 Model 2 Model 3 Model 4 Model 5 
28-item COPDSS Social Stigma Self-blame Physical Limitation Self-inflicted disease 
Variables B SE B Sig. B SE B Sig. B SE B Sig. B SE B Sig. B SE B Sig. 
Alone -0.18 0.20 0.360 -0.15 0.23 0.512 -0.17 0.24 0.490 -0.22 0.23 0.348 -0.32 0.26 0.209 
No dependents -0.66 0.42 0.117 -0.26 0.49 0.599 -0.67 0.51 0.192 -1.12 0.48 0.023 -1.10 0.54 0.044 
With other adults 0.05 0.18 0.789 0.11 0.21 0.593 0.02 0.22 0.913 -0.02 0.20 0.912 -0.04 0.23 0.849 
With dependents 
only 
0.55 0.26 0.039 0.71 0.31 0.023 0.57 0.32 0.073 0.24 0.30 0.429 0.40 0.34 0.242 
With other adult(s) 
and dependent(s) 
0     0   0   0   0   
Occupational status                
Homemaker 0.47 0.35 0.179 0.51 0.41 0.220 0.51 0.43 0.230 0.17 0.40 0.671 0.76 0.45 0.096 
Unemployed 0.07 0.32 0.840 0.16 0.38 0.673 0.32 0.39 0.411 -0.44 0.37 0.235 -0.11 0.41 0.799 
Retired 0.11 0.24 0.638 0.12 0.28 0.660 0.24 0.29 0.421 -0.02 0.28 0.932 -0.04 0.31 0.910 
Disability 0.10 0.24 0.682 0.22 0.28 0.430 0.13 0.29 0.652 -0.13 0.28 0.634 0.05 0.31 0.861 
Leave of absence -0.52 0.54 0.338 -0.40 0.64 0.533 -0.34 0.66 0.614 -1.15 0.63 0.070 -0.28 0.70 0.689 
Part-time employed 0.37 0.37 0.316 0.48 0.44 0.273 0.56 0.45 0.216 0.13 0.43 0.761 0.02 0.48 0.964 
Full-time employed 0.29 0.27 0.284 0.33 0.32 0.304 0.49 0.33 0.138 0.08 0.31 0.804 0.08 0.35 0.820 
Self-employed 0     0   0   0   0   
Tobacco use                
Yes, regularly -0.02 0.12 0.836 0.01 0.14 0.964 0.07 0.14 0.600 -0.22 0.13 0.099 0.01 0.15 0.941 
Yes, occasionally -0.23 0.16 0.154 -0.13 0.19 0.480 -0.25 0.19 0.195 -0.40 0.18 0.034 -0.12 0.21 0.553 
Not anymore 0     0   0   0   0   
Oxygen use                
No 0.03 0.13 0.795 0.13 0.15 0.399 -0.02 0.16 0.905 -0.06 0.15 0.694 -0.02 0.17 0.900 
Yes 0     0   0   0   0   
Inhaler use                
No -0.02 0.14 0.866 0.00 0.17 0.998 -0.02 0.17 0.916 -0.21 0.16 0.198 0.15 0.18 0.421 





Model 1 Model 2 Model 3 Model 4 Model 5 
28-item COPDSS Social Stigma Self-blame Physical Limitation Self-inflicted disease 
Variables B SE B Sig. B SE B Sig. B SE B Sig. B SE B Sig. B SE B Sig. 
Having COPD symptoms                
No 0.10 0.14 0.463 0.09 0.16 0.599 0.19 0.17 0.268 -0.04 0.16 0.790 -0.14 0.14 0.325 
Yes 0     0   0   0   0   
Duration of having COPD 0.00 0.01 0.552 0.00 0.01 0.853 -0.01 0.01 0.127 0.00 0.01 0.825 0.00 0.01 0.658 
CCI 0.26 0.28 0.354 0.18 0.33 0.575 0.36 0.34 0.288 -0.10 0.32 0.746 0.60 0.36 0.098 
HADS 0.39 0.10 0.000 0.32 0.12 0.008 0.37 0.12 0.004 0.54 0.12 0.000 0.37 0.13 0.006 
PROMIS Physical 
Function 
-0.10 0.08 0.233 -0.12 0.09 0.224 -0.09 0.10 0.380 -0.22 0.09 0.020 0.07 0.10 0.510 
R2 0.54 0.44 0.46 0.63 0.44 
Adjusted R2 0.35 0.22 0.24 0.48 0.22 
Note. DV = dependent variable; DV in Model 1 = 28-item COPDSS; DV in Model 2 = Social Stigma; DV in Model 3 = Self-blame; DV in Model 4 = Physical 
Limitation; DV in Model 5 = Self-inflicted disease; COPDSS = COPD-related Stigma Scale; HADS = Hospital Anxiety and Depression Scale; PROMIS Physical 








 Chronic obstructive pulmonary disease (COPD) affects many major aspects of health, 
including physical functions, psychological functions and overall quality of life.  Studies have 
shown that people with COPD often experience stigma due to their history of smoking and the 
perception that they caused the COPD within their bodies (Arne et al., 2007; Berger et al., 2011; 
Halding et al., 2011).  COPD and smoking are stigmatized by the public and by health-care 
providers, which negatively impacts help-seeking behaviors (Gysels & Higginson, 2008; 
Partridge et al., 2011).  Experiencing these stigmas may cause psychological distress in people 
with COPD and affect their health-related behaviors, which will consequently affect their ability 
to function physically and their quality of life. 
 From the systematic review, we found that although people with COPD have similar 
perceptions of stigma to those with lung cancer, there is a lack of evidence about the dimensions 
that constitute COPD-related stigma and how these dimensions are related to health outcomes.  
The fact that there is no existing measure of COPD-related stigma may be partly responsible for 
the delays in advancing science.  Seeking to fill this gap, we interviewed people with COPD in 
order to develop a valid stigma scale for this population and revised the scale items and response 
options based on the interview findings.  While interviewing people about the COPD-related 
Stigma Scale items, we found that most participants were aware of COPD-related stigmas, but 
there were differences in the way they perceived and coped with stigma.  We also found that 




answer.  This tendency influenced participants to select the mid-point option.  Further evaluation 
showed that the frequency of the mid-point responses was decreased when participants were 
required to explain reasons to choose the mid-point option.  After the interview data analysis, we 
dropped one item and revised eleven items.  We also decided to drop the mid-point option from 
the five-point Likert response options. 
Then, we administered the revised version of the COPD-related Stigma Scale (i.e., the 
51-item COPD-related Stigma Scale with a four-point Likert scale) to a large number of people 
with COPD.  Findings support the assertion that the COPD-related Stigma Scale has four 
underlying constructs—social stigma subscale, physical limitations subscale, self-blame 
subscale, and smoking subscale—and is a reliable, valid measure for people with COPD.  
Findings also indicate that experiencing COPD-related stigma is associated with psychological 
distress and physical-function decline.  Overall, the findings of the scale development study 
suggest that further evaluation may be required to confirm the derived factor structure and 
develop strategies to lessen the impact of COPD-related stigma on disease management and 
quality of life. 
   This study had limitations in some respects.  First, our systematic review aimed to 
identify similarities and differences between COPD-related stigma and lung cancer-related 
stigma.  Due to the complexity of stigma associated with COPD or lung cancer, we limited the 
scope of this review to six domains that cover the pathway from stigma to health (Major et al., 
2018).  Second, we only included people with COPD who were 50 years old or older in order to 
rule out the stigma experiences of people with COPD caused by a genetic condition (e.g., alpha-1 
antitrypsin deficiency [AATD]).  Stigma experiences in those with AATD are attributed to 




However, considering the increasing awareness of COPD, excluding people with COPD under 
50 years old may limit the generalizability of the findings.  Finally, we conducted a factor 
analysis test, excluding eight items that inquired about specific triggers for COPD-related stigma, 
the use of inhalers and supplemental oxygen.  Despite the potential stigma associated with using 
these treatment devices, the issue of the eight items was not addressed in this study because 
many subjects were not receiving supplemental oxygen and/or using inhalers.  The inclusion of 
these items will need to be evaluated in future research where there are larger numbers of 
subjects receiving supplemental oxygen and/or using inhalers.   
 Directions for future research include confirming the factor structure (i.e., the four-factor 
structure) as well as establishing measurement invariance across demographic groups, such as 
those based on gender, culture and geography.  In the process of establishing the construct 
validity of the COPD-related Stigma Scale, we found strong associations between stigma 
experiences and psychological distress as well as reduced physical function.  Future studies may 
investigate the impact of COPD-related stigma on self-management and healthcare use as well as 
quality of life.  Based on the findings in the studies discussed above and literature reviews, 
researchers may consider designing and implementing stigma reduction interventions as a part of 
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Appendix A. Shaw et al. (2009) quality assessment checklist for quantitative studies 
Criteria Yes (2/good) Partial (1/fair) No (0/poor) N/A 
Study aims 
1. Is the hypothesis/aim/ 
objective of the study clearly 
and sufficiently described? 








or some information has to 
be gathered from parts of the 




Question or objective not 
reported/incomprehensible 
 
Study design and sample characteristics 
2. Is the study design well 
described and appropriate? 
(If study question not given, infer 
from 
conclusions) 
Design easily identified, well 
described and appropriate 
Design and/or study question 
not clearly described or 
design only partially 
addresses study question 
Design does not answer study 
question or design is poorly 
described 
 
3. Is the method of 
patient/control group 
selection described and 
appropriate? 
Described and appropriate. 
Inclusion/exclusion criteria 
described and defined 
Selection methods (and 
inclusion/ exclusion criteria) 
not completely described but 
no obvious inappropriateness 
or selection strategy likely 
introduces bias but not 




provided or selection bias that 
likely distorts results 
 
4. Are the characteristics of 
patient/control group(s) 





Reproducible criteria used to 
categorize participants clearly 
defined 









Criteria Yes (2/good) Partial (1/fair) No (0/poor) N/A 
5. Are caregiver characteristics 
clearly described (i.e. age, 
gender, relationship to care 




Reproducible criteria used to 
categorize participants clearly 
defined 






6. Were patients/participants 
randomized to intervention 
groups? 
If randomization appropriate: 
evidence of randomization 
with a description of the 
method used (e.g. random 
number tables, block design) 
Randomization mentioned 
but method is not (i.e. may 
be possible that 
randomization was not 
carried out) 
Random allocation not 
mentioned although it would 
have been feasible and 
appropriate (and was possibly 
carried out) 
Study has no control 
group, i.e. observational/ 
survey/case–control 
study, or adequate 
justification for non-
randomization given 
7. For RCTs only  
 
Was randomization/ 
allocation concealed from 
patients? 
Evidence that next allocation 
was concealed from both 
parties (recruiter and 
patient/carer) at the point of 
consent (e.g. remote 
randomization) 
Allocation concealment 
reported but not described 
Allocation concealment would 
have been possible (and was 
possibly carried out) but not 
reported 
Allocation concealment 
not possible because of 
study design (e.g. cluster 
randomized trial) 
8. Have the characteristics of 
patients lost to follow-up 
been described? 
Losses adequately reported 
and not likely to affect results 
Losses not well reported, but 
small and not likely to affect 
results 
No information or losses large 
and likely to affect results 
No patients lost to follow-
up 
9. Are intervention(s) clearly 
described? 
Defined and reproducible Partially defined but 
insufficient detail to 
reproduce design 
Not described  
Data analysis and results 
10. Are the main outcomes to 
be measured clearly 
described in the 
introduction/methods? 
Defined and measured 
according to reproducible 
criteria 
Definition leaves room for 
subjectivity or not sure (i.e. 
not reported in detail, but 
probably acceptable) or 
precise definition(s) are 
missing, but no evidence of 
major problems or 
instrument/mode of 
assessment(s) not reported 
Main outcomes first 
mentioned in results section 




11. If possible, was an attempt 
made to blind those 
measuring the main 
Assessor blind to 
intervention/study group 
Inadequate blinding, i.e. 
assessor may have been 







Criteria Yes (2/good) Partial (1/fair) No (0/poor) N/A 
outcomes of the 
intervention? 
aware of the group that the 
participant was assigned to 
observational/before-
and-after study 
12. Are population 
characteristics (if measured 
and described) controlled 
for and adequately 
described? 
Appropriate control at design/ 
analysis stage or randomized 
study with comparable 
baseline characteristics 
Incomplete 
control/description or not 
considered but unlikely to 
seriously influence results 
Not controlled for and likely to 
seriously influence results 
 
13. Are the main findings clearly 
described? 
Simple outcome data (e.g. 
mean/ prevalence) reported 
for all major findings 





14. Are methods of analysis 
adequately described and 
appropriate? 
Described and appropriate Not reported but probably 
appropriate or some tests 
appropriate, some not 
Methods not described and 
cannot be determined 
 
15. Are estimates of variance 
reported for the main 
results? 
Appropriate estimates 
provided (SD/SE, confidence 
intervals) 
Undefined or estimates 
provided for some but not all 
outcomes 
No information  
16. In trials/cohort studies do 
analyses adjust for different 
lengths of follow-up, or in 
case–control studies is the 
time between intervention 
and outcome the same for 
cases/ controls? 
Different lengths of follow-up 
adjusted for (e.g. survival 
analysis) and adequately 
described 
Different lengths of follow-up 
probably adjusted for but not 
adequately described 
Differences in follow-up 
ignored 
Cross-sectional design or 
same length of follow-up 
17. If appropriate, were data 
analyzed according to ITT 
(intention to treat) principle? 
All participant data analyzed 
regardless of adherence to 
protocol or continuation in trial 
Attempt made to analyze 
data according to ITT 
principle, but inappropriate 
method or some participants 
not included 
No attempt made to carry out 
ITT analysis 
Design not appropriate 
for ITT (e.g. cross-
sectional data) 
Conclusions 
18. Are the conclusions 
supported by the results? 
All conclusions supported by 
data 
Some of the major 
conclusions supported by 
data, some not or speculative 
interpretations are not 
indicated as such 
None/few of the major 






Note. Adapted from “Systematic review of respite care in the frail elderly,” by C. Shaw, R. McNamara, K. Abrams, R. L. Cannings-John, K. Hood, M. Longo, ... & K. 







Appendix B. Shaw et al. (2009) quality assessment checklist for qualitative studies 
Criteria Yes (2/good) Partial (1/fair) No (0/poor) 
Study aims and context 
1. Is the research question 
sufficiently described? 
Research question clearly identified by the end 
of the research process, if not at the outset 
Research question or objective is 
vaguely/incompletely reported 
Question or objective is not 
reported or is incomprehensible 
2. Is qualitative method 
appropriate? 
Qualitative method is appropriate for the aims 
and the qualitative framework is identified and 
justified 
Qualitative method appropriate but the 
methodological framework unclear or 
not adequately justified 
Qualitative methods 
inappropriate for the aims 
3. Is the setting/context clearly 
described? 
*Context/setting is clearly described, 
permitting the reader to relate the findings to 
other settings 
The context/setting is partially 
described 
The context/setting is not 
described 
Sampling    
4. Is the sampling strategy 
clearly described? 
Sampling strategy and rationale clearly 
described and justified 
Sampling strategy not clearly 
described or not fully justified 
Sampling not described 
5. Is sampling method likely to 
recruit all relevant cases? 
(purposive, theoretical 
sampling) 
Sample includes the full range of relevant, 
possible cases (more than simple convenience 
sample) permitting conceptual (rather than 
statistical) generalizations 
Sampling was purposive but does not 
include the full range of possible cases 
No attempt made to sample 
purposively or theoretically or 
sampling strategy not described 
6. Are relevant characteristics 
of the sample given? 
Relevant details of the characteristics of the 
sample given 
Incomplete details of sample 
characteristics given 
No details of sample 
characteristics given 
7. Is rationale for sample size 
(e.g. data saturation) given 
Gives rationale for termination of data 
collection, e.g. data saturation 
Reasons for sample size implied or no 
firm rationale 





Criteria Yes (2/good) Partial (1/fair) No (0/poor) 
Data collection    
8. Are methods of data 
collection clearly described? 
Data collection methods are systematic and 
clearly described allowing an audit trail such 
that procedures could be replicated 
Data collection methods not clearly 
described. Difficult to determine if 
systematic or replicable 
Data collection procedures are 
not described 
9. Is method of data collection 
appropriate for the research 
question and paradigm? 
Data collection methods are appropriate for 
the research aims and the methodological and 
analytical framework 
The appropriateness of the data 
collection methods is unclear 
Data collection inappropriate for 
the aims and methodological 
framework 
10. Has the researcher verified 
the data (e.g. by 
triangulation)? 
More than one method of data collection 
carried out or more than one analyst involved 
or other methods of verification employed (e.g. 
member checking or line of questioning during 
interview) 
Unclear whether triangulation or other 
types of verification used 
No triangulation or other 
methods of verification 
described 
Data analysis    
11. Are data analysis methods 
clearly described? 
Systematic analytic method clearly described 
such that procedures could be replicated 
Analytic methods not clearly described Analytic methods not described 
12. Are data analysis methods 
appropriate? 
Analytic methods seem appropriate and are 
well described 
Analytic methods only partially 
described and/or some concerns about 
appropriateness 
Analytic methods not described 
and/or appropriate 
13. Are competing 
accounts/deviant data taken 
into account? 
Account given of negative or deviant cases in 
the analysis 
Analysis of deviant or negative cases 
not clearly described 
No account given of negative or 
deviant cases 
Reflexivity    
14. To what extent is the 
researcher reflective? 
The researcher explicitly assessed the likely 
impact of their own personal characteristics 
and the methods used on the data obtained 
Possible sources of influence on the 
data obtained were mentioned, but the 
likely impact of the influence was not 
discussed 
No evidence of reflexivity in the 
report 
Conclusions    
15. Are the interpretations and 
conclusions supported by the 
data? 
The interpretations are clearly described and 
supported by the data and are evidenced by 
sufficient participant quotes 
The conclusions are unclear or only 
partially supported by the data or there 
are insufficient raw data to support 
conclusions 
Conclusions are not identified 
or are felt not to be supported 





Note. Adapted from “Systematic review of respite care in the frail elderly,” by C. Shaw, R. McNamara, K. Abrams, R. L. Cannings-John, K. Hood, M. Longo, ... & K. 






Appendix C. The 52-item COPD-related Stigma Scale 
Thank you for participating in this study. I am a doctoral student at the University of Michigan School of Nursing. This 
study is a part of my dissertation research to develop a stigma scale for people with COPD.  Stigma can be defined 
as making someone seem less important or valuable because of his/her illness.  Many people with COPD have 
suffered from stigma because of their history of smoking.  Stigma experiences can affect people’s mental health, 
such as anxiety and depression, as well as the quality of life.  However, there is no well-established measure to show 
the extent to which people experience stigma.  
 
This interview will help improve our questionnaire. We have a number of questions to describe how people with 
COPD feel and how they are treated.  This questionnaire has 52 items and each item has five answer choices. 
Today, we want to talk with you about the questionnaire. You may choose one of five answer choices: “Strongly 
Disagree (SD),” “Disagree (D).” “Neutral (N),” “Agree (A),” or “Strongly Agree (SA).” Then, I will ask some questions 
related to a given item. There are no right or wrong answers.  
 
This interview will take about 1-1.5 hours. During the interview, I will make notes and audiotape our conversation to 
capture your opinions without any omissions.  I would like to confirm that you are okay with having this interview 
recorded.  All records from this interview will be confidential and will only be identified by a study number.  
 
Before starting, do you have any questions? 
 
1 People shy away from me when they see I’m wearing 
oxygen. 
SD D N A SA 
2 
No one seems embarrassed by my coughing. 
SD D N A SA 
3 
My family doesn’t like me to use my inhaler in public. 
SD D N A SA 
4 People who were good friends before I got COPD are still 
good friends. 
SD D N A SA 
5 It’s embarrassing not to be able to keep up with others 
when we’re walking. 
SD D N A SA 
6 I avoid using my oxygen in public so others won’t think I’m 
ill. 
SD D N A SA 
7 It embarrasses me to use the inhaler in front of other 
people. 
SD D N A SA 
8 When I’m with friends, I don’t feel embarrassed about 
having COPD. 
SD D N A SA 
9 I’m more likely to be embarrassed by my symptoms when 
I’m among strangers. 
SD D N A SA 
10 
Others blame a person with COPD for having smoked. 
SD D N A SA 
11 Others think people with COPD are idiots for having 
smoked. 





People think of COPD as a dirty disease. 
SD D N A SA 
13 I’ve been told not to come back to the doctor until I quit 
smoking. 
SD D N A SA 
14 Health care providers have been abrupt with me about 
smoking. 
SD D N A SA 
15 
I feel flawed because I have COPD. 
SD D N A SA 
16 
Having COPD has changed my view of what I can do. 
SD D N A SA 
17 
My COPD puts a burden on my friends and loved ones. 
SD D N A SA 
18 
I avoid using oxygen in front of other people. 
SD D N A SA 
19 I plan my activities carefully so others won’t notice I can’t do 
as much as I used to. 
SD D N A SA 
20 
I blame myself for having COPD. 
SD D N A SA 
21 
Others are put off by my coughing and sputum. 
SD D N A SA 
22 
In many areas of my life, no one knows that I have COPD. 
SD D N A SA 
23 
I feel guilty because I have COPD. 
SD D N A SA 
24 People's attitudes about COPD make me feel worse about 
myself. 
SD D N A SA 
25 
Telling someone I have COPD is risky. 
SD D N A SA 
26 People with COPD lose their jobs when their employers find 
out. 
SD D N A SA 
27 
I work hard to keep my COPD a secret. 
SD D N A SA 
28 I feel I am not as good a person as others because I have 
COPD. 
SD D N A SA 
29 
I never feel ashamed of having COPD. 
SD D N A SA 
30 
People with COPD are treated like outcasts. 
SD D N A SA 
31 
Most people believe that a person who has COPD is dirty. 
SD D N A SA 
32 It is easier to avoid new friendships than worry about telling 
someone that I have COPD. 
SD D N A SA 
33 
Having COPD makes me feel unclean. 




34 Since learning I have COPD, I feel set apart and isolated 
from the rest of the world. 
SD D N A SA 
35 
Most people think that a person with COPD is disgusting. 
SD D N A SA 
36 
Most people with COPD are rejected when others find out. 
SD D N A SA 
37 
I am very careful who I tell that I have COPD. 
SD D N A SA 
38 Some people who know I have COPD have grown more 
distant. 
SD D N A SA 
39 If they learn I have COPD, I worry about people 
discriminating against me. 
SD D N A SA 
40 Most people are uncomfortable around someone with 
COPD. 
SD D N A SA 
41 
I never feel the need to hide the fact that I have COPD. 
SD D N A SA 
42 I worry that people may judge me when they learn I have 
COPD. 
SD D N A SA 
43 
Having COPD is disgusting to me. 
SD D N A SA 
44 I have been hurt by how people reacted to learning I have 
COPD. 
SD D N A SA 
45 
I regret having told some people that I have COPD. 
SD D N A SA 
46 People have told me that getting COPD is what I deserve 
for having smoked cigarettes. 
SD D N A SA 
47 
Some people act as though it's my fault I have COPD. 
SD D N A SA 
48 I have stopped socializing with some people because of 
their reactions to my having COPD. 
SD D N A SA 
49 
I have lost friends by telling them I have COPD. 
SD D N A SA 
50 I have told people close to me to keep the fact that I have 
COPD a secret. 
SD D N A SA 
51 People who know I have COPD tend to ignore my good 
points. 
SD D N A SA 
52 People seem uneasy around me once they learn I have 
COPD. 







Appendix D. COPD-related Stigma Scale 
This study asks about some of the social and emotional aspects of having COPD.  For most of the questions, just 
circle the letters or numbers that go with your answer.  There are no right or wrong answers.  Feel free to write in 
comments as you go through the questions. 
This first set of questions asks about some of your experiences, feelings, and opinions as to how people with COPD 
feel and how they are treated.  Please do your best to answer each question. 













Do you use a supplemental oxygen for COPD?  
 Yes   =>   Please go to No.2 
 No   =>   Please go to No.3 
2 
People shy away from me when they see I’m wearing 
oxygen. 
SD D A SA 
3 
Do you have a cough with COPD?  
 Yes   =>   Please go to No.4 
 No   =>   Please go to No.5 
4 No one seems embarrassed by my coughing. SD D A SA 
5 
Do you use an inhaler for COPD?  
 Yes   =>   Please go to No.6 
 No   =>   Please go to No.7 
6 My family doesn’t like me to use my inhaler in public. SD D A SA 
7 
People who were good friends before I got COPD are 
still good friends. 
SD D A SA 
8 
It’s embarrassing not to be able to keep up with others 
when we’re walking. 
SD D A SA 
9 
Do you use a supplemental oxygen for COPD?  
 Yes   =>   Please go to No.10 
 No   =>   Please go to No.11 
10 
I avoid using my oxygen in public so others won’t think 
I’m ill. 
SD D A SA 
11 
Do you use an inhaler for COPD?  















 No   =>   Please go to No.13 
12 
It embarrasses me to use the inhaler in front of other 
people. 
SD D A SA 
13 
When I’m with friends, I don’t feel embarrassed about 
having COPD. 
SD D A SA 
14 
Do you have symptoms with COPD such as a cough, phlegm, or shortness of breath?  
 Yes   =>   Please go to No.15 
 No   =>   Please go to No.16 
15 
I’m more likely to be embarrassed by my symptoms 
when I’m among strangers. 
SD D A SA 
16 Others blame a person with COPD for having smoked. SD D A SA 
17 
Others think people with COPD are idiots for having 
smoked. 
SD D A SA 
18 
I’ve been told not to come back to the doctor until I quit 
smoking. 
SD D A SA 
19 
Some health care providers have been abrupt with me 
about smoking. 
SD D A SA 
20 I feel flawed because I have COPD. SD D A SA 
21 Having COPD has changed my view of what I can do. SD D A SA 
22 My COPD puts a burden on my friends and loved ones. SD D A SA 
23 
Do you use a supplemental oxygen for COPD?  
 Yes   =>   Please go to No.24 
 No   =>   Please go to No.25 
24 I avoid using oxygen in front of other people. SD D A SA 
25 
I plan my activities carefully so others won’t notice I 
can’t do as much as I used to. 
SD D A SA 
26 I blame myself for having COPD. SD D A SA 
27 
Do you have either a cough or phlegm with COPD?  
 Yes   =>   Please go to No.28 
 No   =>   Please go to No.29 
















In many areas of my life, no one knows that I have 
COPD. 
SD D A SA 
30 I feel guilty because I have COPD. SD D A SA 
31 
People's attitudes about COPD make me feel worse 
about myself. 
SD D A SA 
32 Telling someone I have COPD is risky. SD D A SA 
33 
People with COPD lose their jobs when their employers 
find out. 
SD D A SA 
34 I work hard to keep my COPD a secret. SD D A SA 
35 
I feel I am not as good a person as others because I 
have COPD. 
SD D A SA 
36 I never feel ashamed of having COPD. SD D A SA 
37 People with COPD are treated like outcasts. SD D A SA 
38 
Most people believe that a person who has COPD is 
unclean. 
SD D A SA 
39 
It is easier to avoid new friendships than worry about 
telling someone that I have COPD. 
SD D A SA 
40 Having COPD makes me feel unclean. SD D A SA 
41 
Since learning I have COPD, I feel singled out and 
isolated from the rest of the world. 
SD D A SA 
42 
Most people think that a person with COPD is 
disgusting. 
SD D A SA 
43 
Most people with COPD are rejected when others find 
out. 
SD D A SA 
44 I am very careful who I tell that I have COPD. SD D A SA 
45 
Some people who know I have COPD have grown more 
distant. 
SD D A SA 
46 
If they learn I have COPD, I worry about people 
discriminating against me. 
SD D A SA 
47 
Most people are uncomfortable around someone with 
COPD. 















48 I never feel the need to hide the fact that I have COPD. SD D A SA 
49 
I worry that people may judge me when they learn I have 
COPD. 
SD D A SA 
50 Having COPD is disgusting to me. SD D A SA 
51 
I have been hurt by how people reacted to learning I 
have COPD. 
SD D A SA 
52 I regret having told some people that I have COPD. SD D A SA 
53 
People have told me that getting COPD is what I 
deserve for having smoked cigarettes. 
SD D A SA 
54 Some people act as though it's my fault I have COPD. SD D A SA 
55 
I have stopped socializing with some people because of 
their reactions to my having COPD. 
SD D A SA 
56 I have lost friends by telling them I have COPD. SD D A SA 
57 
I have told people close to me to keep the fact that I 
have COPD a secret. 
SD D A SA 
58 
People who know I have COPD tend to ignore my good 
points. 
SD D A SA 
59 
People seem uneasy around me once they learn I have 
COPD. 






Appendix E. Stigma Scale for Chronic Illness 8 items (SSCI-8) 
Please respond to each question or statement by marking one box per row. 
Lately… Never Rarely Sometimes Often Always 
1. Because of my illness, some people avoided me. 
1 2 3 4 5 
2. Because of my illness, I felt left out of things. 
1 2 3 4 5 
3. Because of my illness, people avoided looking at 
me. 1 2 3 4 5 
4. I felt embarrassed about my illness. 
1 2 3 4 5 
5. Because of my illness, some people seemed 
uncomfortable with me. 1 2 3 4 5 
6. I felt embarrassed because of my physical 
limitations. 1 2 3 4 5 
7. Because of my illness, people were unkind to me. 
1 2 3 4 5 
8. Some people acted as though it was my fault I 
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Appendix F. Charlson Comorbidity Index (CCI) 
Please respond to each item by marking one box per row. 
 No Yes 
1. Have you had a myocardial infarction (MI)? 
0 1 
2. Have you been hospitalized or treated for heart failure (CHF)? 
0 1 
3. Do you have peripheral vascular disease (PVD)? 
0 1 
4. Have you had a cerebrovascular disease (CVA) or transient 
ischemic disease? 0 1 
5. Do you have hemiplegia? 
0 1 
6. Do you have asthma, chronic lung disease, chronic bronchitis 
or emphysema (COPD)? 0 1 
7. Do you have diabetes that requires treatment? 
0 1 
8. Do you have end organ damage from diabetes?  
(For example, retinopathy, neuropathy, or nephropathy 
attributable to diabetes.) 
0 1 
9. Do you have moderate or severe renal disease? 
0 1 
10. Do you have a chronic liver disease?  
(For example, chronic hepatitis B or C) 0 1 
11. Do you have moderate to severe liver disease? 
0 1 
12. Have you had gastric or peptic ulcers? 
0 1 
13. Have you had cancer (other than basal cell skin cancer)? 
0 1 
14. If you have cancer, have you had a lymphoma?  




 No Yes 
15. If you have cancer, have you had a leukemia? 
0 1 
16. If you have cancer, have you had a solid tumor (without 
metastases)? 0 1 
If yes, which solid tumor have you had? (please specify)                 ______________________________ 
17. Have you had a metastatic solid tumor? 
0 1 






 Other: (please specify) ____________________________ 
18. Do you have Alzheimer’s dementia from any etiology or any 
serious cognitive impairment? 0 1 
19. Do you have any rheumatic or connective tissue disease? 
0 1 







Appendix G. Hospital Anxiety and Depression Scale (HADS) 
 
 
Tick the box beside the reply that is closest to how you have been feeling in the past week. 




1. I feel tense or ‘wound up’: 
3 Most of the time 
2 A lot of the time 
1 From time to time, occasionally 
0 Not at all 
 
2. I still enjoy the things I used to enjoy: 
0 Definitely as much 
1 Not quite so much 
2 Only a little 
3 Hardly at all 
 
3. I get a sort of frightened feeling as if 
something awful is about to happen: 
3 Very definitely and quite badly 
2 Yes, but not too badly 
1 A little, but it doesn't worry me 
0 Not at all 
 
4. I can laugh and see the funny side of 
things: 
0 As much as I always could 
1 Not quite so much now 
2 Definitely not so much now 
3 Not at all 
 
5. Worrying thoughts go through my mind: 
3 A great deal of the time 
2 A lot of the time 
1 From time to time, but not too often 
0 Only occasionally 
 
 
6. I feel cheerful: 
3 Not at all 
2 Not often 
1 Sometimes 
0 Most of the time 
 
7. I can sit at ease and feel relaxed: 
0 Definitely 
1 Usually 
2 Not often 
3 Not at all 
 
8. I feel as if I am slowed down: 
3 Nearly all the time 
2 Very often 
1 Sometimes 
0 Not at all 
 
9. I get a sort of frightened feeling like 
'butterflies' in the stomach: 
0 Not at all 
1 Occasionally 
2 Quite often 
3 Very often 
 
10. I have lost interest in my appearance: 
3 Definitely 
2 I don't take as much care as I should 
1 I may not take quite as much care 






11. I feel restless as I have to be on the 
move: 
3 Very much indeed 
2 Quite a lot 
1 Not very much 
0 Not at all 
 
12. I look forward with enjoyment to things: 
0 As much as I ever did 
1 Rather less than I used to 
2 Definitely less than I used to 
3 Hardly at all 
 
13. I get sudden feelings of panic: 
3 Very often indeed 
2 Quite often 
1 Not very often 
0 Not at all 
 




2 Not often 
3 Very seldom 
 
 






Appendix H. PROMIS Physical Function (Short Form-10a) 
Please respond to each item by marking one box per row. 










1. Does your health now limit 
you in doing vigorous 
activities, such as running, 
lifting heavy objects, 
participating in strenuous 
sports? 
5 4 3 2 1 
2. Does your health now limit 
you in walking more than 
a mile? 
5 4 3 2 1 
3. Does your health now limit 
you in climbing one flight 
of stairs? 
5 4 3 2 1 
4. Does your health now limit 
you in lifting or carrying 
groceries? 
5 4 3 2 1 
5. Does your health now limit 
you in bending, kneeling, 
or stooping? 
















6. Are you able to do chores 
such as vacuuming or 
yard work? 
5 4 3 2 1 
7. Are you able to dress 
yourself, including tying 
shoelaces and doing 
buttons? 
5 4 3 2 1 
8. Are you able to shampoo 
your hair? 5 4 3 2 1 
9. Are you able to wash and 




10. Are you able to get on and 
off the toilet? 5 4 3 2 1 
 
 




Appendix I. Descriptive Statistics of the 51-item COPD-related Stigma Scale 
 




10. Others blame a person with COPD for having 
smoked. d 
145 3.09 0.87 1 4 6.8 35.1 
15. Having COPD has changed my view of what I 
can do. c 
148 2.96 0.88 1 4 8.1 28.4 
11. Others think people with COPD are idiots for 
having smoked. d 
147 2.93 0.92 1 4 8.1 30.4 
19. I blame myself for having COPD. 145 2.93 0.77 1 4 4.7 20.9 
5. It's embarrassing not to be able to keep up with 
others when we're walking. c 
148 2.85 0.94 1 4 12.2 25.0 
2. No one seems embarrassed by my coughing. 112 2.64 0.78 1 4 4.7 9.5 
21. In many areas of my life, no one knows that I 
have COPD. 
145 2.63 0.79 1 4 9.5 9.5 
13. Some health care providers have been abrupt 
with me about smoking. d 
148 2.56 0.94 1 4 16.9 14.9 
20. Others are put off by my coughing and sputum. 130 2.56 0.82 1 4 8.8 9.5 
46. Some people act as though it's my fault I have 
COPD. b 
147 2.56 0.9 1 4 14.2 13.5 
28. I never feel ashamed of having COPD 146 2.45 0.86 1 4 13.5 10.8 
9. I'm more likely to be embarrassed by my 
symptoms when I'm among strangers. 
142 2.44 0.93 1 4 16.9 12.2 
22. I feel guilty because I have COPD. b 146 2.43 0.87 1 4 13.5 11.5 
14. I feel flawed because I have COPD. c 148 2.42 0.99 1 4 20.9 15.5 
45. People have told me that getting COPD is 
what I deserve for having smoked cigarettes. d 
146 2.38 0.96 1 4 20.3 12.8 
18. I plan my activities carefully so others won't 
notice I can't do as much as I used to. c 
145 2.3 0.85 1 4 18.9 6.1 
6. I avoid using my oxygen in public so others 
won't think I'm ill. 
30 2.27 0.98 1 4 4.7 2.7 
16. My COPD puts a burden on my friends and 
loved ones. c 
142 2.27 0.92 1 4 22.3 8.1 
23. People's attitudes about COPD make me feel 
worse about myself. b 
146 2.26 0.92 1 4 20.3 11.5 
17. I avoid using oxygen in front of other people. 36 2.22 0.9 1 4 4.7 2.7 
40. I never feel the need to hide the fact that I 
have COPD. b 
147 2.2 0.82 1 4 18.2 7.4 
42. Having COPD is disgusting to me. b 147 2.2 0.79 1 4 16.9 6.1 
8. When I'm with friends, I don't feel embarrassed 
about having COPD. 
147 2.18 0.92 1 4 25.7 8.8 
1. People shy away from me when they see I'm 
wearing oxygen. 
25 2.16 0.75 1 4 2.7 0.7 
41. I worry that people may judge me when they 
learn I have COPD. b 
146 2.12 0.76 1 4 19.6 3.4 
27. I feel I am not as good a person as others 
because I have COPD. b 









29. People with COPD are treated like outcasts. a 144 2.1 0.72 1 4 17.6 3.4 
24. Telling someone I have COPD is risky. 146 2.08 0.75 1 4 20.3 3.4 
36. I am very careful who I tell that I have COPD. 145 2.08 0.79 1 4 23.0 4.1 
25. People with COPD lose their jobs when their 
employers find out. 
133 2.04 0.68 1 4 16.2 2.7 
44. I regret having told some people that I have 
COPD. b 
146 2.01 0.75 1 4 23.6 3.4 
39. Most people are uncomfortable around 
someone with COPD. a 
143 1.99 0.74 1 4 23.6 2.7 
38. If they learn I have COPD, I worry about 
people discriminating against me. a 
145 1.98 0.78 1 4 27.7 2.7 
26. I work hard to keep my COPD a secret. b 146 1.97 0.78 1 4 26.4 5.4 
43. I have been hurt by how people reacted to 
learning I have COPD. a 
146 1.96 0.77 1 4 26.4 4.7 
47. I have stopped socializing with some people 
because of their reactions to my having COPD. a 
145 1.93 0.76 1 4 27.7 4.1 
7. It embarrasses me to use the inhaler in front of 
other people. 
120 1.91 0.88 1 4 31.8 3.4 
37. Some people who know I have COPD have 
grown more distant. 
145 1.9 0.73 1 4 29.1 2.0 
31. It is easier to avoid new friendships than worry 
about telling someone that I have COPD. a 
145 1.89 0.72 1 4 29.1 2.0 
30. Most people believe that a person who has 
COPD is unclean. a 
144 1.88 0.66 1 4 25.0 2.7 
51. People seem uneasy around me once they 
learn I have COPD. 
147 1.86 0.67 1 4 29.1 1.4 
33. Since learning I have COPD, I feel singled out 
and isolated from the rest of the world. 
147 1.84 0.76 1 4 34.5 3.4 
34. Most people think that a person with COPD is 
disgusting. a 
146 1.81 0.69 1 4 32.4 2.0 
35. Most people with COPD are rejected when 
others find out. a 
146 1.79 0.63 1 4 30.4 1.4 
50. People who know I have COPD tend to ignore 
my good points. a 
147 1.78 0.66 1 4 32.4 2.0 
48. I have lost friends by telling them I have 
COPD. 
145 1.75 0.64 1 4 33.8 1.4 
49. I have told people close to me to keep the fact 
that I have COPD a secret. 
147 1.74 0.62 1 4 33.8 1.4 
32. Having COPD makes me feel unclean. 146 1.65 0.64 1 4 42.6 0.7 
4. People who were good friends before I got 
COPD are still good friends. 
148 1.63 0.83 1 4 54.1 5.4 
12. I've been told not to come back to the doctor 
until I quit smoking. 
146 1.55 0.75 1 4 56.8 3.4 
3. My family doesn't like me to use my inhaler in 
public. 
118 1.5 0.74 1 4 48.6 2.7 
Note. SD = Standard Deviation; a = Social Stigma subscale; b = Self-blame subscale; c = Physical Limitation 
subscale; d = Self-inflicted disease subscale 
 
 
 
 
